CN1341098A - W-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors - Google Patents

W-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors Download PDF

Info

Publication number
CN1341098A
CN1341098A CN00802685A CN00802685A CN1341098A CN 1341098 A CN1341098 A CN 1341098A CN 00802685 A CN00802685 A CN 00802685A CN 00802685 A CN00802685 A CN 00802685A CN 1341098 A CN1341098 A CN 1341098A
Authority
CN
China
Prior art keywords
substituted
phenyl
acid
group
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN00802685A
Other languages
Chinese (zh)
Other versions
CN1219764C (en
Inventor
B·里德
J·迪马
U·基海尔
T·B·洛因格
W·J·斯科特
R·A·史密斯
J·E·伍德
M-K·莫纳汉
R·纳特罗
J·雷尼克
R·N·西布利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27381740&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1341098(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of CN1341098A publication Critical patent/CN1341098A/en
Application granted granted Critical
Publication of CN1219764C publication Critical patent/CN1219764C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N47/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid
    • A01N47/08—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom not being member of a ring and having no bond to a carbon or hydrogen atom, e.g. derivatives of carbonic acid the carbon atom having one or more single bonds to nitrogen atoms
    • A01N47/28—Ureas or thioureas containing the groups >N—CO—N< or >N—CS—N<
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C275/36—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with at least one of the oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. N-aryloxyphenylureas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/50—Iso-indoles; Hydrogenated iso-indoles with oxygen and nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Description

Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
Description of related applications this application is a continuation-in-part application on days 09/257,266, 2/1999 and 60/115,877, 1/1999, 13/1999.
Technical Field
The present invention relates to the use of a group of aryl ureas in the treatment of raf mediated diseases, and pharmaceutical compositions for use in such treatment.
Background
p21rasOncogenes are one of the major causes of human parenchymal carcinogenesis and progression, and mutations have occurred in this gene in 30% of cancer patients (Bolton et al, Ann. Rep. Med. chem.1994, 29, 165-74; Bos. cancer. Res.1989, 49, 4682-9). The non-mutated normal form of ras protein is a key element in the signaling cascade directed by growth factor receptors in almost all tissues (Avruch et al, Trends biochem. sci.1994, 19, 279-83). Biochemically, ras is a guanine nucleotide-binding protein and the cycle between GTP-bound active state and GDP-bound resting state is tightly controlled by ras endogenous gtpase activity and other regulatory proteins. Mutant ras in cancer cells has increased endogenous gtpase activity, and as a result, downstream effectors of this protein, such as raf kinase, signal constitutive growth. Thus, cancerous growth of cells harboring these mutants is caused (Magnuson et al, Semin. cancer biol.1994, 5, 247-53). It is known that the effects of active ras are suppressed by inhibiting the raf kinase signaling pathway, for example by administering a deactivating antibody to raf kinase or co-expressing a dominant negative raf kinase or a dominant negative MEK as a substrate for raf kinase, to restore transformed cells to a normal growth phenotype (see: Daum et al, Trends biochem. Sci.1994, 19, 474-80; Fridman et al, J.biol. chem.1994, 269, 30105-8). Kolch et al, (Nature, 1991, 349, 426-28) further indicated that inhibition of raf expression with antisense RNA in membrane-associated oncogenes inhibits cell proliferation. Similarly, raf kinase inhibition (with antisense oligodeoxynucleotides) has been found to be associated with inhibition of growth of a variety of human tumors, both in vitro and in vivo (Monia et al, nat. Med.1996, 2, 668-75).
Summary of The Invention
The present invention provides compounds that are inhibitors of raf kinase. Since the enzyme is p21rasThe inhibitors of the invention may be used in pharmaceutical compositions for inhibition of the raf kinase pathway in humans or animals as indicated, for example, in the treatment of tumors or cancerous growth of cells mediated by raf kinase. In particular, these compounds are useful in therapyHuman or animal cancers, e.g. murine, parenchymal cancers, are readily treated by interrupting the cascade, e.g. by inhibiting raf kinase, since the development of these cancers is dependent on the ras protein signaling cascade. Thus, the compounds of the invention are useful in the treatment of solid cancers such as malignant cancers (e.g., lung, pancreas, thyroid, bladder or colon cancer), myelopathies (e.g., myeloid leukemia) or adenomas (e.g., villous colon adenoma).
Accordingly, the present invention provides compounds, collectively referred to as aryl ureas, including aryl and heteroaryl analogs, which inhibit the raf pathway. The invention also provides methods of treating raf mediated diseases in humans or animals. Accordingly, the present invention relates to compounds that inhibit raf kinase, compounds, compositions and methods for treating raf kinase mediated cancer cell recruitment, comprising administering a compound of formula I:
A-D-B (I) wherein D is-NH-C (O) -NH-,
a is a compound of the formula-L- (M-L)1)qWherein L is a 5-6 membered ring directly attached to D, L is1Is an at least 5-membered, substituted ring, M is a bridging group of at least one atom, q is an integer from 1 to 3; rings L and L1Each containing 0 to 4 nitrogen, oxygen or sulfur,
b is a substituted or unsubstituted, up to tricyclic, below 30-carbon aryl or heteroaryl radical in which at least one 6-membered ring is directly connected to D and contains 0 to 4 nitrogen, oxygen or sulfur,
wherein L1 is substituted with at least one substituent selected from the group consisting of-SO2Rx，-C(O)Rxand-C (NR)y)RzThe substituent (b) of (a) is substituted,
Ryis hydrogen, or a carbon skeleton group of 24 carbons or less, may contain heteroatoms selected from N, S and O, may be halogenated or up to perhalogenated,
Rzis hydrogen, or a carbon skeleton group of 30 or less carbons, which may contain heteroatoms selected from N, S and O, which may be substituted by halogen, hydroxy or another carbon skeleton group of 24 or less carbons, which may contain heteroatoms selected from N, S and O, and which may be halogenated;
Rxis RzOr NRaRbWherein R isaAnd RbIs that
a) Each of which is hydrogen, is a hydrogen atom,
carbon skeleton groups of 30 carbons or less, which may contain heteroatoms selected from N, S and O, which may be substituted by halogen, hydroxy and further carbon skeleton groups of 24 carbons or less, which may contain heteroatoms selected from N, S and O and which may be halogenated; or
-OSi(Rf)3，RfIs hydrogen or a carbon skeleton group of 24 carbons or less, may contain heteroatoms selected from N, S and O, may be substituted by halogen, hydroxy and a further carbon skeleton group of 24 carbons or less, may contain heteroatoms selected from N, S and O and may be halogenated; or
b)RaAnd RbTaken together to form a 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from N, S and O, or a 5-7 membered substituted heterocyclic ring containing 1-3 heteroatoms selected from N, S and O, and substituted with halogen, hydroxy or another 24 carbon or less carbon backbone group, which may contain heteroatoms selected from N, S and O and which may be halogenated; or
c)RaAnd RbOne of them being-C (O) -, C1-5Divalent alkylene radicals or C1-5Divalent substituted alkylene which is bonded to L to form a ring having at least 5 members, C1-5The substituent of the divalent substituted alkylene group is selected from halogen, hydroxyl and carbon skeleton group of 24 carbon or less, the substituent may contain hetero atom selected from N, S and O and may be halogenated;
wherein B is substituted, L is substituted, or L1Is further substituted with a substituent selected from the group consisting of halogen, perhalogenated, and Wn, n is 0 to 3;
w is each selected from-CN, -CO2R7，-C(O)NR7R7，-C(O)-R7，-NO2，-OR7-，-SR7，-NR7R7，-NR7C(O)OR7，-NR7C(O)R7Q-Ar and a carbon skeleton group of 24 carbons or less, which group may contain hetero atoms of N, S and O and may be mono-or polysubstituted, a substituentSelected from-CN, -CO2R7，-C(O)-R7，-C(O)NR7R7，-OR7-，-SR7，-NR7R7，-NO2，-NR7C(O)R7，-NR7C(O)OR7And halo or to perhalo; each R7Carbon skeleton groups selected from H or less than 24 carbon, which may contain heteroatoms of N, S and O and which may be halogenated,
q is-O-, -S-, -N (R)7)-，-(CH2)m-，-C(O)-，-CH(OH)-，-(CH2)m-O-，-(CH2)m-S-，-(CH2)mN(R7)-，-O(CH2)m-，-CHXa-，-CXa 2-，-S-(CH2)m-, and-N (R)7)(CH2)m-, m ═ 1 to 3, XaIs halogen;
ar is a 5-or 6-membered aromatic structure containing 0 to 2 heteroatoms selected from nitrogen, oxygen and sulfur, which may be halogenated or up to perhalogenated, or by Zn1Substituted, n1 is 0 to 3, each Z is independently selected from-CN, -CO2R7，-C(O)R7，-C(O)NR7R7，-NO2，-OR7，-SR7，-NR7R7，-NR7C(O)OR7，-NR7C(O)R7And a carbon skeleton group of 24 carbons or less, which may contain hetero atoms of N, S and O and may be mono-or polysubstituted by halogen, the substituents being selected from the group consisting of-CN, -CO2R7，-COR7，-C(O)NR7R7，-OR7，-SR7，-NO2，-NR7R7，-NR7C(O)R7and-NR7C(O)OR7，R7As previously described.
Suitable heteroaryl groups B in formula I include, but are not limited to, aromatic rings of 5 to 12 carbon atoms or one to three ring systems, at least one of which is aromatic, wherein one or more, for example 1 to 4, carbon atoms in one or more of the rings may be substituted by oxygen, nitrogen or sulfur atoms. Each ring typically contains 3 to 7 atoms. For example, B may be 2-or 3-furyl, 2-or 3-thienyl, 2-or 4-triazinyl, 1-, 2-or 3-pyrrolyl, 1-, 2-, 4-or 5-imidazolyl, 1-, 3-, 4-or 5-pyrazolyl, 2-, 4-or 5-oxazolyl, 3-, 4-or 5-isoxazolyl, 2-, 4-or 5-thiazolyl, 3-, 4-or 5-isothiazolyl, 2-, 3-or 4-pyridyl, 2-, 4-, 5-or 6-pyrimidinyl, 1, 2, 3-triazol-1-, -4-or-5-yl, 1, 2, 4-triazol-1-, -3-or-5-yl, 1-or 5-tetrazolyl, 1, 2, 3-oxadiazol-4-or-5-yl, 1, 2, 4-oxadiazol-3-or-5-yl, 1, 3, 4-thiadiazol-2-or-5-yl, 1, 3, 4-thiadiazol-3-or-5-yl, 1, 2, 3-thiadiazol-4-or-5-yl, 2-, 3-, 4-, 5-or 6-2H-thiopyranyl, 2-, 3-or 4-4H-thiopyranyl, 3-or 4-pyridazinyl, thiadiazolyl, Pyrazinyl, 2-, 3-, 4-, 5-, 6-or 7-benzofuranyl, 2-, 3-, 4-, 5-, 6-or 7-benzothienyl, 1-, 2-, 3-, 4-, 5-, 6-or 7-indolyl, 1-, 2-, 4-or 5-benzimidazolyl, 1-, 3-, 4-, 5-, 6-or 7-benzopyrazolyl, 2-, 4-, 5-, 6-or 7-benzoxazolyl, 3-, 4-, 5-, 6-or 7-benzisoxazolyl, 1-, 3-, 4-, 5-, 6-or 7-benzothiazolyl, 2-, 4-, 5-, 6-or 7-benzisothiazolyl, 2-, 4-, 5-, 6-or 7-benzo-1, 3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7-or 8-quinolinyl, 1-, 3-, 4-, 5-, 6-, 7-or 8-isoquinolinyl, 1-, 2-, 3-, 4-or 9-carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-or 9-acridinyl, or 2-, 4-, 5-, 6-, 7-or 8-quinazolinyl, or, phenyl which may be further substituted, 2-or 3-thienyl, 1, 3, 4-thiadiazolyl, 3-pyrrolyl, 3-pyrazolyl, 2-thiazolyl or 5-thiazolyl, and the like. For example, B may be 4-methyl-phenyl, 5-methyl-2-thienyl, 4-methyl-2-thienyl, 1-methyl-3-pyrrolyl, 1-methyl-3-pyrazolyl, 5-methyl-2-thiazolyl or 5-methyl-1, 2, 4-thiadiazol-2-yl.
Suitable alkyl or alkoxy groups and the like include the alkyl portion of the groups herein methyl, ethyl, propyl, butyl and the like, including all straight and branched chain isomers, such as isopropyl, isobutyl, sec-butyl, tert-butyl and the like.
Suitable heteroatom-free aryl radicals are, for example, phenyl and 1-and 2-naphthyl.
"cycloalkyl" as used herein means with or without alkyl substituentsOf ring structures, e.g. "C4Cycloalkyl "includes methyl-substituted cyclopropyl and cyclobutyl. "cycloalkyl" also includes saturated heterocyclic groups.
Suitable halogens include F, Cl, Br and/or I, and if the alkyl group is substituted with a halogen, it may be mono-to fully substituted (i.e., all H atoms are substituted with halogen atoms), and may be a mixture of different halogen atoms.
The invention also relates to compounds of formula I.
The invention also relates to pharmaceutically acceptable salts of formula I. Suitable pharmaceutically acceptable salts are familiar to those skilled in the art and include basic salts of inorganic and organic acids such as hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, trifluoromethanesulfonic, benzenesulfonic, p-toluenesulfonic, 1-naphthalenesulfonic, 2-naphthalenesulfonic, acetic, trifluoroacetic, malic, tartaric, citric, lactic, oxalic, succinic, fumaric, maleic, benzoic, salicylic, phenylacetic and mandelic acids. In addition, pharmaceutically acceptable salts also include acid salts of inorganic bases, e.g., containing an alkali metal cation (e.g., Li)+，Na+Or K+) Alkaline earth metal cations (e.g. Mg)+2，Ca+2Or Ba+2) And salts of ammonium cations, and acid salts of organic bases including ammonium and quaternary ammonium cations substituted with aliphatic or aromatic groups from triethylamine, N-diethylamine, N-dicyclohexylamine, lysine, pyridine, N-Dimethylaminopyridine (DMAP), 1, 4-diazabicyclo [2.2.2 ]]Octane (DABCO), 1, 5-diazabicyclo [4.3.0]Non-5-ene (DBN) and 1, 8-diazabicyclo [5.4.0]Undec-7-ene (DBU).
Many compounds of formula I have asymmetric carbon atoms and can exist in racemic or optically active forms. Methods for enantiomeric and diastereomeric mixtures are familiar to those skilled in the art. The present invention includes any isolated racemic or optically active form of a compound of formula I having raf kinase inhibitory activity.
General preparation method
The compounds of formula I may be prepared from commercially available starting materials using known chemical reactions or processes. However, the following general preparation methods are provided and detailed examples are given in the examples section describing the working examples to assist the person skilled in the art in the synthesis of the inhibitors.
Substituted anilines were generated by standard methods (March, Advanced Organic Chemistry, 3)rdEdition; john Wiley: new York (1985) Larock, Comprehensive Organic Transformations; vchpublishers: new York (1989)). As shown in scheme I, the catalyst is prepared by using metal catalyst such as Ni, Pd or Pt and the like and H2Or formate, cyclohexadiene or borohydride, to synthesize arylanilines by reducing nitroarenes (rylander. hydrogenation Methods; Academic Press: London, UK (1985)). For example, LiAlH may be used4By the aluminium-and Borohydrides in Organic Synthesis; VCH Publishers: New York (1991)), or by direct reduction of nitroarenes with zero-valent metals such as Fe, Sn or Ca, usually in acidic media. There are many methods for the synthesis of nitroarenes (March. advanced Organic Chemistry, 3rd edition; John Wiley: New York (1985), Larock, Comprehensive Organic Transformations; VCH publishers: New York (1989)).Scheme I: reducing nitroaromatic hydrocarbon to aryl aniline by conventional method and using HNO3Or other NO2+The aromatic of the source is electrophilically nitrated to form nitroarenes.
The nitroarenes may be further modified prior to reduction. Thus, nitroarenes substituted with a latent leaving group (e.g., F, Cl, Br, etc.) can undergo a substitution reaction with nucleophiles such as thiolates (e.g., scheme II) or phenoxides. MirabiliteThe alkylaromatic hydrocarbons may also be subjected to Ullman-type coupling reactions (scheme II).
Figure A0080268500241
Scheme II: nucleophilic aromatic substitution with nitroarenes
Nitroarenes can also undergo cross-linking coupling reactions mediated by transition metals. For example, a nitroarene electrophile such as a nitroarene bromide, iodide, or trifluoromethanesulfonate and an aryl nucleophile such as aryl boronic acid (Suzuki reaction, for example, hereinafter), aryl tin (Stille reaction), or aryl zinc (Negishi reaction) undergo a palladium-mediated cross-linking coupling reaction to obtain biaryl (5).
Figure A0080268500242
Either the nitroarene or aniline can be converted to the corresponding arylsulfonyl chloride (7) by chlorosulfonic acid treatment. The sulfonyl chloride is then reacted with a fluorine source, such as KF, to form sulfonyl fluoride (8). The reaction of sulfonyl fluoride (8) with trimethylsilyltrifluoromethane in the presence of a fluorine source, such as tris (dimethylamino) sulfonium difluorotrimethylsilicate (TASF), produces the corresponding trifluoromethyl sulfone (9). Alternatively, sulfonyl chloride 7 can be reduced to aryl thiol (10) with, for example, zinc amalgam. Thiol 10 with CHCl2F is reacted in the presence of a base to form trifluoromethylthiol (11), which may comprise CrO3Oxidation of various oxidants including acetic anhydride to sulfone (12) (Sedova et al, zh. org. khim.1970, 6, (568)).
Figure A0080268500251
Scheme III: selected methods of synthesizing fluorinated aryl sulfones
As shown in FIG. IV, aryl isocyanate (14) reacts with arylamine (13) to form an asymmetric urea. Heteroarylisocyanates can be synthesized by reacting a heteroarylamine with phosgene or its counterpart such as trichloromethyl chloroformate (diphosphasol), bis (trichloromethyl carbonate (triphosgene) or N, N' -Carbonyldiimidazole (CDI). The isocyanates can also be produced from heterocyclic carboxylic acid derivatives such as esters, acid halides or anhydrides by Curtius rearrangement.accordingly, acid derivative 16 is reacted with a source of azide and then rearranged to produce the isocyanate.the corresponding carboxylic acid (17) can also be subjected to Curtius rearrangement with Diphenylphosphorylazide (DPPA) or a similar reagent.
Figure A0080268500261
Scheme IV: selected method of forming asymmetric ureas
Finally, the urea obtained can be further processed by methods familiar to the person skilled in the art.
The invention also includes pharmaceutical compositions comprising a compound of formula I and a physiologically acceptable carrier.
The compounds of the invention may be administered by injection, inhalation or spray, or rectally, orally, dermally, parenterally, or in unit dosage forms. "administration by injection" includes intravenous, intramuscular, subcutaneous and parenteral injection, as well as the use of infusion techniques. Dermal administration includes topical or transdermal administration. The one or more compounds may be present with one or more pharmaceutically acceptable non-toxic carriers and, optionally, other active ingredients.
The oral compositions may be prepared according to any suitable method known in the art for the manufacture of pharmaceutical compositions. In order to improve the mouthfeel of the formulation, the composition may contain one or more of the following agents: diluents, sweeteners, flavors, colorants and preservatives. Tablets contain the active ingredient in admixture with pharmaceutically acceptable, non-toxic excipients which are suitable for the manufacture of tablets. Such excipients as inert diluents, for example calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, such as corn starch or alginic acid; binders, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. The compounds may also be prepared in solid, fast-release form.
Oral formulations may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil, for example peanut oil, liquid paraffin or olive oil.
Aqueous suspensions containing the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions may also be employed. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropyl-methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a natural phospholipid, for example lecithin, or a condensation product of ethylene oxide with a fatty acid, for example polyoxyethylene stearate, or a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example heptadecaoxyethylene cetyl alcohol, or a condensation product of ethylene oxide with a partial ester of a fatty acid with a hexitol such as polyoxyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.
Dispersible powders or granules suitable for constitution with water in an aqueous suspension, the active ingredient being mixed with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents may be mentioned as examples above. Other excipients, for example sweetening, flavouring and colouring agents, may also be present.
The compounds may also be in the form of non-aqueous liquid preparations, for example oily suspensions, which may be formulated by suspending the active ingredient in a vegetable oil such as arachis oil, olive oil, sesame oil or peanut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. To improve the mouthfeel, the above-mentioned sweeteners and flavors may be added. The composition can be preserved by adding an antioxidant such as ascorbic acid.
The pharmaceutical compositions of the present invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil such as olive oil or peanut oil, or a mineral oil such as liquid beeswax, or a mixture thereof. Suitable emulsifying agents may be natural gums such as tragacanth and acacia, or natural phosphatides, for example soya bean lecithin or lecithin; partial esters of fatty acids with anhydrohexitols, such as but not limited to sorbitan oleate; condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monooleate. The emulsion may also contain sweeteners and flavors.
Syrups and elixirs may also be formulated with sweetening agents, for example glycerol, polypropylene glycol, sorbitol or sucrose. Such formulations may also contain emollients, preservatives and fragrances and coloring agents.
The compounds may also be administered in the form of suppositories for rectal or vaginal administration. Such compositions may be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal or vaginal temperatures and will therefore melt in the rectum or vagina to release the drug. Such materials include cocoa butter and polyethylene glycols.
In all treatment regimens herein using compounds of formula I, the daily oral dose is preferably from 0.01 to 200mg/kg body weight. The daily dosage of injection, including intravenous, intramuscular, subcutaneous and parenteral injection and application of infusion techniques, is preferably 0.01-200mg/kg body weight. The daily dosage for rectal administration is preferably from 0.01 to 200mg/kg body weight. The daily dosage for external use is 1 to 4 times daily, preferably 0.1 to 200mg each time. The daily dose for inhalation is preferably 0.01-10mg/kg body weight.
One skilled in the art will recognize that the particular mode of administration depends on a variety of factors, all of which are often considered in conventional administration. However, it will also be appreciated that the specific dose for a particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age of the patient, the weight of the patient, the general health of the patient, the sex of the patient, the diet of the patient, the time of administration, the route of administration, the rate of excretion, the drug combination and the severity of the condition being treated. The skilled person will also find that the optimal treatment regime, i.e. the treatment pattern over a certain number of days and the number of daily administrations of the compound of formula I or a pharmaceutically acceptable salt thereof, can be determined by the skilled person using routine treatment trials.
It will be apparent that the specific recorded level for a particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age of the patient, the weight of the patient, the general health of the patient, the sex of the patient, the diet of the patient, the time of administration, the route of administration, the rate of excretion, the drug combination and the severity of the condition being treated.
All patent applications, patents, and publications cited herein are hereby incorporated by reference in their entirety, including provisional application 60/115,877 filed on 13.1.1999 and non-provisional application 09/257,266 filed on 25.2.1999.
The compounds of the present invention can be prepared from known compounds (or starting materials which can be prepared from known compounds), by, for example, the general methods described later. The activity of the known raf kinase of each compound can be determined by the usual method described later. The following examples are given by way of illustration only and not by way of limitation.
Examples
All reactions were carried out in either flame-dried or oven-dried glassware under positive pressure of dry argon or dry nitrogen with magnetic stirring, unless otherwise noted. The sensitive liquid or solution is transferred by a syringe or a catheter and introduced into the reaction vessel through a rubber septum. Unless otherwise specified, "concentration under reduced pressure" means concentration with a Buchi rotary evaporator at about 15 mmHg. Unless otherwise specified, "under high vacuum" means a vacuum of 0.4 to 1.0 mmHg.
All temperatures reported here are uncorrected ℃. All parts and percentages are by weight unless otherwise indicated.
Commercial grade reagents were used directly without further purification. N-cyclohexyl-N' - (Methylpolystyrene) carbodiimide was purchased from Calbiochem-Novabiochem Corp. 3-tert-butylaniline, 5-tert-butyl-2-methoxyaniline, 4-bromo-3- (trifluoromethyl) aniline, 4-chloro-3- (trifluoromethyl) aniline, 2-methoxy-5- (trifluoromethyl) aniline, 4-tert-butyl-2-nitroaniline, 3-amino-2-naphthol, ethyl 4-isocyanatobenzoate, N-acetyl-4-chloro-2-methoxy-5- (trifluoromethyl) aniline and 4-chloro-3- (trifluoromethyl) phenyl isocyanate are commercially available without further purification. Synthesis of 3-amino-2-methoxyquinoline (E, Cho et al, WO 98/00402; A. Cordi et al, EP542,609; IBID biochemistry and chemistry 3, 1995, 129), 4- (3-carbamoylphenoxy) -1-nitrobenzene (K, Ikawa, J. Pharma. 79, 1959, 760; chemical abstracts 53, 1959, 12761b), 3-tert-butylphenyl isocyanate (O. Rohr et al, DE2436108), isocyanic acid and 2-methoxy-5- (trifluoromethyl) phenyl ester (K, Inukai et al, JP42,025,067; IBID Kogyo J. chem. 70, 1967, 491) are known.
Thin Layer Chromatography (TLC) was performed on Whatman precoated glass-lined silica gel 60A F-254 μm plates. The sheets were observed using one or more of the following techniques: (a) ultraviolet light emission, (b) exposure to iodine vapor, (c) immersing the sheet in a 10% ethanol solution of phosphomolybdic acid and then heating, (d) immersing the sheet in a cerium sulfate solution and then heating, and/or (e) immersing the sheet in an acidic ethanol solution of 2, 4-dinitrophenylhydrazine and then heating. Column chromatography (flash chromatography) was performed with 230-.
Melting points were determined with a Thomas-Hoover melting point apparatus or a Mettler FP66 automatic melting point apparatus without calibration. Fourier transform infrared spectra were obtained using a Mattson 4020 Galaxy Series spectrophotometer. Using a General Electric GN-Omega 300(300MHz) spectrometer, with Me4Si (d0.00) or residual protonated solvent (CHCl)3δ 7.26; MeOH, δ 3.30; DMSO, delta 2.49) as standard, determination of protons (H)1) Nuclear Magnetic Resonance (NMR) spectroscopy. Using a General Electric GN-Omega 300(75MHz) spectrometer, with solvent (CDCl)3，δ77.0；MeOD-d3；δ49.0；MeOD-d3(ii) a δ 39.5) as standard, determination of carbon: (13C) NMR spectrum. Low resolution Mass Spectrometry (MS) and High Resolution Mass Spectrometry (HRMS) were determined using Electron Impact (EI) mass spectrometry or fast atom bombardment mass spectrometry (FAB). Electron impact mass spectrometry (EI-MS) was obtained using a Hewlett Packard 5989A mass spectrometer equipped with a Vaccumetics desorption chemical ionization probe for introduction into the sample. The ion source was maintained at 250 ℃. Electron impact ionization was performed with a trapping current of 300. mu.A at an electron energy of 70 eV. An upgraded version of the fast atom bombardment, liquid-cerium secondary ion mass spectrum (FAB-MS), was obtained using a Kratos Concept 1-H spectrometer. Hewlett Packard MS-Engine (5989A) with methane or ammonia as the reaction gas (1X 10)-4To 2.5X 10-4torr), chemical ionization mass spectrum (CI-MS) was obtained. Direct insertion desorption ionization (DCI) probes (Vaccumetics, Inc.) were raised from 0 amps to 1.5 amps in 10 seconds and held at 10 amps until all micro-samples were consumedLose (about 1-2 minutes). 2 sec/radiation, from 120-. HPLC-electrospray mass spectrometry (HPLC ES-MS) was obtained using a Hewlett packard 1100 HPLC equipped with a quaternary pump, variable wavelength detector, C-18 column and a Finnigan LCQ ion trap mass spectrometer with electrospray ionization. The mass spectrum was scanned from 120-. Gas chromatography-ion selective mass spectrometry (GC-MS) was obtained using a Hewlett Packard 5890 chromatograph equipped with an HP-1 methyl silica gel column (0.33mM coating; 25 m.times.0.2 mM) and a Hewlett Packard 5971 mass selective detector (70eV ionization energy). Elemental analysis was performed by roberston icrolit Labs, Madison NJ.
NMR, LRMS and elemental analysis or HRMS of all compounds appeared to be consistent with the required structure.
List of abbreviations and acronyms
AcOH acetic acid
anh anhydrous
atm atmospheric pressure
BOC tert-butoxycarbonyl
CDI 1, 1' -carbonyldiimidazole
conc concentrated, concentrated
d days
dec decomposition
DMAC N, N-Dimethylacetamide
DMPU 1, 3-dimethyl-3, 4, 5, 6-tetrahydro-2 (1H) -pyrimidinone
DMF N, N-dimethylformamide
DMSO dimethyl sulfoxide
DPPA phenyl phosphoryl azide
EDCI 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide
EtOAc ethyl acetate
EtOH ethanol (100%)
Et2O Ether
Et3N-Triethylamine
h hours
HOBT 1-hydroxybenzotriazole
m-CPBA 3-chloroperoxybenzoic acid
MeOH methanol
Ether petroleum ether (boiling point between 30-60 ℃ C.)
temp. temperature
THF tetrahydrofuran
TFA trifluoroacetic acid
Tf trifluoromethanesulfonyl radical
A. General procedure for the Synthesis of substituted anilines
A1. General procedure for the synthesis of arylamines: the ether is formed first, then the ester is saponified, Curtius rearranges, and the carbamate is deprotected. Synthesis of 2-amino-3-methoxynaphthalene
Figure A0080268500311
Step 1: 3-methoxy-2-naphthoic acid methyl ester
Methyl 3-hydroxy-2-naphthoate (10.1g, 50.1mmol) and K2CO3A slurry of (7.96g, 57.6mmol) in DMF (200ml) was stirred at room temperature for 15 minutes and then reacted with methyl iodide (3.43ml, 55.1 mmol). The mixture was stirred at room temperature overnight, then water (200ml) was added. The resulting mixture was extracted with EtOAc (2X 200 mL). The combined organic layers were washed with saturated NaCl solution (100ml) and dried (MgSO)4) Concentrated under reduced pressure (about 0.4mmHg, overnight) to give methyl 3-methoxy-2-naphthoate (10.30g) as an amber oil:1HNMR(DMSO-d6)δ2.70(s，3H)，2.85(s，3H)，7.38(appt，J＝8.09Hz，1H)，7.44(s，1H)，7.53(appt，J＝8.09Hz，1H)，7.84(d，J＝8.09Hz，1H)，7.90(s，1H)，8.21(s，1H)。
Figure A0080268500312
step 2: 3-methoxy-2-naphthoic acid
A solution of methyl 3-methoxy-2-naphthoate (6.28g, 29.10mmol) and water (10ml) in MeOH (100ml) was stirred at room temperature and reacted with a solution of 1N NaOH (33.4ml, 33.4 mmol). The mixture was heated to reflux for 3 hours, cooled to room temperature, and acidified with 10% citric acid solution. The resulting mixture was extracted with EtOAc (2X 100 mL). The combined organic layers were washed with saturated NaCl solution and dried (MgSO)4) And concentrating under reduced pressure. Trituration of the residue with hexane followed by several washes with hexane afforded 3-methoxy-2-naphthoic acid as a white solid (5.40g, 92%):1H NMR(DMSO-d6)δ3.88(s，3H)，7.34-7.41(m，2H)，7.49-7.54(m，1H)，7.38(d，J＝8.09Hz，1H)，7.91(d，J＝8.09Hz，1H)，8.19(s，1H)，12.83(brs，1H)。
Figure A0080268500321
and step 3: 2- (N- (carbobenzoxy) amino-3-methoxynaphthalene
3-methoxy-2-naphthoic acid (3.36g, 16.6mmol) and Et3A solution of N (2.59ml, 18.6mmol) in dry toluene (70ml) was stirred at room temperature for 15 minutes, and then a solution of DPPA (5.12g, 18.6mmol) in toluene (10ml) was added dropwise. The resulting mixture was heated at 80 ℃ for 2 hours. After cooling to room temperature, benzyl alcohol (2.06ml, 20mmol) was injected via syringe. The mixture was then incubated at 80 ℃ overnight. The resulting mixture was cooled to room temperature, quenched with 10% citric acid solution and extracted with EtOAc (2X 100 ml). The combined organic layers were washed with saturated NaCl solution and dried (MgSO)4) And concentrating under reduced pressure. The residue was purified by column chromatography (14% EtOAc/86% hexanes) to give 2- (N- (carbobenzoxy) amine-3-methoxynaphthalene (5.1g, 100%):1H NMR(DMSO-d6)δ3.89(s，3H)，5.17(s，2H)，7.27-7.44(m，8H)，7.72-7.75(m，2H)，8.20(s，1H)，8.76(s，1H)。
Figure A0080268500322
and 4, step 4: 2-amino-3-methoxynaphthalene
A slurry of 2- (N- (carbobenzyloxy) amino-3-methoxynaphthalene (5.0g, 16.3mmol) and 10% Pd/C (0.5g) in EtOAc (70ml) was in H at room temperature2Atmosphere (balloon) overnight. The resulting mixture was filtered through Celite, concentrated under reduced pressure to give 2-amino-3-methoxynaphthalene as a pale pink powder (2.40g, 85%):1HNMR(DMSO-d6)δ3.86(s，3H)，6.86(s，2H)，7.04-7.16(m，2H)，7.43(d，J＝8.0Hz，1H)，7.56(d，J＝8.0Hz，1H)；EI-MS m/z 173(M+)。
A2. synthesis of omega-carbamoylanilines: carbamoylpyridines are formed first and then coupled nucleophilically with arylamines. Synthesis of 4- (2-N-methylcarbamoyl-4-pyridyloxy) aniline
Step 1 a: synthesis of 4-chloro-N-methyl-2-pyridinecarboxamide by Menisci reaction
Note that: this is a high risk, potentially explosive reaction. A solution of 4-chloropyridine (10.0g) in N-methylformamide (250ml) was added concentrated H with stirring at room temperature2SO4(3.55ml), an exotherm occurred. Adding H to the mixture2O2(30 wt% aqueous solution, 17ml) and FeSO was then added4·7H2O (0.56g), exothermic again. The resulting mixture was stirred at room temperature for 1 hour in the dark and then slowly raised to 45 ℃ over 4 hours. When bubbling stopped, the reaction was carried out at 60 ℃ for 16 hours. The resulting cloudy brown solution was diluted with water (700ml) and then 10% NaOH solution (250ml) was added. The resulting mixture was extracted with EtOAc (3X 500 mL). The organic layers were washed separately with saturated NaCl solution (3X 150ml), the washings combined and dried (MgSO)4) Filtered through silica gel with the aid of EtOAc. The resulting brown oil was purified by column chromatography (gradient of 50% EtOAc/50% hexanes to 80% EtOAc/20% hexanes) of the residue. The residue obtained is recrystallized at 0 ℃ for 72 hours to give 4-chloro-N-methyl-2-pyridinecarboxamide:1H NMR(CDCl3)δ3.04(d，J＝5.1Hz，3H)，7.43(dd，J＝5.4，2.4Hz，1H)，7.96(brs，1H)，8.21(s，1H)，8.44(d，J＝5.1Hz，1H)；CI-MS m/z 171((M＋H)+)。
Figure A0080268500331
step 1 b: hydrochloride salt formation from picolinic acid to 4-chloropyridine-2-carbonyl chloride
DMF (6.0ml) was added slowly to SOCl between 40 ℃ and 50 ℃2(180 ml). The solution was stirred at this temperature range for 10 minutes, then picolinic acid (60.0g, 487mmol) was added in portions over 30 minutes. The resulting solution was heated at 72 ℃ for 16 hours (vigorous release of SO)2) A yellow solid precipitate was produced. The resulting mixture was cooled to room temperature, diluted with toluene (500ml) and concentrated to 200 ml. The above toluene/concentration process was repeated 2 times. The resulting near-dry residue was filtered, and the solid was washed with toluene (2X 200ml) and dried under high vacuum for 4 hours to give the hydrochloride salt of 4-chloropyridine-2-carbonyl chloride as a yellow-orange solid (92.0g, 89%).
Figure A0080268500332
Step 2: synthesis of 4-chloropyridine-2-carboxylic acid methyl ester hydrochloride
DMF (10.0ml) was added slowly to SOCl between 40 ℃ and 48 ℃2(300 ml). The solution was stirred at this temperature range for 10 minutes, then picolinic acid (100g, 812mmol) was added over 30 minutes. The resulting solution was heated at 72 ℃ for 16 hours (vigorous release of SO)2) A yellow solid precipitate was produced. The resulting mixture was cooled to room temperature,diluted with toluene (500ml) and concentrated to 200 ml. The above toluene/concentration process was repeated 2 times. The resulting near dry residue was filtered and the solid washed with toluene (50ml) and dried under high vacuum for 4 hours to give 4-chloropyridine-2-carboxylic acid chloride hydrochloride as a beige solid (27.2g, 16%). Temporarily storing the substance.
The red filtrate was added to MeOH (200ml) controlling the speed, keeping the internal temperature below 55 ℃. Stirring at room temperature for 45 min, cooling to 5 deg.C, and dropping Et2O (200 ml). The resulting solid was filtered and washed with Et2O (200ml) and dried at 35 ℃ under reduced pressure to give 4-chloropyridine-2-carboxylic acid methyl ester hydrochloride as a white solid (110g, 65%): mp.108-112 ℃;1H NMR(DMSO-d6)δ3.88(s，3H)，7.82(dd，J＝5.5，2.2Hz，1H)；8.08(d，J＝2.2Hz，1H)；8.68(d，J＝5.5Hz，1H)；10.68(brs，1H)；HPLC ES-MS m/z172((M＋H)+)。
Figure A0080268500341
step 3 a: synthesis of 4-chloro-N-methyl-2-pyridinecarboxamide from methyl 4-chloropyridine-2-carboxylate
To a suspension of 4-chloropyridine-2-carboxylic acid methyl ester hydrochloride (89.0g, 428mmol) in 0 ℃ MeOH (75ml) was added 2.0M methylamine THF solution (1L) with rate control to maintain the internal temperature below 5 ℃. The resulting mixture was left at 3 ℃ for 5 hours and then concentrated under reduced pressure. The resulting solid was suspended in EtOAc (1L) and filtered. The filtrate was washed with saturated NaCl solution (500ml) and dried (Na)2SO4) And concentrated under reduced pressure to obtain yellow crystals of 4-chloro-N-methyl-2-pyridinecarboxamide (71.2g, 97%): mp.41-43 deg.C;1H NMR(DMSO-d6)δ2.81(s，3H)，7.74(dd，J＝5.1，2.2Hz，1H)；8.00(d，J＝2.2Hz，1H)；8.61(d，J＝5.5Hz，1H)；8.85(brs，1H)；CS-MS m/z 171((M＋H)+)。
Figure A0080268500342
and step 3 b: synthesis of 4-chloro-N-methyl-2-pyridinecarboxamide from 4-chloropyridine-2-carbonyl chloride
4-chloropyridine-2-carbonyl chloride hydrochloride (7.0g, 32.95mmol) was added portionwise to a 2.0M mixture of methylamine in THF (100ml) and MeOH (20ml) at 0 ℃. The resulting mixture was left at 3 ℃ for 4 hours and then concentrated under reduced pressure. The resulting near-dry solid was suspended in EtOAc (100mL) and filtered. The filtrate was washed with saturated NaCl solution (2X 100ml) and dried (Na)2SO4) Concentrated under reduced pressure, 4-chloro-N-methyl-2-pyridinecarboxamide yellow crystals (4.95g, 88%): mp.37-40 deg.C;
and 4, step 4: synthesis of 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline
To a solution of 4-aminophenol (9.60g, 88.0mmol) in anhydrous DMF (150ml) was added potassium tert-butoxide (10.29g, 91.7mmol), and the resulting reddish brown mixture was stirred at room temperature for 2 hours. To this was added 4-chloro-N-methyl-2-pyridinecarboxamide (15.0g, 87.9mmol) andK2CO3(6.50g, 47.0mmol) and then heated at 80 ℃ for 8 hours. The mixture was cooled to room temperature and partitioned between EtOAc (500ml) and saturated NaCl (500 ml). The aqueous phase was back extracted with EtOAc (300 mL). The combined organic layers were washed with saturated NaCl solution (4X 1000ml) and dried (Na)2SO4) And concentrating under reduced pressure. The resulting solid was dried at 35 ℃ under reduced pressure for 3 hours to give 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline as a light brown solid (17.9g, 84%):1H NMR(DMSO-d6) δ 2.77(d, J ═ 4.8Hz, 3H), 5.17(brs, 2H), 6.64, 6.86(AA 'BB', four peaks, J ═ 8.4Hz, 4H); 7.06(dd, J ═ 5.5, 2.5Hz, 1H); 7.33(d, J ═ 2.5Hz, 1H); 8.44(d, J ═ 5.5Hz, 1H); 8.73(brd, 1H); HPLCES-MS M/z 244((M + H)+)。
A3: general procedure for the synthesis of aniline: nucleophilic aromatic addition reaction, and then nitryl aromatic hydrocarbon reduction. Synthesis of 5- (4-aminophenoxy) isoindole-1, 3-dione
Figure A0080268500352
Step 1: synthesis of 5-hydroxyisoindole-1, 3-dione
To a mixture of ammonium carbonate (5.28g, 54.9mmol) and concentrated AcOH (25ml) was slowly added 4-hydroxyphthalic acid (5.0g, 27.45 mmol). The resulting mixture was heated at 120 ℃ for 45 minutes, and the resulting clear, bright yellow mixture was then heated at 160 ℃ for 2 hours. The resulting mixture was incubated at 160 ℃ and concentrated to about 15ml, then cooled to room temperature and the pH adjusted to 10 with 1N NaOH solution. The mixture was cooled to 0 ℃ and slowly acidified to pH5 with 1N HCl. The precipitate formed was collected by filtration and dried under reduced pressure to give 5-hydroxyisoindole-1, 3-dione as a pale yellow powder (3.24g, 72%):1H NMR(DMSO-d6)δ7.00-7.03(m，2H)，7.55(d，J＝9.3Hz，1H)。
Figure A0080268500361
step 2: synthesis of 5- (4-nitrophenoxy) isoindole-1, 3-dione
To a slurry of NaH (1.1g, 44.9mmol) in DMF (40ml) at 0 ℃ was added dropwise a solution of 5-hydroxyisoindole-1, 3-dione (3.2g, 19.6mmol) in DMF (40ml) with stirring. Let this light upThe yellow-green mixture was allowed to return to room temperature, stirred for 1 hour, and then 1-fluoro-4-nitrobenzene (2.67g, 18.7mmol) was added in 3-4 portions by syringe. The resulting mixture was heated at 70 ℃ overnight, then cooled to room temperature, slowly diluted with water (150ml) and extracted with EtOAc (2X 100 ml). The combined organic layers were dried (MgSO)4) And concentrated under reduced pressure to give 5- (4-nitrophenoxy) isoindole-1, 3-dione as a yellow solid (3.3g, 62%): TLC (30% EtOA/70% hexane) Rf0.28；1HNMR(DMSO-d6)δ7.32(d，J＝12Hz，2H)，7.52-7.57(m，2H)，7.89(d，J＝7.8Hz，1H)，8.29(d，J＝9Hz，2H)，11.43(brs，1H)；CI-MS m/z 285((M＋H)+，100％)。
And step 3: synthesis of 5- (4-aminophenoxy) isoindole-1, 3-dione
A solution of 5- (4-nitrophenoxy) isoindole-1, 3-dione (0.6g, 2.11mmol) in concentrated AcOH (12ml) and water (0.1ml) was stirred under argon flow while iron powder (0.59g, 55.9mmol) was slowly added. The mixture was stirred at room temperature for 72 h, then diluted with water (25ml) and extracted with EtOAc (3X 50 ml). The combined organic layers were dried (MgSO)4) And concentrated under reduced pressure to give 5- (4-aminophenoxy) isoindole-1, 3-dione as a brown solid (0.4g, 75%): TLC (50% EtOA/50% hexane) Rf0.27；1H NMR(DMSO-d6)δ5.14(br，s，2H)，6.62(d，J＝8.7Hz，2H)，6.84(d，J＝8.7Hz，2H)，7.03(d，J＝2.1Hz，1H)，7.23(dd，1H)，7.75(d，J＝8.4Hz，1H)，11.02(s，1H)；HPLC EI-MS m/z 255((M＋H)+，100％)。
A4: general procedure for the synthesis of pyrrolylanilines. Synthesis of 5-tert-butyl-2- (2, 5-dimethylpyrrolyl) aniline
Step 1: synthesis of 1- (4-tert-butyl-2-nitrophenyl) -2, 5-dimethylpyrrole
A solution of 2-nitro-4-tert-butylaniline (0.5g, 2.57mmol) in cyclohexane (10ml) was stirred while AcOH (0.1ml) and acetonylacetone (0.2 ml) were added thereto by syringe99g, 2.63 mmol). The reaction mixture was heated at 120 ℃ for 72 hours to azeotropically remove the volatile components. The reaction mixture was cooled to room temperature and quenched with CH2Cl2Diluted (10ml), washed successively with IN HCl (15ml), 1N NaOH (15ml) and saturated NaCl (15ml), dried ((MgSO 2)4) And concentrating under reduced pressure. The orange-brown solid obtained is subjected to column chromatography (60g SiO)2(ii) a Gradient of 6% EtOAc/94% hexanes to 25% EtOAc/75% hexanes) to give 1- (4-tert-butyl-2-nitrophenyl) -2, 5-dimethylpyrrole orange-brown solid (0.34g, 49%): TLC (15% EtOA/85% hexane) Rf0.67；1H NMR(CDCl3)d1.34(s，9H)，1.89(s，6H)，5.84(s，2H)，7.19-7.24(m，1H)，7.62(dd，1H)，7.88(d，J＝2.4Hz，1H)；CI-MS m/z 273((M＋H)+，50％)。
Figure A0080268500372
Step 2: synthesis of 5-tert-butyl-2- (2, 5-dimethylpyrrolyl) aniline
1- (4-tert-butyl-2-nitrophenyl) -2, 5-dimethylpyrrole (0.341g, 1.25mmol) 10% Pd/C (0.056g) and EtOAc (50ml) were slurried in H2Stirred for 72 hours under the atmosphere and then filtered with Celite ®. The filtrate was concentrated under reduced pressure to give 5-tert-butyl-2- (2, 5-dimethylpyrrolyl) aniline as a yellow solid (0.30g, 99%): TLC (10% EtOA/90% hexane) Rf0.43；1H NMR(CDCl3)δ1.28(s，9H)，1.87-1.91(m，8H)，5.85(brs，2H)，6.73-6.96(m，3H)，7.28(brs，1H)。
A5: general procedure for the synthesis of anilines from anilines by nucleophilic aromatic substitution. Synthesis of 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-methylaniline HCl salt.
Figure A0080268500381
To a solution of 4-amino-3-methylphenol (5.45g, 44.25mmol) in anhydrous dimethylacetamide (75ml) was added potassium tert-butoxide (10.86g, 96.77mmol) and the black mixture was stirred at room temperature until the beaker reached room temperature. 4-chloro-N-methyl-2-pyridinecarboxamide (step 3b of method A2; 7.52g, 44.2mmol) was added thereto, and heated at 110 ℃ for 8 hours. The mixture was cooled to room temperature and diluted with water (75 ml). By usingThe organic layer was extracted with EtOAc (5X 100 mL). The organic layers were combined, washed with saturated NaCl solution (200ml), and dried ((MgSO)4) And concentrating under reduced pressure. Et was added to the remaining black oil2O (50ml), and ultrasonic treatment was performed. The solution was then reacted with HCl (1M Et)2O solution; 100ml) was added, and stirred at room temperature for 5 minutes. The dark pink solid formed (7.04g, 24.1mmol) was filtered off and stored at 0 ℃ in an oxygen-free environment before use:1H NMR(DMSO-d6)δ2.41(s，3H)，2.78(d，J＝4.4Hz，3H)，4.93(br s，2H)，7.19(dd，J＝8.5，2.6Hz，1H)，7.23(dd，J＝5.5，2.6Hz，1H)，7.26(d，J＝2.6Hz，1H)，7.55(d，J＝2.6Hz，1H)，7.64(d，J＝8.8Hz，1H)，8.55(d，J＝5.9Hz，1H)，8.99(q，J＝4.8Hz，1H)。
a6: general procedure for the preparation of anilines from hydroxyanilines by N-protection, nucleophilic aromatic substitution and deprotection. Synthesis of 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-chloroaniline.
Figure A0080268500382
Step 1: synthesis of 3-chloro-4- (2, 2, 2-trifluoroacetylamino) phenol
Iron (3.24g, 58.00mmol) was added to TFA (200ml) with stirring. To the slurry were added 2-chloro-4-nitrophenol (10.0g, 58.0mmol) and trifluoroacetic anhydride (20 ml). The grey slurry was stirred at room temperature for 6 days. Filtering to remove iron powder, and concentrating the solution under reduced pressure. The resulting grey solid was dissolved in water (20 ml). To the resulting yellow solution was added saturated NaHCO3Solution (50 ml). The precipitate in the solution was removed. The reaction was stopped by slowly adding sodium bicarbonate solution to the filtrate until product separation from the solution was visible (as determined with a small prep tube). The slightly cloudy yellow solution was extracted with EtOAc (3X 125 ml). The organic layers were combined, washed with saturated NaCl solution (125ml), and dried ((MgSO)4) And concentrating under reduced pressure.1H NMR showed a 1: 1 ratio of nitrophenol starting material to desired product 3-chloro-4- (2, 2, 2-trifluoroacetylamino) phenol. The crude product was used directly in the subsequent reaction without purification.
Figure A0080268500391
Step 2: 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-chlorophenyl (2, 2, 2-trifluoro) acetamide
To a solution of crude 3-chloro-4- (2, 2, 2-trifluoroacetylamino) phenol (5.62g, 23.46mmol) in anhydrous dimethylacetamide (50ml) was added potassium tert-butoxide (5.16g, 45.98mmol) and the brown mixture was stirred at room temperature until the flask cooled to room temperature. 4-chloro-N-methyl-2-pyridinecarboxamide (step 3b of method A2; 1.99g, 11.7mmol) was added thereto, and the mixture was heated at 110 ℃ for 4 days under an argon atmosphere. The black mixture was cooled to room temperature and poured into cold water (100 ml). The mixture was extracted with EtOAc (3X 75 mL). The organic layers were combined and concentrated under reduced pressure. The remaining brown oil was purified by column chromatography (gradient of 20% EtOAc/% petroleum ether to 40% EtOAc/% petroleum ether) to give 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-chlorophenyl (2, 2, 2-trifluoro) acetamide as a yellow solid (8.59g, 23.0 mmol).
Figure A0080268500392
And step 3: synthesis of 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-chloroaniline
To a solution of crude 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-chlorophenyl (2, 2, 2-trifluoro) acetamide (8.59g, 23.0mmol) in anhydrous 4-dioxane (20ml) was added a 1N NaOH solution (20 ml). The brown solution was stirred for 8 hours. To the solution was added EtOAc (40 mL). The green organic layer was extracted with EtOAc (3X 40mL), concentrated to remove solvent and allowed to stand to give 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-chloroaniline as a green oil (2.86g, 10.30 mmol):1H NMR(DMSO-d6)δ2.77(d，J＝4.8Hz，3H)，5.51(s，2H)，6.60(dd，J＝8.5，2.6Hz，1H)，6.76(d，J＝2.6Hz，1H)，7.03(d，J＝8.5Hz，1H)，7.07(dd，J＝5.5，2.6Hz，1H)，7.27(d，J＝2.6Hz，1H)，8.64(d，J＝5.5Hz，1H)，8.75(q，J＝4.8Hz，1H)。
a7: general procedure for deprotection of acylated anilines. Synthesis of 4-chloro-2-methoxy-5- (trifluoromethyl) aniline
Figure A0080268500393
A suspension of 3-chloro-6- (N-acetyl) -4- (trifluoromethyl) anisole (4.00g, 14.95mmol) in 6M HCl (24ml) was refluxed for 1 hour. The resulting solution was allowed to cool to room temperature during which it precipitated slightly. The resulting mixture was diluted with water (20ml) and then NaOH solid and saturated sodium bicarbonate solution were added until the solution was basic. By CH2Cl2The organic layer was extracted (3X 50 ml). The combined organic layers were dried (MgSO)4) After concentration under reduced pressure, 4-chloro-2-methoxy-5- (trifluoromethyl) aniline brown oil (3.20g, 14.2mmol) was obtained:1H NMR(DMSO-d6)δ3.84(s，3H)，5.30(s，2H)，7.01(s，2H)。
a8: general procedure for the synthesis of omega-alkoxy-omega-carboxyphenylanilines. Synthesis of 4- (3- (N-methylcarbamoyl) -4-methoxyphenoxy) aniline.
Step 1: 4- (3-methoxycarbonyl-4-methoxyphenoxy) -1-nitrobenzene:
to a solution of 4- (3-carboxy-4-hydroxyphenoxy) -1-nitrobenzene (12mmol, prepared from 2, 5-dihydroxybenzoic acid according to method A13, step 1) in acetone was added K2CO3(5g) And dimethyl sulfate (3.5 ml). The resulting mixture was refluxed overnight, then cooled to room temperature and filtered through Celite @. Concentrating the resulting solution under reduced pressure using SiO2Absorption and purification by column chromatography (50% EtOAc/50% hexanes) gave 4- (3-methoxycarbonyl-4-methoxyphenoxy) -1-nitrobenzene as a yellow powder (3 g): mp.115-118 deg.C.
Figure A0080268500402
Step 2: 4- (3-carboxy-4-methoxyphenoxy) -1-nitrobenzene:
4- (3-methoxycarbonyl-4-methoxyphenoxy) -1-nitrobenzene (1.2g), KOH (0.33g) and water (5ml) were combined in MeOH (45ml), stirred overnight at room temperature and then refluxed for 4 hours. The resulting mixture was cooled to room temperature and concentrated under reduced pressure. The residue was dissolved in water (50ml) and made acidic with 1N HCl solution. The resulting mixture was extracted with EtOAc (50 mL). Drying (MgSO)4) Concentrating the organic layer under reduced pressure to obtain 4- (3-carboxy-4-methoxyphenoxy) -1-nitrobenzene (1.04g)
Figure A0080268500411
And step 3: 4- (3- (N-methylcarbamoyl) -4-methoxyphenoxy) -1-nitrobenzene:
to 4- (3-carboxy-4-methoxyphenoxy) -1-nitrobenzene (0.50g, 1.75mmol) in CH2Cl2Adding SOCl into the solution in batches2(0.64ml, 8.77 mmol). The resulting solution was refluxed for 18 hours, then cooled to room temperature and concentrated under reduced pressure. The yellow solid formed is dissolved in CH2Cl2(3ml) to the resulting solution was added methylamine solution (2.0M in THF, 3.5ml, 7.02mmol) in portions (note: gas evolution) and stirred at room temperature for 4 hours. To the resulting mixture was added 1N NaOH solution followed by CH2Cl2(25ml) extraction. The organic layer was dried (Na)2SO4) After concentration under reduced pressure, 4- (3- (N-methylcarbamoyl) -4-methoxyphenoxy) -1-nitrobenzene was obtained (0.50g, 95%).
And 4, step 4: 4- (3- (N-methylcarbamoyl) -4-methoxyphenoxy) aniline
A slurry of 4- (3- (N-methylcarbamoyl) -4-methoxyphenoxy) -1-nitrobenzene (0.78g, 2.60mmol) and 10% Pd/C (0.20g) in EtOH (55 ml) was stirred under a hydrogen atmosphere of 1atm (balloon) for 2.5 days, then filtered through Celite, and the resulting solution was concentrated under reduced pressure to give 4- (3- (N-methylcarbamoyl) -4-methoxyphenoxy) aniline as a beige solid (0.68g, 96%): TLC (0.1% Et%3N/99.9％EtOAc)Rf0.36。
A9: general procedure for the preparation of omega-alkylphthalimide-containing anilines. Synthesis of 5- (4-aminophenoxy) -2-methylisoindole-1, 3-dione.
Figure A0080268500413
Step 1: synthesis of 5- (4-nitrophenoxy) -2-methylisoindole-1, 3-dione
A slurry of 5- (4-nitrophenoxy) isoindole-1, 3-dione (A3 step 2; 1.0g, 3.52mmol) and NaH (0.13g, 5.27mmol) in DMF (15ml) was stirred at room temperature for 1 hour, then methyl iodide was added(0.3ml, 4.57 mmol). The resulting mixture was stirred at room temperature overnight, then cooled to 0 ℃ and water (10ml) was added. The resulting solid was collected and dried under reduced pressure to give 5- (4-nitrophenoxy) -2-methylisoindole-1, 3-dione as a bright yellow solid (0.87g, 83%): TLC (35% EtAc/65% hexane) Rf0.61。
Step 2: synthesis of 5- (4-aminophenoxy) -2-methylisoindole-1, 3-dione
A slurry of 5- (4-nitrophenoxy) -2-methylisoindole-1, 3-dione (0.87g, 2.78mmol) and 10% Pd/C (0.10g) in MeOH (55 ml) was stirred overnight under an atmosphere of 1atm hydrogen (balloon) then filtered through Celite, the resulting solution was concentrated under reduced pressure2Filtration (60% EtOAc/40% hexane) afforded 5- (4-aminophenoxy) -2-methylisoindole-1, 3-dione as a yellow solid (0.67g, 86%): TLC (40% EtOAc/60% hexane) Rf0.27。
A10: general procedure for the synthesis of omega-carbamoylanilines by reaction of omega-alkoxycarbonylaryl precursors with amines. Synthesis of 4- (2- (N- (2-morpholin-4-ylethyl) carbamoyl) pyridyloxy) aniline
Figure A0080268500422
Step 1: synthesis of 4-chloro- (2- (N- (2-morpholin-4-ylethyl) carbamoyl) pyridine
To a solution of 4-chloropyridine-2-carboxylic acid methyl ester HCl salt (method A2 step 2; 1.01g, 4.86mmol) in THF (20ml) was added 4- (2-aminoethyl) morpholine (2.55ml, 19.4mmol) dropwise, the resulting solution was refluxed for 20 hours, cooled to room temperature, and water (50ml) was added. The resulting mixture was extracted with EtOAc (50 mL). Drying (MgSO)4) The organic layer was concentrated under reduced pressure to give 4-chloro- (2- (N- (2-morpholin-4-ylethyl) carbamoyl) pyridine as a yellow oil (1.25g, 95%): TLC (10% MeOH/90% EtOAc) Rf0.50。
Figure A0080268500423
Step 2: synthesis of 4- (2- (N- (2-morpholin-4-ylethyl) carbamoyl) pyridyloxy) aniline 4-aminophenol (0.49g, 4.52mmol) and potassium tert-butoxide (0.53g, 4.75mmol) in DMF (8ml)) Solutions ofStirring was carried out at room temperature for 2 hours, and 4-chloro- (2- (N- (2-morpholin-4-ylethyl) carbamoyl) pyridine (1.22g, 4.52mmol) and K were added in succession2CO3(0.31g, 2.26 mmol). The resulting mixture was cooled to room temperature at 75 ℃ overnight, and partitioned between EtOAc (25ml) and saturated NaCl solution (25 ml). The aqueous phase was back extracted with EtOAc (25 mL). The combined organic layers were washed with saturated NaCl solution (3X 25ml) and concentrated under reduced pressure. The brown solid formed was purified by column chromatography (58g, gradient 100% EtOAc to 25% MeOH/75% EtOAc) to give 4- (2- (N- (2-morpholin-4-ylethyl) carbamoyl) pyridyloxy) aniline (1.0g, 65%): TLC (10% MeOH/90% EtOAc) Rf0.32。
A11: general procedure for the reduction of nitroarenes to arylamines. Synthesis of 4- (3-carboxyphenoxy) aniline
Figure A0080268500431
A slurry of 4- (3-carboxyphenoxy) -1-nitrobenzene (5.38g, 20.7mmol) and 10% Pd/C (0.50g) in MeOH (120ml) was stirred under an atmosphere of hydrogen (balloon) for 2 days. The resulting mixture was filtered through Celite to give 4- (3-carboxyphenoxy) aniline brown solid (2.26g, 48%): TLC (10% MeOH/90% CH)2Cl2)Rf0.44。
A12: general procedure for the synthesis of isoindolone-containing anilines. Synthesis of 4- (1-oxoisoindol-5-yloxy) aniline
Figure A0080268500432
Step 1: synthesis of 5-hydroxyisoindol-1-one
To a solution of 5-hydroxyphthalimide (19.8g, 121mmol) in AcOH (500ml) was added zinc dust (47.6g, 729mmol) slowly in portions, then refluxed for 40 minutes, filtered hot and concentrated under reduced pressure. The reaction was repeated on the same scale and the oily residue was combined and purified by column chromatography (1.1kg, SiO)2(ii) a Gradient: 60% AcOH/40% hexane) to give 5-hydroxyisoindol-1-one (3.77 g): TLC (100% EtOAc) Rf0.17；HPLCES-MS m/z 150(M＋H)+)。
Figure A0080268500441
Step 2: synthesis of 4- (1-isoindolone-5-yloxy) -1-nitrobenzene
To a slurry of NaH (0.39g, 16.1mmol) in DMF0 deg.C was added 5-hydroxyisoindol-1-one (2.0g, 13.4mmol) in portions. The resulting slurry was allowed to warm to room temperature, stirred for 45 minutes, then 4-fluoro-1-nitrobenzene was added and the mixture was heated at 72 ℃ for 3 hours. The mixture was cooled to 0 ℃ and water was added dropwise until a precipitate formed. The solid formed was collected to give 4- (1-isoindolon-5-yloxy) -1-nitrobenzene as a dark yellow solid (3.23g, 89%): TLC 100% EtOAc) Rf0.35。
Figure A0080268500442
And step 3: synthesis of 4- (1-oxoisoindol-5-yloxy) aniline
4- (1-isoindolon-5-yloxy) -1-nitrobenzene (2.12g, 7.8mmol) and 10% Pd/C (0.20g) in EtOH (50ml) slurry were stirred under a hydrogen atmosphere (balloon) for 4 hours. Filtered through Celite @. Concentrating the filtrate under reduced pressure to obtain 4- (1-oxoisoindol-5-yloxy) aniline dark yellow solid: TLC (100% EtOAc) Rf0.15。
A13: general procedure for the synthesis of omega-carbamoylanilines: the nitroarenes are then reduced by EDCI-mediated amide formation. Synthesis of 4- (3-N-methylcarbamoylphenoxy) aniline
Step 1: synthesis of 4- (3-ethoxycarbonylphenoxy) -1-nitrobenzene
4-fluoro-1-nitrobenzene (16ml, 150mmol), ethyl 3-hydroxybenzoate (25g, 150mmol) and K2CO3A mixture of (41g, 300mmol) in DMF (125ml) was refluxed overnight, cooled to room temperature and water (250ml) was added. The resulting mixture was extracted with EtOAc (3X 150 mL). The combined organic phases were finely divided with water (3X 100ml) and saturated NaCl solution (2X 100ml) in succession and dried (Na)2SO4) And concentrating under reduced pressure. Purification by column chromatography (10% EtOAc/90% hexane) afforded 4- (3-ethoxycarbonylphenoxy) -1-nitrobenzene as an oil (38 g).
Figure A0080268500451
Step 2: synthesis of 4- (3-carboxyphenoxy) -1-nitrobenzene
A solution of 4- (3-ethoxycarbonylphenoxy) -1-nitrobenzene (5.14g, 17.9mmol) in 3: 1 THF/water (75ml) was stirred vigorously while adding LiOH. H2O (1.50g, 35.8mmol) in water (36 ml). The resulting mixture was heated at 50 ℃ overnight, then cooled to room temperature, concentrated under reduced pressure, and adjusted to pH2 with 1M HCl solution. The resulting bright yellow solid was filtered and washed with hexane to give 4- (3-carboxyphenoxy) -1-nitrobenzene (4.40g, 95%).
Figure A0080268500452
And step 3: synthesis of 4- (3- (N-methylcarbamoyl) phenoxy) -1-nitrobenzene
4- (3-carboxyphenoxy) -1-nitrobenzene (3.72g, 14.4mmol), EDCI. HCl (3.63g, 18.6mmol), N-methylmorpholine (1.6ml, 14.5mmol) and methylamine (2.0M in TMF, 8ml, 16mmol) in CH2Cl2(45ml) was added to the reaction solution, and the mixture was stirred at room temperature for 3 days, followed by concentration under reduced pressure. The residue was dissolved in EtOAc (50ml) and extracted with 1M HCl solution (50 ml). The combined aqueous phases were back extracted with EtOAc (2X 50 mL). The combined organic phases were washed with saturated NaCl solution (50ml) and dried (Na)2SO4) Then, the mixture was concentrated under reduced pressure to give 4- (3- (N-methylcarbamoyl) phenoxy) -1-nitrobenzene as an oily substance (1.89 g).
And 4, step 4: synthesis of 4- (3- (N-methylcarbamoyl) phenoxy) aniline
4- (3- (N-methylcarbamoyl) phenoxy) -1-nitrobenzene (1.89g, 6.95mmol) and 5% Pd/C (0.24g) were slurried in EtOAc (20mL) and stirred overnight under an atmosphere of hydrogen (balloon). The resulting mixture was filtered through Celite followed by concentration under reduced pressure. The residue was purified by column chromatography (5% MeOH/95% CH)2Cl2). The resulting oil solidified in vacuo overnight to give 4- (3- (N-methylcarbamoyl) phenoxy) aniline as a yellow solid (0.95g, 56%).
A14: general procedure for the synthesis of omega-carbamoylanilines: the nitroarenes are then reduced by EDCI-mediated amide formation. Synthesis of 4-3- (5-methylcarbamoylphenoxy) aniline
Figure A0080268500461
Step 1: synthesis of 4- (3- (5-methoxycarbonyl) pyridyloxy) -1-nitrobenzene
To a slurry of NaH (0.63g, 26.1mmol) in DMF (20ml) was added a solution of methyl 5-hydroxynicotinate (2.0g, 13.1mmol) in DMF (10 ml). The resulting mixture was added to a solution of 4-fluoronitrobenzene (1.4ml, 13.1mmol) in DMF (10ml), the resulting mixture was heated at 70 ℃ overnight and then cooled to room temperature, MeOH (5ml) was added, followed by water (50 ml). The resulting mixture was extracted with EtOAc (100 mL). The organic phase was concentrated under reduced pressure. The residue was purified by column chromatography (30% EtOAc/70% hexane) to give 4- (3- (5-methoxycarbonyl) pyridyloxy) -1-nitrobenzene (0.60 g).
Figure A0080268500462
Step 2: synthesis of 4- (3- (5-methoxycarbonyl) pyridyloxy) aniline
4- (3- (5-methoxycarbonyl) pyridyloxy) -1-nitrobenzene (0.60g, 2.20mmol) and 10% Pd/C in MeOH/EtOAc form a mixture which is stirred under an atmosphere of hydrogen (balloon) for 72 h. The resulting mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (gradient: 10% EtOAc/90% hexane to 30% EtOAc/70% hexane) to give 4- (3- (5-methoxycarbonyl) pyridyloxy) aniline (0.28g, 60%):1HNMR(CDCl3)δ3.92(s，3H)，6.71(d，2H)，6.89(d，2H)，7.73(，1H)，8.51(d，1H)，8.87(d，1H)。
a15: aniline is synthesized by electrophilic nitration followed by reduction. Synthesis of 4- (3-methylsulfamoylphenoxy) aniline.
Step 1: synthesis of N-methyl-3-bromobenzenesulfonamide
To a solution of 3-bromobenzenesulfonyl chloride (2.5g, 11.2mmol) in THF (15mL) at 0 deg.C was added methylamine (2.0M in THF, 28mL, 56 mmol). The resulting solution was allowed to warm to room temperature and stirred at room temperature overnight. The resulting mixture was partitioned between EtOAc (25ml) and 1M HCl solution (25 ml). The aqueous phase was back extracted with EtOAc (2X 25 mL). The combined organic phases were washed with water (2X 25ml) and saturated NaCl solution (25ml) and driedDried (MgSO)4) And concentrated under reduced pressure to obtain N-methyl-3-bromobenzenesulfonamide as white solid (2.8g, 99%).
Step 2: synthesis of 4- (3- (N-methylsulfamoyl) phenyloxy) benzene
Phenol (1.9g, 20mmol), K2CO3(6.0g, 40mmol) and CuI (4g, 20mmol) were slurried in DMF (25ml) to which was added N-methyl-3-bromobenzenesulfonamide (2.5g, 10mmol) and the resulting mixture was stirred at reflux overnight, cooled to room temperature and partitioned between EtOAc (50ml) and 1N HCl solution (50 ml). The aqueous phase was back extracted with EtOAc (2X 50 mL). The combined organic phases were washed with water (2X 50ml) and saturated NaCl solution (50ml) and dried (MgSO 4)4) Then, the mixture was concentrated under reduced pressure to give 4- (3- (N-methylsulfamoyl) phenoxy) benzene (0.30 g).
And step 3: synthesis of 4- (3- (N-methylsulfamoyl) phenoxy) -1-nitrobenzene
To a solution of 4- (3- (N-methylsulfamoyl) phenyloxy) benzene (0.30g, 1.14mmol) in TFA (6ml) at-10 deg.C was added NaNO portionwise over 5 minutes2(0.097g, 1.14 mmol). The resulting mixture was stirred at-10 ℃ for 1 hour, then warmed to room temperature and concentrated under reduced pressure. The residue was partitioned between EtOAc (10ml) and water (10 ml). The organic phase was washed with water (10ml) and saturated NaCl solution (10ml) and dried (MgSO)4) Concentrated under reduced pressure, 4- (3- (N-methylsulfamoyl) phenoxy) -1-nitrobenzene (0.20 g). This material was used directly in the next step without purification.And 4, step 4: synthesis of 4- (3- (N-methylsulfamoyl) phenoxy) aniline
A mixture of 4- (3- (N-methylsulfamoyl) phenyloxy) -1-nitrobenzene (0.30g) and 10% Pd/C (0.030g) in EtOAc (20ml) was stirred under an atmosphere of hydrogen (balloon) overnight. The resulting mixture was filtered through Celite sieves and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (30% EtOAc/70% hexane) to give 4- (3- (N-methylsulfamoyl) phenoxy) aniline (0.070 g).
A16: modification of omega-ketones. 4- (4- (1- (N-methoxy) iminoethyl) phenoxyaniline HCl salt
Figure A0080268500481
To a slurry of 4- (4-acetylphenoxy) aniline HCl salt (prepared according to A13 step 4, 1.0g, 3.89mmol) in a mixture of EtOH (10ml) and pyridine (1.0ml) was added O-methylhydroxylamine HCl salt (0.65g, 7.78mmol, 2.0 equiv.). The resulting solution was refluxed for 30 minutes, cooled to room temperature and concentrated under reduced pressure. The resulting solid, triturated with water (10ml), was washed with water to give 4- (4- (1- (N-methoxy) iminoethyl) phenoxyaniline HCl salt as a yellow solid (0.85g) TCL (50% EtOAc/50% petroleum ether) Rf0.78；1H NMR(DMSO-d6)δ3.90(s，3H)，5.70(s，3H)；HPLC-MS m/z257(M＋H)+)。
A17: synthesis of N- (. omega. -silyloxy alkyl) amides. Synthesis of 4- (4- (2- (N- (2-triisopropylsilyloxy) ethylcarbamoyl) pyridyloxyaniline.
Figure A0080268500482
Step 1: 4-chloro-N- (2-triisopropylsilyloxy) ethylpyridine-2-carboxamide
To a solution of 4-chloro-N- (2-hydroxyethyl) pyridine-2-carboxamide (prepared according to A2 step 3b, 1.5g, 7.4mmol) in anhydrous DMF (7ml) was added triisopropylsilyl chloride (1.59g, 8.2mmol, 1.1 equiv.) and imidazole (1.12g, 16.4mmol, 2.2 equiv.). The resulting yellow solution was stirred at room temperature for 3 hours and then concentrated under reduced pressure. The residue was partitioned between water (10ml) and EtOAc (10 ml). The aqueous phase was extracted with EtOAc (3X 10 mL). The combined organic phases were dried (MgSO)4) And concentrated under reduced pressure to give 4-chloro-N- (2-triisopropylsilyloxy) ethylpyridine-2-carboxamide as an orange oil (2.32g, 88%). This material was used directly in the next step without purification.
Figure A0080268500491
Step 2: 4- (4- (2- (N- (2-triisopropylsilyloxy) ethylcarbamoyl) pyridyloxyaniline
To a solution of 4-hydroxyaniline (0.70g, 6.0mmol) in anhydrous DMF (8ml) was added potassium tert-butoxide (0.67g, 6.0mmol, 1.0 equiv.) in one portion, resulting inExothermic. After the mixture was cooled to room temperature, a solution of 4-chloro-N- (2-triisopropylsilyloxy) ethylpyridine-2-carboxamide as an orange oil (2.32g, 6mmol, 1 eq) in DMF (4ml) was added followed by K2CO3(0.42g, 3.0mmol, 0.50 equiv.). The resulting mixture was heated at 80 ℃ overnight. Potassium tert-butoxide (0.34g, 3mmol, 0.5 eq.) was added again and the mixture heated at 80 ℃ for an additional 4 hours. The mixture was cooled to 0 ℃ with an ice bath and then water (ca. 1ml) was slowly added dropwise. The organic layer was extracted with EtOAc (3X 10 mL). The combined organic layers were washed with saturated NaCl solution (20ml) and dried (MgSO)4) And concentrating under reduced pressure. By column chromatography (SiO)230% EtOAc/70% petroleum ether) to give 4- (4- (2- (N- (2-triisopropylsilyloxy) ethylcarbamoyl) pyridyloxyaniline as a clear, light brown oil (0.99g, 38%).
A18: 2-pyridine carboxylate is synthesized by oxidation of 2-methylpyridine. Synthesis of 4- (5- (2-methoxycarbonyl) pyridyloxy) aniline
Step 1: 4- (5- (2-methyl) pyridyloxy) -1-nitrobenzene
5-hydroxy-2-methylpyridine (10.0g, 91.6mmol), 1-fluoro-4-nitrobenzene (9.8ml, 91.6mmol, 1.0 eq), K2CO3(25g, 183mmol, 2.0 equiv.) A mixture in DMF (100ml) was refluxed overnight. The resulting mixture was cooled to room temperature, water (200ml) was added and extracted with EtOAc (3X 100 ml). The combined organic phases were washed with water (2X 100ml) and saturated NaCl solution (100ml) and dried (MgSO 4)4) Then, concentrated under reduced pressure to give 4- (5- (2-methyl) pyridyloxy) -1-nitrobenzene as a brown solid (12.3 g).
Step 2: synthesis of 4- (5- (2-methoxycarbonyl) pyridyloxy) -1-nitrobenzene
A mixture of 4- (5- (2-methyl) pyridyloxy) -1-nitrobenzene (1.70g, 7.39mmol) and selenium dioxide (2.50g, 22.2mmol, 3.0 eq) in pyridine (20ml) was refluxed for 5 hours and then cooled to room temperature. The resulting slurry was filtered and concentrated under reduced pressure. The residue is dissolved in MeOH (100 ml). Concentrated hydrochloric acid (7ml) was added to the solution, refluxed for 3 hours, cooled to room temperature and concentrated under reduced pressure. The residue was partitioned between EtOAc (50ml) and 1NNaOH (50 ml). The aqueous layer was extracted with EtOAc (2X 50 mL). The combined organic phases were washed with water (2X 50ml) and saturated NaCl solution (50ml) and dried (MgSO 4)4) And concentrating under reduced pressure. Column chromatography (SiO)250% EtOAc/50% hexane) to give 4- (5- (2-methoxycarbonyl) pyridyloxy) -1-nitrobenzene (0.70 g).
Figure A0080268500501
And step 3: synthesis of 4- (5- (2-methoxycarbonyl) pyridyloxy) aniline
A mixture of 4- (5- (2-methoxycarbonyl) pyridyloxy) -1-nitrobenzene (0.50g) and 10% Pd/C (0.050g) in EtOAc (20ml) was placed under a hydrogen atmosphere (balloon) overnight. The resulting mixture was filtered through Celite sieves and the filtrate was concentrated under reduced pressure. By column chromatography ((SiO)270% EtOAc/30% hexane) to give 4- (5- (2-methoxycarbonyl) pyridyloxy) aniline (0.40 g).
A19: synthesis of omega-sulfonyl phenyl aniline. Synthesis of 4- (4-methylsulfonylphenoxy) aniline
Figure A0080268500502
Step 1: 4- (4-methylsulfonylphenoxy) -1-nitrobenzene:
to a solution of 4- (4-methylthiophenoxy) -1-nitrobenzene (2.0g, 7.7mmol) in CH2Cl2To a 0 ℃ solution (75ml) was slowly added m-CPBA (57-86%, 4.0g), and the reaction was stirred at room temperature for 5 hours. To the reaction mixture was added 1N NaOH solution (25 ml). The organic phase was washed successively with 1N NaOH solution (25ml), water (25ml) and saturated NaCl solution (25ml), dried (MgSO)4) Then, the mixture was concentrated under reduced pressure to give 4- (4-methylsulfonylphenoxy) -1-nitrobenzene as a solid (2.1 g).
Step 2: 4- (4-methylsulfonylphenoxy) -1-aniline:
4- (4-Methylsulfonylphenoxy) -1-nitrobenzene was reduced to aniline according to the method of step 3A 18.
B. Synthesis of urea precursors
B1: from anilines by CDIGeneral procedure for the formation of isocyanates. Synthesis of 4-bromo-3- (trifluoromethyl) phenyl isocyanate
Figure A0080268500511
Step 1: synthesis of 4-bromo-3- (trifluoromethyl) aniline HCl salt
To 4-bromo-3- (trifluoromethyl) aniline (64g, 267mmol) in Et2O (500ml) solution HCl solution (1M Et) was added dropwise2O solution, 300ml), the resulting mixture was stirred at room temperature for 16 hours. The pink-white precipitate formed is filtered off and Et2O (50ml) gave 4-bromo-3- (trifluoromethyl) aniline HCl salt (73g, 98%).
Figure A0080268500512
Step 2: synthesis of 4-bromo-3- (trifluoromethyl) phenyl isocyanate
To a suspension of 4-bromo-3- (trifluoromethyl) aniline HCl salt (36.8g, 133mmol) in toluene (278ml) was added dropwise trichloromethyl chloroformate and the resulting mixture was refluxed for 18 hours. The resulting mixture was concentrated under reduced pressure. Toluene (500ml) was added to the residue, and the mixture was concentrated under reduced pressure. Adding CH to the residue2Cl2(500ml), concentrated under reduced pressure. Repeat CH2Cl2Work-up/concentration step to give an amber oil which was left at-20 ℃ for 16 h to give 4-bromo-3- (trifluoromethyl) phenyl isocyanate as a brown solid (35.1g, 86%): GC-MS M/z 265 (M)+)。
C. Method for forming urea
C1 a: general procedure for the synthesis of ureas from the reaction of isocyanates with anilines. Synthesis of N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea
To 4-chloro-3- (trifluoromethyl) phenyl isocyanate (14.60g, 65.90mmol) in CH at 0 deg.C2Cl2(35ml) 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline (method A2, step 4, 16.0g, 65.77mmol) in CH solution was added dropwise2Cl2(35ml) suspension. The resulting mixture was stirred at room temperature for 72 hours. The yellow solid formed is filtered off and washed with CH2Cl2Washed (2X 30ml) and dried under reduced pressure (ca.1 mmHg) to give N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea as a beige solid (28.5g, 93%): mp.207-209 ℃;1H-NMR(DMSO-d6)δ2.77(d，J＝4.8Hz，3H)，7.16(m，3H)，7.37(d，J＝2.5Hz，1H)，7.62(m，4H)，8.11(d，J＝2.5Hz，1H)，8.49(d，J＝5.5Hz，1H)，8.77(brd，1H)，8.99(s，1H)，9.21(s，1H)；HPLC ES-MS m/z 465(M＋H)+)。
c1 b: general procedure for the synthesis of ureas from the reaction of isocyanates with anilines. Synthesis of N- (4-bromo-3- (trifluoromethyl) phenyl) -N' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea
Figure A0080268500521
To 4-bromo-3- (trifluoromethyl) phenyl isocyanate (step 2, 8.0g, 30.1mmol of method B1) at 0 deg.C was added CH2Cl2(80ml) 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline (method A2, step 4, 7.0g, 28.8mmol) in CH solution was added dropwise2Cl2(40ml) suspension. The resulting mixture was stirred at room temperature for 16 hours. The yellow solid formed is filtered off and washed with CH2Cl2(2X 50ml) and dried at 40 ℃ under reduced pressure (about 1mmHg) to give N- (4-bromo-3- (trifluoromethyl) phenyl) -N' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea as a pale yellow solid (13.2g, 90%): mp.203-205 ℃;1H-NMR(DMSO-d6)δ2.77(d，J＝4.8Hz，3H)，7.16(m，3H)，7.37(d，J＝2.5Hz，1H)，7.58(m，4H)，7.77(d，J＝8.8Hz，1H)，8.11(d，J＝2.5Hz，1H)，8.49(d，J＝5.5Hz，1H)，8.77(brd，1H)，8.99(s，1H)，9.21(s，1H)；HPLCES-MS m/z 509(M＋H)+)。
C1C: general procedure for the synthesis of ureas from the reaction of isocyanates with anilines. Synthesis of N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (2-methyl-4- (2- (N-methylcarbamoyl) (4-pyridyloxy) phenyl) urea
Figure A0080268500522
To 2-methyl-4- (2- (N-methylcarbamoyl) (4-pyridyloxy) aniline (process)A5; 0.11g, 0.45mmol) of CH2Cl2(1ml) to the solution Et was added3N (0.16ml) and 4-chloro-3- (trifluoromethyl) phenyl isocyanate (0.10g, 0.45 mmol). The resulting brown solution was stirred at room temperature for 6 hours, then water (5ml) was added. The aqueous phase was back extracted with EtOAc (3X 5 mL). The combined organic phases were dried (MgSO)4) Then, the mixture was concentrated under reduced pressure to give N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (2-methyl-4- (2- (N-methylcarbamoyl) (4-pyridyloxy) phenyl) urea as a brown oil (0.11g, 0.22 mmol):1H-NMR(DMSO-d6)δ2.27(s，3H)，2.77(d，J＝4.8Hz，3H)，7.03(d，J＝2.6Hz，1H)，7.11(d，J＝2.9Hz，1H)，7.15(dd，J＝5.5，2.6Hz，1H)，7.38(d，J＝2.6Hz，1H)，7.62(appd，J＝2.6Hz，2H)，7.84(d，J＝8.8Hz，1H)，8.12(s，1H)，7.37(d，J＝2.5Hz，1H)，7.58(m，4H)，7.77(d，J＝8.8Hz，1H)，8.11(d，J＝2.5Hz，1H)，8.50(d，J＝5.5Hz，1H)，8.78(q，J＝5.2Hz，1H)，9.52(s，1H)；HPLC ES-MS m/z 479(M＋H)+)。
c1 d: general procedure for the synthesis of ureas from the reaction of isocyanates with anilines. Synthesis of N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4-aminophenyl) urea
To 4-chloro-3- (trifluoromethyl) phenyl isocyanate (2.27g, 10.3mmol) in CH2Cl2To the solution (308ml) was added p-phenylenediamine (3.32g, 30.7mmol) in one portion. The resulting mixture was stirred at room temperature for 1 hour, CH was added2Cl2(100ml), concentrated under reduced pressure. The pink solid formed was dissolved in a mixture of EtOAc (110ml) and MeOH (15ml) and the clear solution was washed with 0.05N HCl. The organic layer was concentrated under reduced pressure to give impure N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4-aminophenyl) urea (3.3 g): TLC (100% EtOAc) Rf0.72。
C1 e: general procedure for the synthesis of ureas from the reaction of isocyanates with anilines. Synthesis of N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4-ethoxycarbonylphenyl) urea
Figure A0080268500532
To ethyl 4-isocyanatobenzoate (3.14g, 16.4mmol) in CH2Cl2(30ml) to the solution was addedIntroduction of 4-chloro-3- (trifluoromethyl) aniline (3.21g, 16.4mmol), the solution was stirred at room temperature overnight. The formed slurry is mixed with CH2Cl2Diluted (50ml) and filtered to give N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4-ethoxycarbonylphenyl) urea as a white solid (5.93g, 97%): TLC (40% EtOAc/60% hexane) Rf0.44。
C1 f: general procedure for the synthesis of ureas from the reaction of isocyanates with anilines. Synthesis of N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (3-carboxyphenyl) urea
Figure A0080268500541
To a solution of 4-chloro-3- (trifluoromethyl) phenyl isocyanate (1.21g, 5.46mmol) in 8ml) was added 4- (3-carboxyphenoxy) aniline (method A11, 0.81g, 5.76mmol), and the resulting mixture was stirred at room temperature overnight, followed by addition of MeOH (8ml) and stirring for an additional 2 hours. The resulting mixture was concentrated under reduced pressure. The resulting brown solid was triturated with 1: 1 EtOAc/hexanes to give N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (3-carboxyphenyl) urea as an off-white solid (1.21g, 76%).
C2 a: general procedure for the synthesis of urea by reaction of aniline with N, N' -carbonyldiimidazole, followed by addition of a second aniline. Synthesis of N- (2-methoxy-5- (trifluoromethyl) phenyl) -N' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea
Figure A0080268500542
To a solution of 2-methoxy-5- (trifluoromethyl) aniline (0.15g) in CH2Cl2To a solution (15ml) at 0 ℃ was added CDI (0.13 g). The resulting solution was allowed to warm to room temperature over 1 hour, stirred at room temperature for 16 hours, and then 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline (0.18g) was added. The resulting yellow solution was stirred at room temperature for 72 hours, then water (125ml) was added. The aqueous mixture was extracted with EtOAc (2X 150 mL). The combined organic phases were washed with saturated NaCl solution (100ml) and dried (MgSO)4) And concentrating under reduced pressure. The residue was triturated (90% EtOAc/10% hexane). The white solid formed was collected by filtration and washed with EtOAc. The filtrate was concentrated under reduced pressure and the remaining oil was purified by column chromatography (gradient: 33% EtOAc/67% hexane to 50% EtOAc/50% hexane) to giveN- (2-methoxy-5- (trifluoromethyl) phenyl) -N' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea as a beige solid (0.098g, 30%): TLC (100% EtOAc) Rf0.62；1H-NMR(DMSO-d6) δ 2.76(d, J ═ 4.8Hz, 3H), 3.96(s, 3H), 7.1-7.6 and 8.4-8.6(m, 11H), 8.75(d, J ═ 4.8Hz, 1H), 9.55(s, 1H); FAB-MS M/z 461((M + H)+)。
C2 b: general procedure for the synthesis of urea by reaction of aniline with N, N' -carbonyldiimidazole, followed by addition of a second aniline. A symmetrical urea as a by-product of the N, N' -carbonyldiimidazole reaction. Synthesis of bis (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea
Figure A0080268500551
Anhydrous CH of 3-amino-2-methoxyquinoline (0.14g) was stirred at 0 deg.C2Cl2(15ml) solution to which was added CDI (0.13 g). The resulting solution was allowed to warm to room temperature over 1 hour and stirred at room temperature for 16 hours. The resulting mixture was reacted with 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline (0.18 g). The resulting solution was stirred at room temperature for 72 hours, then water (125ml) was added. The aqueous mixture was extracted with EtOAc (2X 150 mL). The combined organic phases were washed with saturated NaCl solution (100ml) and dried (MgSO)4) And concentrating under reduced pressure. The residue was triturated (90% EtOAc/10% hexane). The white solid formed was collected by filtration and washed with EtOAc to give bis (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea (0.081g, 44%): TLC (100% EtOAc) Rf0.50；1H-NMR(DMSO-d6)δ2.76(d，J＝5.1Hz，6H)，7.1-7.6(m，12H)，8.48(d，J＝5.4Hz，1H)，8.75(d，J＝4.8Hz，2H)，8.86(s，2H)；HPLC ES-MS m/z 513((M＋H)+)。
C2C: general procedure for the synthesis of urea by reaction of aniline with isocyanate. Synthesis of N- (2-methoxy-5- (trifluoromethyl) phenyl) -N' - (4- (1, 3-dioxoisoindol-5-yloxy) phenyl) urea
Figure A0080268500552
To a solution of 2-methoxy-5- (trifluoromethyl) phenyl isocyanate (0.10g, 0.47mmol) in CH2Cl2To the solution (1.5ml) was added 5- (4-aminophenoxy) isoindol-1, 3-dione in one portion (method A3, step 3; 0.12g, 0.47 mmol).The resulting mixture was stirred for 12 hours, then CH was added2Cl2(10ml) and MeOH (5 ml). The resulting mixture was washed successively with 1N HCl solution (15ml) and saturated NaCl solution (15ml), dried (MgSO)4) And concentrated under reduced pressure to give N- (2-methoxy-5- (trifluoromethyl) phenyl) -N' - (4- (1, 3-dioxoisoindol-5-yloxy) phenyl) urea as a white solid (0.2g, 96%): TLC (70% EtOAc/30% hexane) Rf0.50；1H-NMR(DMSO-d6)δ3.95(s，3H)，7.31-7.10(m，6H)，7.57(d，J＝9.3Hz，1H)，7.80(d，J＝8.7Hz，1H)，8.53(brs，2H)，9.57(s，1H)，11.27(brs，1H)；HPLC 472.0((M＋H)+，100％)。
C2 d: general procedure for the synthesis of urea by reaction of aniline with N, N' -carbonyldiimidazole, followed by addition of a second aniline. Synthesis of N- (5-tert-butyl) -2- (2, 5-dimethylpyrrolyl) phenyl) -N' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea
Figure A0080268500561
CDI (0.2lg, 1.30mmol) in CH was stirred2Cl2(2ml) solution while adding 5- (tert-butyl) -2- (2, 5-dimethylpyrrolyl) aniline in one portion (method A4, step 2; 0.30g, 1.24 mmol). The resulting solution was stirred at room temperature for 4 hours, then 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline (0.065g, 0.267mmol) was added in one portion. The resulting mixture was heated at 36 ℃ overnight, then cooled to room temperature and diluted with EtOAc (5 mL). The resulting mixture was washed successively with water (15ml) and 1N HCl solution (15ml) and filtered through silica gel (50g) to give N- (5-tert-butyl) -2- (2, 5-dimethylpyrrolyl) phenyl) -N' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea as a yellow solid (0.033g, 24%): TLC (40% EtOAc/60% hexane) Rf0.24；1H-NMR (acetone-d)6)δ1.37(s，9H)，1.89(s，6H)，2.89(d，J＝4.8Hz，3H)，5.83(s，2H)，6.87-7.20(m，6H)，7.17(dd，1H)，7.51-7.58(m，3H)，8.43(d，J＝5.4Hz，1H)，8.57(d，J＝2.1Hz，1H)，8.80(brs，2H；HPLC ES-MS 512((M＋H)+，100％)。
C3: combined method for synthesizing diphenyl urea by using triphosgene
One of the anilines to be coupled was dissolved in dichloromethane (0.10M). This solution (0.5ml) was added to dichloromethane (1ml) in an 8ml test tube. To this was added bis (trichloromethyl) carbonate (0.12M in dichloromethane, 0.2ml, 0.4 eq) followed by diisopropylethylamine (0.35M in dichloromethane, 0.2ml, 1.2 eq). The tube was covered and heated at 80 ℃ for 5 hours, and after about 10 hours, it was cooled to room temperature. A second aniline (0.10M, 0.5ml, 1.0 equiv.) was added followed by diisopropylethylamine (0.35M in dichloromethane, 0.2ml, 1.2 equiv.). The resulting mixture was heated at 80 ℃ for 4h, cooled to room temperature and MeOH (0.5ml) was added. The resulting mixture was concentrated under reduced pressure and the product was purified by reverse phase HPLC.
C4: the general process for the synthesis of urea is carried out by reacting one aniline with phosgene and then adding a second aniline. N- (2-methoxy-5- (trifluoromethyl) phenyl) -N' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea
Figure A0080268500571
Stirring phosgene CH at 0 deg.C2Cl2(20ml) solution (1.9M in toluene, 2.07ml, 0.21g, 1.30mmol) was added along with pyridine (0.32ml) followed by 2-methoxy-5- (trifluoromethyl) aniline (0.75 g). The yellow solution was allowed to warm to room temperature during which time a precipitate formed. The yellow mixture was stirred for 1 hour and then concentrated under reduced pressure. The resulting solid was treated with toluene (20ml), 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline (prepared according to method A2, 0.30g) was then added, and the resulting suspension was heated at 80 ℃ for 20 hours and then cooled to room temperature. The resulting mixture was diluted with water (100ml) and made basic with sodium bicarbonate (2-3 ml). The basic solution was extracted with EtOAc (2X 250 ml). The organic layers were washed with saturated NaCl solution, respectively, then combined and dried (MgSO)4) And concentrating under reduced pressure. The pink-brown residue formed is dissolved in MeOH and adsorbed to SiO2(100g) The above. Column chromatography (300g, SiO)2(ii) a Gradient: 1% Et3N/33% EtOAc/66% hexane to 1% Et3N/99% EtOAc to 1% Et3N/20% MeOH/79% EtOAc), then concentrated at 45 ℃ under reduced pressure to give a warm concentrated EtOAc solution which, upon treatment with hexane (10ml), slowly formed crystals, i.e., N- (2-methoxy-5- (trifluoromethyl) phenyl) -N' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) urea (0.44 g): TLC (1% Et)3N/99％EtOAc)Rf0.40。
D. Interconversion of ureas
D1 a: conversion of omega-aminophenyl urea to omega- (aroylamino) phenyl urea. Synthesis of N- (4-chloro-3- ((trifluoromethyl) phenyl) -N' - (4- (3-methoxycarbonylphenyl) carboxyaminophenyl) urea
To 4-chloro-3- ((trifluoromethyl) phenyl) -N' - (4-aminophenyl) urea (method C1 d; 0.050g, 1.52mmol), monomethyl isophthalate (0.25g, 1.38mmol), HOBT. H2A solution of O (0.41g, 3.03mmol) and N-methylmorpholine (0.33ml, 3.03mmol) in DMF (8ml) was added EDCI. HCl (0.29g, 1.52 mmol). The resulting mixture was stirred overnight at room temperature, diluted with EtOAc (25mL), and then with water (25mL) followed by saturated NaHCO3The solution (25ml) was washed. The organic layer was dried (Na)2SO4) And concentrating under reduced pressure. The resulting solid was triturated with EtOAc solution (80% EtOAc/20% hexane) to give N- (4-chloro-3- ((trifluoromethyl) phenyl) -N' - (4- (3-methoxycarbonylphenyl) carboxyaminophenyl) urea (0.27g, 43%): mp 121-122; TLC (80% EtOAc/20% hexane) R%f0.75。
D1 b: conversion of omega-carboxyphenylurea to omega- (arylcarbamoyl) phenylurea. Synthesis of N- (4-chloro-3- ((trifluoromethyl) phenyl) -N' - (4- (3-methylcarbamoylphenyl) carbamoylphenyl) urea
To N- (4-chloro-3- ((trifluoromethyl) phenyl) -N' - (4- (3-methoxycarbonylphenyl) carboxyaminophenyl) urea (0.14g, 0.48mmol), 3-methylcarbamoylaniline (0.080g, 0.53mmol), HOBT. H.sub.2EDCI. HC was added to a solution of O (0.14g, 1.07mmol) and N-methylmorpholine (0.5ml, 1.07mmol) in DMF (3ml)l (0.10g, 0.53 mmol). The resulting mixture was allowed to warm to room temperature and stirred overnight. To the resulting mixture was added water (10ml), followed by extraction. The organic layer was concentrated under reduced pressure. The resulting yellow solid was dissolved in EtOAc (3mL) and then washed with silica gel (17g, gradient: 70% EtOAc/30% hexanes to 10% MeOH/90% EtOAc) to afford N- (4-chloro-3- ((trifluoromethyl) phenyl) -N' - (4- (3-methylcarbamoylphenyl) carbamoylphenyl) urea (0.097g, 41%): mp 225-229; TLC (100% EtOAc) Rf0.23。
D1 c: a combined process for the conversion of omega-carboxyphenylurea to omega- (arylcarbamoyl) phenylurea. Synthesis of N- (4-chloro-3- ((trifluoromethyl) phenyl) -N' - (4- (N- (3- (N- (3-pyridinyl) carbamoyl) phenyl) carbamoylphenyl) urea
Figure A0080268500591
N- (4-chloro-3- ((trifluoromethyl) phenyl) -N '- (3-carboxyphenyl) urea (method C1 f; 0.030g, 0.067mmol) and N-cyclohexyl-N' - (methyl polystyrene) carbodiimide (55mg) were combined in 1, 2-dichloromethane (1ml) and 3-aminopyridine CH was added2Cl2Solution (1M; 0.074ml, 0.074 mmol). (if no dissolution or turbidity occurs, a small amount of DMSO may be added). The resulting mixture was heated at 36 ℃ overnight. THF (1ml) was then added to the cloudy reaction solution and heating was continued for 18 hours. To the resulting mixture was added poly (4- (isocyanatomethyl) styrene) (0.040g), and the resulting mixture was stirred at 36 ℃ for 72 hours, then cooled to room temperature and filtered. The resulting solution was filtered through silica gel (1 g). Concentrating under reduced pressure to obtain N- (4-chloro-3- ((trifluoromethyl) phenyl) -N' - (4- (N- (3- (N- (3-pyridyl) carbamoylphenyl) carbamoyl) phenyl) urea (0.024g, 59%): TLC (70% EtOAc/30% hexane) Rf0.12。
D2: conversion of omega-alkoxycarbonylaryl ureas to omega-carbamoylaryl ureas. Synthesis of N- (4-chloro-3- ((trifluoromethyl) phenyl) -N' - (4- (3-methylcarbamoylphenyl) carboxyaminophenyl) urea.
Figure A0080268500592
To a sample of N- (4-chloro-3- ((trifluoromethyl) phenyl) -N' - (4- (3-methoxycarbonylphenyl) carboxyaminophenyl) ureaTo sample (0.17g, 0.34mmol) was added methylamine (2M in THF; 1ml, 1.7mmol) and the resulting mixture was stirred overnight at room temperature and then concentrated under reduced pressure to give N- (4-chloro-3- ((trifluoromethyl) phenyl) -N' - (4- (3-methylcarbamoylphenyl) carboxyamidophenyl) urea as a white solid, mp.247, TLC (100% EtOAc) Rf0.35。
D3: conversion of omega-alkoxycarbonylaryl ureas to omega-carboxycarbonylaryl ureas. Synthesis of N- (4-chloro-3- ((trifluoromethyl) phenyl) -N' - (4-carboxyphenyl) urea.
Figure A0080268500593
To a slurry of N- (4-chloro-3- ((trifluoromethyl) phenyl) -N '- (4-ethoxycarbonylphenyl) urea (method C1 e; 5.93g, 15.3mmol) in MeOH (75ml) was added aqueous KOH (2.5N, 10ml, 23 mmol.) the resulting mixture was heated at reflux for 12 h, cooled to room temperature, concentrated under reduced pressure, the residue was diluted with water (50ml) and then adjusted to pH2-3 with 1N HCl solution the solid formed was collected and dried under reduced pressure to give N- (4-chloro-3- ((trifluoromethyl) phenyl) -N' - (4-carboxyphenyl) urea as a white solid (5.05g, 92%).
D4: conversion of omega-alkoxy esters to omega-alkyl amides. Synthesis of N- (4-chloro-3- ((trifluoromethyl) phenyl) -N' - ((4- (3- (5- (2-dimethylaminoethyl) carbamoyl) pyridinyl) oxyphenyl) urea.
Figure A0080268500601
Step 1: synthesis of N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - ((4- (3- (5-carboxypyridinyl) oxyphenyl) urea
Preparation of N- (4-chloro-3- (trifluoromethyl) phenyl) -N '- ((4- (3- (5-methoxycarbonylpyridinyl) oxyphenyl) urea, N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - ((4- (3- (5-methoxycarbonylpyridinyl) oxyphenyl) urea) (0.26g, 0.56mmol) in MeOH (10ml) suspension from 4-chloro-3- (trifluoromethyl) phenyl isocyanate and 4- (3- (5-methoxycarbonylpyridinyl) oxyaniline (method A14, step 2) according to method C1a was treated with a solution of KOH (0.14g, 2.5mmol) in water (1ml), stirred at room temperature for 1 h. the resulting mixture was adjusted to pH5 with 1N HCl solution and the precipitate formed was filtered off, washed with water. The resulting solid solution in EtOH (10ml) was concentrated under reduced pressure to give a solution. The EtOH/concentration procedure was repeated twice to give N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - ((4- (3- (5-carboxypyridyl) oxyphenyl) urea (0.18g, 71%).
Figure A0080268500602
Step 2: synthesis of N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - ((4- (3- (5- (2-dimethylaminoethyl) carbamoyl) pyridyl) oxyphenyl) urea
N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - ((4- (3- (5-carboxypyridyl) oxyphenyl) urea (0.050g, 0.011mmol), N, N-dimethylethylenediamine (0.22mg, 0.17mmol), HOBT (0.028g, 0.17mmol), N-A mixture of methylmorpholine (0.035g, 0.28mmol) and EDCI. HCl (0.032g, 0.17mmol) in DMF (2.5ml) was stirred overnight at room temperature. The resulting solution was partitioned between EtOAc (50ml) and water (50 ml). The organic phase was washed with water (35ml) and dried (MgSO)4) And concentrating under reduced pressure. The residue was dissolved in a small amount of dichloromethane (about 2 ml). Et was added dropwise to the resulting solution2O to give N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - ((4- (3- (5- (2-dimethylaminoethyl) carbamoyl) pyridinyl) oxyphenyl) urea as a white precipitate (0.48g, 84%:1H NMR(DMSO-d6)δ2.10(s，6H)，3.26(s，H)，7.03(d，2H)，7.52(d，2H)，7.60(m，3H)，8.05(s，1H)，8.43(s，1H)，8.58(t，1H)，8.69(s，1H)，8.90(s，1H)，9.14(s，1H)；PHLC ES-MS m/z 522((M＋H)+)。
d5: general procedure for deprotection of N- (. omega. -siloxyalkyl) amides. Synthesis of N- (4-chloro-3- ((trifluoromethyl) phenyl) -N' - (4- (4- (2- (N- (2-hydroxy) ethylcarbamoyl) pyridyloxyphenyl) urea
To a solution of N- (4-chloro-3- ((trifluoromethyl) phenyl) -N' - (4- (4- (2- (N- (2-triisopropylsiloxy) ethylcarbamoyl) pyridyloxyphenyl) urea (prepared according to procedure C1 a; 0.25g, 0.37mmol) in anhydrous THF (2ml) was added tetrabutylammonium fluoride (1.0M in THF; 2 ml.) the mixture was stirred at room temperature for 5 minutes, then treated with water (10 ml.) the aqueous mixture was extracted with EtOAc (3X 10 ml.) the organic layers were combined and dried (MgSO 10)4) Decrease, decreaseAnd (5) concentrating under pressure. Column chromatography purification of the residue (SiO)2: gradient: 100% hexanes to 40% EtOAc/60% hexanes) to give N- (4-chloro-3- ((trifluoromethyl) phenyl) -N' - (4- (4- (2- (N- (2-hydroxy) ethylcarbamoyl) pyridyloxyphenyl) urea as a white solid (0.019g, 10%).
Synthesis of exemplary Compounds
(see tables for Compound Properties)
Compound 1: 4- (3-N-methylcarbamoylphenoxy) aniline, prepared according to method A13. The urea is formed by the reaction of C3, 3-tert-butylaniline with bis (trichloromethyl) carbonate and then with 4- (3-N-methylcarbamoylphenoxy) aniline.
Compound 2: the 4-fluoro-1-nitrobenzene reacts with p-hydroxyacetophenone according to step 1 of method A13 to obtain 4- (4-acetylphenoxy) -1-nitrobenzene. The 4- (4-acetylphenoxy) -1-nitrobenzene is reduced according to step 4 of method A13 to give 4- (4-acetylphenoxy) aniline. According to method C3, 3-tert-butylaniline was reacted with bis (trichloromethyl) carbonate and then with 4- (4-acetylphenoxy) aniline to form urea.
Compound 3: reaction of 3-tert-butylaniline with CDI according to procedure C2d followed by reaction with 4- (3-N-methylcarbamoyl-4-methoxyphenoxy) aniline (prepared according to procedure A8) formed urea.
Compound 4: 5-tert-butyl-2-methoxyaniline was converted into 5-tert-butyl-2-methoxyphenyl isocyanate according to method B1. 4- (3-N-methylcarbamoyl) aniline prepared according to method A13 is reacted with the isocyanate according to method C1a to form urea.
Compound 5: reaction of 5-tert-butyl-2-methoxyaniline with CDI according to procedure C2d, followed by reaction with 4- (3-N-methylcarbamoyl-4-methoxyphenoxy) aniline prepared according to procedure A8, leads to the formation of urea.
Compound 6: 5- (4-Aminophenoxy) isoindol-1, 3-dione is prepared according to method A3. The procedure is as described for 2d, 5-tert-butyl-2-methoxyaniline with CDI and then with 5- (4-aminophenoxy) isoindole-1, 3-dione to form urea.
Compound 7: synthesis of 4- (1-oxoisoindol-5-yloxy) aniline according to method A12. The procedure is followed as 2d, 5-tert-butyl-2-methoxyaniline with CDI and then with 4- (1-oxoisoindol-5-yloxy) aniline to form urea.
Compound 8: synthesis of 4- (3-N-methylcarbamoylphenoxy) aniline according to method A13. Following procedure C2a, 2-methoxy-5- (trifluoromethyl) aniline was reacted with CDI and then with 4- (3-N-methylcarbamoylphenoxy) aniline to form urea.
Compound 9: 2, 4-Hydroxyacetophenone was reacted with 2-chloro-5-nitropyridine to form 4- (4-acetylphenoxy) -5-nitropyridine according to procedure A3. 4- (4-Acetylphenoxy) -5-nitropyridine was reduced to 4- (4-acetylphenoxy) -5-aminopyridine according to method A8, step 4. 2-methoxy-5- (trifluoromethyl) aniline was converted to 2-methoxy-5- (trifluoromethyl) phenyl isocyanate according to method B1. The isocyanate was reacted with 4- (4-acetylphenoxy) -5-aminopyridine to form urea according to method C1.
Compound 10: 1, 4-fluoro-1-nitrobenzene was reacted with p-hydroxyacetophenone to form 4- (4-acetylphenoxy) -1-nitrobenzene according to procedure A13. 4- (4-Acetylphenoxy) -1-nitrobenzene was reduced to 4- (4-Acetylphenoxy) aniline according to method A13, step 4. The urea is formed by reaction of 5- (trifluoromethyl) -2-methoxybutylaniline with bis (trichloromethyl) carbonate and then with 4- (4-acetylphenoxy) aniline according to procedure C3.
Compound 11: synthesis of 4-chloro-N-methyl-2-pyridinecarboxamide according to procedure A2, step 3a, and reaction with 3-aminophenol according to procedure A2, step 4, using DMAC instead of DMF, gave 3- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline. According to method C4, 2-methoxy-5- (trifluoromethyl) aniline is reacted with phosgene and then with 3- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline to form urea.
Compound 12: the 4-chloropyridine-2-carbonyl chloride HCl salt was reacted with ammonia to form 4-chloro-2-pyridinecarboxamide according to procedure A2, step 3 b. Following method A2, step 4, 4-chloro-2-pyridinecarboxamide is reacted with 3-aminophenol using DMAC instead of DMF to form 3- (2-carbamoyl-4-pyridyloxy) aniline. According to method C2a, 2-methoxy-5- (trifluoromethyl) aniline is reacted with phosgene and then with 3- (2-carbamoyl-4-pyridyloxy) aniline to form urea.
Compound 13: synthesis of 4-chloro-N-methyl-2-pyridinecarboxamide according to procedure A2, step 3 b. Following method A2, step 4, 4-chloro-N-methyl-2-pyridinecarboxamide is reacted with 4-aminophenol using DMAC instead of DMF to form 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline. Following procedure C2a, 2-methoxy-5- (trifluoromethyl) aniline was reacted with CDI and then with 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline to form a urea.
Compound 14: the 4-chloropyridine-2-carbonyl chloroHCl salt was reacted with ammonia gas to form 4-chloro-2-pyridinecarboxamide according to procedure A2, step 3 b. Following method A2, step 4, 4-chloro-2-pyridinecarboxamide is reacted with 4-aminophenol using DMAC instead of DMF to form 4- (2-carbamoyl-4-pyridyloxy) aniline. According to method C4, 2-methoxy-5- (trifluoromethyl) aniline is reacted with phosgene and then with 4- (2-carbamoyl-4-pyridyloxy) aniline to form urea.
Compound 15: reaction of 5- (trifluoromethyl) -2-methoxyaniline with CDI according to procedure C2d, followed by reaction with 4- (3- (N-methylcarbamoyl) -4-methoxyphenoxy) aniline prepared according to procedure A8 led to the formation of urea.
Compound 16: synthesis of 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-methylaniline according to method A5. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-methylaniline to form a urea according to method C1C.
Compound 17: synthesis of 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-chloroaniline according to method A6. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-chloroaniline to form a urea according to method C1 a.
Compound 18: step 4, 5-amino-2-methylphenol according to method A2 was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide synthesized according to method A2, step 3b to form 3- (2- (N-methylcarbamoyl) -4-pyridyloxy) -4-methylaniline. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 3- (2- (N-methylcarbamoyl) -4-pyridyloxy) -4-methylaniline to form a urea according to method C1 a.
Compound 19: 4-Chloropyridine-2-carbonyl chloride was reacted with ethylamine as in procedure A2 step 3 b. The 4-chloropyridine-N-ethyl-2-pyridinecarboxamide formed was reacted with 4-aminophenol according to method A2 step 4 to form 4- (2- (N-ethylcarbamoyl) -4-pyridyloxy) aniline. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 4- (2- (N-ethylcarbamoyl) -4-pyridyloxy) aniline to form a urea according to method C1 a.
Compound 20: step 4, 4-amino-2-chlorophenol according to procedure A2 was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, synthesized according to procedure A2, step 3b, to form 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -3-chloroaniline. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -3-chloroaniline to form a urea according to method C1 a.
Compound 21: 4- (4-Methylthiophenoxy) -1-nitrobenzene was oxidized to 4- (4-methylsulfonylphenoxy) -1-nitrobenzene according to method A19, step 1. The nitrobenzene was reduced to 4- (4-methylsulfonylphenoxy) aniline according to method A19, step 2. 5- (trifluoromethyl) -2-methoxyphenyl isocyanate was reacted with 4- (4-methylsulfonylphenoxy) aniline according to method C1a to form a urea.
Compound 22: 4- (3-carbamoylphenoxy) -1-nitrobenzene was reduced to 4- (3-carbamoylphenoxy) aniline according to method A15, step 4. 5- (trifluoromethyl) -2-methoxyphenyl isocyanate was reacted with 4- (3-carbamoylphenoxy) aniline according to method C1a to form urea.
Compound 23: synthesis of 5- (4-aminophenoxy) isoindol-1, 3-dione as procedure A3. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 5- (4-aminophenoxy) isoindole-1, 3-dione to form a urea according to method C1 a.
Compound 24: 4-chloropyridine-2-carbonyl chloride was reacted with dimethylamine in procedure A2, step 3 b. The 4-chloro-N, N-dimethyl-2-pyridinecarboxamide formed was reacted with 4-aminophenol according to method A2 step 4 to form 4- (2- (N, N-dimethylcarbamoyl) -4-pyridyloxy) aniline. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 4- (2- (N, N-dimethylcarbamoyl) -4-pyridyloxy) aniline to form a urea according to method C1 a.
Compound 25: synthesis of 4- (1-oxoisoindol-5-yloxy) aniline according to method A12. Following procedure C2d, 5- (trifluoromethyl) -2-methoxyaniline was reacted with CDI and then with 4- (1-oxoisoindol-5-yloxy) aniline to form a urea.
Compound 26: the reaction of 1, 4-hydroxyacetophenone with 4-fluoronitrobenzene to form 4- (4-acetylphenoxy) nitrobenzene is carried out according to method A13. The nitrobenzene is reduced to 4- (4-acetylphenoxy) aniline according to method A13 step 4, then converted to 4- (4- (1- (N-methoxy) iminoethyl) phenoxyaniline HCl salt according to method A16 5- (trifluoromethyl) -2-methoxyaniline is converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1 the isocyanate is reacted with 4- (4- (1- (N-methoxy) iminoethyl) phenoxyaniline HCl salt to form urea according to method C1 a.
Compound 27: synthesis of 4-chloro-N-methylpyridine-carboxamide according to procedure A2, step 3 b. The chloropyridine is reacted with 4-aminophenol to form 4- (4- (2- (N, -methylcarbamoyl) thiophenyl) aniline according to method A2 step 4. 5- (trifluoromethyl) -2-methoxyaniline is converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. the isocyanate is reacted with 4- (4- (2- (N-methylcarbamoyl) thiophenyl) aniline to form urea according to method C1 a.
Compound 28: synthesis of 5- (4-aminophenoxy) -2-methylisoindole-1, 3-dione according to method A9. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 5- (4-aminophenoxy) -2-methylisoindole-1, 3-dione according to method Cla to form a urea.
Compound 29: synthesis of 4-chloro-N-methylpyridine-carboxamide according to procedure A2, step 3 b. The chloropyridine is reacted with 3-aminophenol to form 3- (4- (2- (N-methylcarbamoyl) thiophenyl) aniline according to method A2 step 4. 5- (trifluoromethyl) -2-methoxyaniline is converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. the isocyanate is reacted with 3- (4- (2- (N, -methylcarbamoyl) thiophenyl) aniline to form urea according to method C1 a.
Compound 30: 4-Chloropyridine-2-carbonyl chloride was reacted with isopropylamine according to method A2, step 3 b. 4-chloro-N-isopropyl-2-pyridinecarboxamide was formed according to method A2, step 4. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1, which was reacted with 4-aminophenol to give 4- (2- (N-isopropylcarbamoyl) -4-pyridyloxy) aniline. The isocyanate was reacted with 4- (2- (N-isopropyl-carbamoyl-4-pyridylamino) aniline according to method Cla to form urea.
Compound 31: synthesis of 4- (3- (5-methoxycarbonyl) pyridyloxy) aniline according to method A14. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 4- (3- (5-methoxycarbonyl) pyridyloxy) aniline to form urea according to method C1 a. N- (5- (trifluoromethyl) -2-methoxyphenyl) -N' - (4- (3- (5-methoxycarbonylpyridinyl) oxy) phenyl) urea was saponified according to method 4D, step 1, and the resulting acid was coupled with 4- (2-aminoethyl) morpholine to form the amide according to method D4, step 2.
Compound 32: synthesis of 4- (3- (5-methoxycarbonyl) pyridyloxy) aniline according to method A14. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 4- (3- (5-methoxycarbonyl) pyridyloxy) aniline to form urea according to method C1 a. N- (5- (trifluoromethyl) -2-methoxyphenyl) -N' - (4- (3- (5-methoxycarbonylpyridinyl) oxy) phenyl) urea was saponified according to method 4D, step 1, and the resulting acid was coupled with methylamine to form the amide according to method D4, step 2.
Compound 33: synthesis of 4- (3- (5-methoxycarbonyl) pyridyloxy) aniline according to method A14. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 4- (3- (5-methoxycarbonyl) pyridyloxy) aniline to form urea according to method Cla. N- (5- (trifluoromethyl) -2-methoxyphenyl) -N' - (4- (3- (5-methoxycarbonylpyridinyl) oxy) phenyl) urea was saponified according to method 4D, step 1, and the resulting acid was coupled with N, N-dimethylethylenediamine to form an amide according to method D4, step 2.
Compound 34: synthesis of 4- (3-carboxyphenoxy) aniline according to method A11. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 4- (3-carboxyphenoxy) aniline according to method C1f to form N- (5- (trifluoromethyl) -2-methoxyphenyl) -N' - (3-carboxyphenyl) urea, which was coupled with 3-aminopyridine according to method D1C.
Compound 35: synthesis of 4- (3-carboxyphenoxy) aniline according to method A11. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 4- (3-carboxyphenoxy) aniline according to method C1f to form N- (5- (trifluoromethyl) -2-methoxyphenyl) -N' - (3-carboxyphenyl) urea, which was coupled with N- (4-fluorophenyl) piperazine according to method D1C.
Compound 36: synthesis of 4- (3-carboxyphenoxy) aniline according to method A11. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 4- (3-carboxyphenoxy) aniline according to method C1f to form N- (5- (trifluoromethyl) -2-methoxyphenyl) -N' - (3-carboxyphenyl) urea, which was coupled with 4-fluoroaniline according to method D1C.
Compound 37: synthesis of 4- (3-carboxyphenoxy) aniline according to method A11. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 4- (3-carboxyphenoxy) aniline according to method C1f to form N- (5- (trifluoromethyl) -2-methoxyphenyl) -N' - (3-carboxyphenyl) urea, which was coupled with 4- (dimethylamino) aniline according to method D1C.
Compound 38: synthesis of 4- (3-carboxyphenoxy) aniline according to method A11. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 4- (3-carboxyphenoxy) aniline according to method C1f to form N- (5- (trifluoromethyl) -2-methoxyphenyl) -N' - (3-carboxyphenyl) urea, which was coupled with 5-amino-2-methoxypyridine according to method D1C.
Compound 39: synthesis of 4- (3-carboxyphenoxy) aniline according to method A11. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 4- (3-carboxyphenoxy) aniline according to method C1f to form N- (5- (trifluoromethyl) -2-methoxyphenyl) -N' - (3-carboxyphenyl) urea, which was coupled with 4-morpholinoaniline according to method D1C.
Compound 40: synthesis of 4- (3-carboxyphenoxy) aniline according to method A11. 5- (trifluoromethyl) -2-methoxyaniline was converted to 5- (trifluoromethyl) -2-methoxyphenyl isocyanate according to method B1. The isocyanate was reacted with 4- (3-carboxyphenoxy) aniline according to method C1f to form N- (5- (trifluoromethyl) -2-methoxyphenyl) -N' - (3-carboxyphenyl) urea, which was coupled with N- (2-pyridyl) piperazine according to method D1C.
Compound 41: synthesis of 4- (3- (N-methylcarbamoyl) phenoxy) aniline according to method A13. 4-chloro-3- (trifluoromethyl) aniline was converted to isocyanate and then reacted with 4- (3- (N-methylcarbamoyl) phenoxy) aniline to form urea according to procedure C3.
Compound 42: synthesis of 4- (2-N-methylcarbamoyl-4-pyridyloxy) aniline according to method A2. According to method C1a, 4-chloro-3- (trifluoromethyl) phenyl isocyanate is reacted with 4- (2-N-methylcarbamoyl-4-pyridyloxy) aniline to form urea.
Compound 43: the 4-chloropyridine-2-carbonyl chloride HCl salt was reacted with ammonia to form 4-chloro-2-pyridinecarboxamide according to procedure A2, step 3 b. 4, 4-chloro-2-pyridinecarboxamide reacts with 4-aminophenol according to procedure A2 step to form 4- (2-carbamoyl-4-pyridyloxy) aniline. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (2-carbamoyl-4-pyridyloxy) aniline according to method C1a to form a urea.
Compound 44: the 4-chloropyridine-2-carbonyl chloride HCl salt was reacted with ammonia to form 4-chloro-2-pyridinecarboxamide according to procedure A2, step 3 b. 4, 4-chloro-2-pyridinecarboxamide reacts with 3-aminophenol according to procedure A2 step to form 3- (2-carbamoyl-4-pyridyloxy) aniline. According to method C1a, 4-chloro-3- (trifluoromethyl) phenyl isocyanate is reacted with 3- (2-carbamoyl-4-pyridyloxy) aniline to form urea.
Compound 45: synthesis of 4-chloro-N-methyl-2-pyridinecarboxamide according to method A2, step 3a, followed by reaction of amine method A2, step 4, with 3-aminophenol to form 3- (2- (N-methylcarbamoyl-4-pyridyloxy) aniline 4-chloro-3- (trifluoromethyl) phenyl isocyanate is reacted with 3- (2- (N-methylcarbamoyl-4-pyridyloxy) aniline to form urea according to method C1 a.
Compound 46: synthesis of 5- (4-aminophenoxy) isoindol-1, 3-dione as procedure A3. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 5- (4-aminophenoxy) isoindol-1, 3-dione to form a urea according to method C1 a.
Compound 47: synthesis of 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-methylaniline according to method A5. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 5- (4-aminophenoxy) isoindol-1, 3-dione to form a urea according to method C1C.
Compound 48: synthesis of 4- (3- (N-methylaminosulfonyl) phenyloxy) aniline according to method A15. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3- (N-methylaminosulfonyl) phenoxy) aniline to form urea according to method C1C.
Compound 49: synthesis of 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-chloroaniline according to method A6. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-chloroaniline to form urea according to procedure C1C.
Compound 50: step 4, 5-amino-2-methylphenol according to method A2 was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide prepared according to method A2, step 3b to form 3- (2- (N-methylcarbamoyl) -4-pyridyloxy) -4-methylaniline. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 3- (2- (N-methylcarbamoyl) -4-pyridyloxy) -4-methylaniline according to procedure C1C to form a urea.
Compound 51: 4-Chloropyridine-2-carbonyl chloride was reacted with ethylamine as in procedure A2 step 3 b. The 4-chloro-N-ethyl-2-pyridinecarboxamide formed was reacted with 4-aminophenol according to procedure A2, step 4, to form 4- (2- (N-ethylcarbamoyl) -4-pyridyloxy) aniline. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (2- (N-ethylcarbamoyl) -4-pyridyloxy) aniline according to method C1a to form a urea.
Compound 52: step 4, 4-amino-2-chlorophenol according to procedure A2 was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide prepared according to procedure A2, step 3b, to form 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -3-chloroaniline. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -3-chloroaniline according to procedure C1a to form a urea.
Compound 53: 4- (4-Methylthiophenoxy) -1-nitrobenzene was oxidized to 4- (4-methylsulfonylphenoxy) -1-nitrobenzene according to method A19, step 1. The nitrobenzene was reduced to 4- (4-methylsulfonylphenoxy) aniline according to method A19, step 2. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (4-methylsulfonylphenoxy) aniline according to method C1a to form a urea.
Compound 54: reaction of 1, 4-bromobenzenesulfonyl chloride with methylamine as in procedure A15 gave N-methyl-4-bromobenzenesulfonamide. N-methyl-4-bromobenzenesulfonamide was coupled with phenol to 4- (4- (N-methylsulfamoyl) phenoxy) benzene as per procedure A15, step 2. 4- (4- (N-Methylsulfamoyl) phenoxy) benzene was converted to 4- (4- (N-methylsulfamoyl) phenoxy) -1-nitrobenzene according to method A15, step 3. 4- (4- (N-Methylsulfamoyl) phenoxy) -1-nitrobenzene was reduced to 4- (4- (N-methylsulfamoyl) phenoxy) aniline according to method A15, step 4. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (4- (N-methylsulfamoyl) phenoxy) aniline to form urea according to method C1 a.
Compound 55: coupling of 1, 5-hydroxy-2-methylpyridine with 1-fluoro-4-nitrobenzene to form 4- (5- (2-methyl) pyridyloxy) -1-nitrobenzene according to procedure A18 step. The picoline was oxidized with a different carboxylic acid and then esterified to 4- (5- (2-methoxycarbonyl) pyridyloxy) -1-nitrobenzene as in method A18, step 2. The nitrobenzene was reduced to 4- (5- (2-methoxycarbonyl) pyridyloxy) aniline according to method A18, step 3. The nitrobenzene was reacted with 4-chloro-3- (trifluoromethyl) phenyl isocyanate to form urea according to method C1 a.
Compound 56: coupling of 1, 5-hydroxy-2-methylpyridine with 1-fluoro-4-nitrobenzene to form 4- (5- (2-methyl) pyridyloxy) -1-nitrobenzene according to procedure A18 step. The picoline was oxidized with a different carboxylic acid and then esterified to 4- (5- (2-methoxycarbonyl) pyridyloxy) -1-nitrobenzene as in method A18, step 2. The nitrobenzene was reduced to 4- (5- (2-methoxycarbonyl) pyridyloxy) aniline according to method A18, step 3. The aniline was reacted with 4-chloro-3- (trifluoromethyl) phenyl isocyanate to form N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4- (2-methoxycarbonyl) -5-pyridyloxy) phenyl) urea according to method C1 a. The methyl ester was reacted with methylamine as in method D2 to form N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4- (2-methoxycarbamoyl) -5-pyridyloxy) phenyl) urea.
Compound 57: n- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4-aminophenyl) urea was prepared according to step C1 d. N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4-aminophenyl) urea was coupled with monomethyl isophthalate to form urea according to method D1 a.
Compound 58: n- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4-aminophenyl) urea was prepared according to step C1 d. N- (4-chloro-3- (trifluoromethyl) phenyl) -N '- (4-aminophenyl) urea was coupled with monomethyl isophthalate according to method D1a to form N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4- (3-methoxycarbonylphenyl) carboxyaminophenyl) urea. N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4- (3-methoxycarbonylphenyl) carboxyaminophenyl) urea was reacted with methylamine to form the corresponding methylamide according to method D2.
Compound 59: 4-chloropyridine-2-carbonyl chloride was reacted with dimethylamine in procedure A2, step 3. The resulting 4-chloro-N-dimethyl-2-pyridinecarboxamide was reacted with 4-aminophenol according to procedure a2, step 4, to form 4- (2- (N, N-dimethylcarbamoyl) -4-pyridyloxy) aniline. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (2- (N, N-dimethylcarbamoyl) -4-pyridyloxy) aniline according to method C1a to form a urea.
Compound 60: 1, 4-Hydroxyacetophenone was reacted with 4-fluoronitrobenzene to form 4- (4-acetylphenoxy) nitrobenzene according to procedure A13. The nitrobenzene is reduced to 4- (4-acetylphenoxy) aniline according to method 13, step 4, and then converted to 4- (4- (1- (N-methoxy) iminoethyl) phenoxyaniline HCl salt according to method A16 4-chloro-3- (trifluoromethyl) phenyl isocyanate reacts with 4- (4-acetylphenoxy) aniline according to method C1a to form urea.
Compound 61: synthesis of 4- (3-carboxyphenoxy) -1-nitrobenzene according to procedure A13, step 2. Coupling of 4- (3-carboxyphenoxy) -1-nitrobenzene with 4- (2-aminoethyl) morpholine as in procedure A13 step 3 gave 4- (3- (N- (2-morpholinoethyl) carbamoyl) phenoxy) -1-nitrobenzene. 4- (3- (N- (2-morpholinoethyl) carbamoyl) phenoxy) -1-nitrobenzene was reduced to 4- (3- (N- (2-morpholinoethyl) carbamoyl) phenoxy) aniline according to method A13, step 4. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3- (N- (2-morpholinoethyl) carbamoyl) phenoxy) aniline according to method C1a to form urea.
Compound 62: synthesis of 4- (3-carboxyphenoxy) -1-nitrobenzene according to procedure A13, step 2. Coupling of 4- (3-carboxyphenoxy) -1-nitrobenzene with 1- (2-aminoethyl) pyridine formed 4- (3- (N- (2-pyridylethyl) carbamoyl) phenoxy) -1-nitrobenzene according to procedure A13 step 3. 4- (3- (N- (2-pyridylethyl) carbamoyl) phenoxy) -1-nitrobenzene was reduced to 4- (3- (N- (2-pyridylethyl) carbamoyl) phenoxy) aniline according to method A13, step 4. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3- (N- (2-pyridylethyl) carbamoyl) phenoxy) aniline to form urea according to method C1 a.
Compound 63: synthesis of 4- (3-carboxyphenoxy) -1-nitrobenzene according to procedure A13, step 2. Coupling of 4- (3-carboxyphenoxy) -1-nitrobenzene with tetrahydrofurfuryl amine according to procedure A13 step 3 formed 4- (3- (N- (2-tetrahydrofurylmethyl) carbamoyl) phenoxy) -1-nitrobenzene. 4- (3- (N- (2-tetrahydrofurylmethyl) carbamoyl) phenoxy) -1-nitrobenzene is reduced to 4- (3- (N- (2-tetrahydrofurylmethyl) carbamoyl) phenoxy) aniline according to method A13, step 4. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3- (N- (2-tetrahydrofurylmethyl) carbamoyl) phenoxy) aniline according to method C1a to form urea.
Compound 64: synthesis of 4- (3-carboxyphenoxy) -1-nitrobenzene according to procedure A13, step 2. Coupling of 4- (3-carboxyphenoxy) -1-nitrobenzene with 2-aminomethyl-1-ethylpyrrolidine as in procedure A13 step formed 4- (3- (N- ((1-methylpyrrolidinyl) methyl) carbamoyl) phenoxy) -1-nitrobenzene. 4- (3- (N- ((1-methylpyrrolidinyl) methyl) carbamoyl) phenoxy) -1-nitrobenzene was reduced to 4- (3- (N- ((1-methylpyrrolidinyl) methyl) carbamoyl) phenoxy) aniline according to method A13, step 4. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3- (N- ((1-methylpyrrolidinyl) methyl) carbamoyl) phenoxy) aniline to form urea according to procedure C1 a.
Compound 65: synthesis of 4-chloro-N-methylpyridine carboxamide according to procedure A2, step 3 b. The chloropyridine was reacted with 4-aminothiophenol according to method A2 step 4 to form 4- (4- (2- (N-methylcarbamoyl) thiophenyl) aniline 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (4- (2- (N-methylcarbamoyl) thiophenyl) aniline according to method C1a to form urea.
Compound 66: 4-chloro-2-carbonyl chloride was reacted with isopropylamine according to method A2, step 3 b. The 4-chloro-N-isopropyl-2-pyridinecarboxamide formed was reacted with 4-aminophenol according to method A2, step 4, to form 4- (2- (N-isopropylcarbamoyl) -4-pyridyloxy) aniline. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (2- (N-isopropylcarbamoyl) -4-pyridyloxy) aniline according to method C1a to form urea.
Compound 67: synthesis of N- (4-chloro-3- (trifluoromethyl) phenyl-N' - (4-ethoxycarbonylphenyl) urea by method C1e, by method D3, saponification of N- (4-chloro-3- (trifluoromethyl) phenyl-N ' - (4-ethoxycarbonylphenyl) urea to form N- (4-chloro-3- (trifluoromethyl) phenyl-N ' - (4-carboxyphenyl) urea in accordance with method D1b, coupling of N- (4-chloro-3- (trifluoromethyl) phenyl-N ' - (4-carboxyphenyl) urea with 3-methylcarbamoylaniline, n- (4-chloro-3- (trifluoromethyl) phenyl-N' - (4- (3-methylcarbamoylphenyl) carbamoylphenyl) urea is formed.
Compound 68: synthesis of 5- (4-aminophenoxy) -2-methylisoindole-1, 3-dione according to method A9. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 5- (4-aminophenoxy) -2-methylisoindole-1, 3-dione to form a urea according to procedure C1 a.
Compound 69: synthesis of 4-chloro-N-methylpyridine carboxamide according to procedure A2, step 3. The chloropyridine was reacted with 3-aminothiophenol according to method A2 step 4 to form 3- (4- (2- (N-methylcarbamoyl) thiophenyl) aniline 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 3- (4- (2- (N-methylcarbamoyl) thiophenyl) aniline according to method C1a to form urea.
Compound 70: synthesis of 4- (2- (N- (2-morpholin-4-ylethyl) carbamoyl) aniline according to method A10 4-chloro-3- (trifluoromethyl) -2-methoxyphenyl isocyanate was reacted with 4- (2- (N- (2-morpholin-4-ylethyl) carbamoyl) aniline according to method C1a to form urea.
Compound 71: synthesis of 4- (3- (5-methoxycarbonyl) pyridyloxy) aniline according to method A14. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3- (5-methoxycarbonyl) pyridyloxy) aniline according to method C1a to form a urea. N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4- (3- (5-methoxycarbonylpyridyl) oxy) phenyl) urea was saponified according to procedure D4, step 1, and the corresponding acid was coupled with 4- (2-aminoethyl) morpholine to form the amide.
Compound 72: synthesis of 4- (3- (5-methoxycarbonyl) pyridyloxy) aniline according to method A14. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3- (5-methoxycarbonyl) pyridyloxy) aniline according to method C1a to form a urea. N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4- (3- (5-methoxycarbonylpyridyl) oxy) phenyl) urea was saponified according to method D4, step 1 and the corresponding acid was coupled with methylamine to form the amide according to method D4, step 2.
Compound 73: synthesis of 4- (3- (5-methoxycarbonyl) pyridyloxy) aniline according to method A14. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3- (5-methoxycarbonyl) pyridyloxy) aniline according to method C1a to form a urea. N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4- (3- (5-methoxycarbonylpyridyl) oxy) phenyl) urea was saponified according to procedure D4, step 1 and the corresponding acid was coupled with N, N-dimethylethylenediamine to form an amide according to procedure D4, step 2.
Compound 74: the 4-chloropyridine-2-carbonyl chloride HCl salt was reacted with 2-hydroxyethylamine according to procedure A2 step 3b to form 4-chloro-N- (2-triisopropylsilyloxy) ethylpyridine-2-carboxamide. By the method A17, 4-chloro-N- (2-triisopropylsilyloxy) ethylpyridine-2-carboxamide is reacted with triisopropylsilylchloride, and then reacted with 4-aminophenol to form 4- (4- (2- (N- (2-triisopropylsilyloxy) ethylcarbamoylpyridyloxyaniline by method C1a, 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (4- (2- (N- (2-triisopropylsilyloxy) ethylcarbamoylpyridyloxybenzene to form N- (4-chloro-3- ((trifluoromethyl) phenyl-N' -4- (4- (2- (N- (2-triisopropylsilyloxy) ethylcarbamoylpyridyloxyphenyl) urea.
Compound 75: synthesis of 4- (3-carboxyphenoxy) aniline according to method A11. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3-carboxyphenoxy) aniline to form urea according to method C1f, which was then coupled with 3-aminopyridine according to method D1C.
Compound 76: synthesis of 4- (3-carboxyphenoxy) aniline according to method A11. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3-carboxyphenoxy) aniline to form urea according to procedure C1f, which was coupled with N- (4-acetylphenyl) piperazine according to procedure D1C.
Compound 77: synthesis of 4- (3-carboxyphenoxy) aniline according to method A11. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3-carboxyphenoxy) aniline to form urea according to procedure C1f, which was then coupled with 4-fluoroaniline according to procedure D1C.
Compound 78: synthesis of 4- (3-carboxyphenoxy) aniline according to method A11. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3-carboxyphenoxy) aniline to form urea according to procedure C1f, which was then coupled with 4- (dimethylamino) aniline according to procedure D1C.
Compound 79: synthesis of 4- (3-carboxyphenoxy) aniline according to method A11. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3-carboxyphenoxy) aniline to form urea according to method C1f, which was then coupled with N-phenylethylenediamine according to method D1C.
Compound 80: synthesis of 4- (3-carboxyphenoxy) aniline according to method A11. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3-carboxyphenoxy) aniline to form urea according to procedure C1f and coupled with 2-methoxyethylamine according to procedure D1C.
Compound 81: synthesis of 4- (3-carboxyphenoxy) aniline according to method A11. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3-carboxyphenoxy) aniline to form urea according to procedure C1f, which was then coupled with 5-amino-2-methoxypyridine according to procedure D1C.
Compound 82: synthesis of 4- (3-carboxyphenoxy) aniline according to method A11. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3-carboxyphenoxy) aniline to form urea according to procedure C1f, which was then coupled with 4-morpholinoaniline according to procedure D1C.
Compound 83: synthesis of 4- (3-carboxyphenoxy) aniline according to method A11. 4-chloro-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (3-carboxyphenoxy) aniline to form a urea according to procedure C1f, which was then coupled with N- (2-pyridyl) piperazine according to procedure D1C.
Compound 84: the 4-chloropyridine-2-carbonyl chloride HCl salt was reacted with 2-hydroxyethylamine according to procedure A2 step 3b to form 4-chloro-N- (2-triisopropylsilyloxy) ethylpyridine-2-carboxamide. 4-chloro-N- (2-triisopropylsilyloxy) ethylpyridine-2-carboxamide reacts with triisopropylsilylchloride and then with 4-aminophenol to form 4- (2- (N- (2-triisopropylsilyloxy) ethylcarbamoyl pyridyloxyaniline according to method A17 4-chloro-3- ((trifluoromethyl) phenyl-N' -4- (4- (2- (N- (2-triisopropylsilyloxy) ethylcarbamoyl) pyridyloxyphenyl) urea is formed by reacting 4-chloro-3- (trifluoromethyl) phenyl isocyanate with 4- (2- (N- (2-triisopropylsilyloxy) ethylcarbamoyl) pyridyloxybenzene according to method C1 a. The urea was deprotected according to method D5 to give N- (4-chloro-3- ((trifluoromethyl) phenyl-N' -4- (4- (2- (N- (2-hydroxy) ethylcarbamoyl) pyridyloxyphenyl) urea.
Compound 85: synthesis of 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline according to method A2. 4-bromo-3- (trifluoromethyl) aniline was converted to 4-bromo-3- (trifluoromethyl) phenyl isocyanate according to method B1. 4-bromo-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline according to procedure C1a to form a urea.
Compound 86: synthesis of 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-chloroaniline according to method A6. 4-bromo-3- (trifluoromethyl) aniline was converted to 4-bromo-3- (trifluoromethyl) phenyl isocyanate according to method B1. 4-bromo-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-chloroaniline to form urea according to procedure C1 a.
Compound 87: step 4, 4-amino-2-chlorophenol according to procedure A2 was reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, prepared according to procedure A2, step 3, to form 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -3-chloroaniline. 4-bromo-3- (trifluoromethyl) aniline was converted to 4-bromo-3- (trifluoromethyl) phenyl isocyanate according to method B1. 4-bromo-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -3-chloroaniline according to procedure C1a to form a urea.
Compound 88: 4-Chloropyridine-2-carbonyl chloride was reacted with ethylamine as in procedure A2 step 3 b. The 4-chloro-N-ethyl-2-pyridinecarboxamide formed was reacted with 4-aminophenol according to method A2 step 4 to form 4- (2- (N-ethylcarbamoyl) -4-pyridyloxy) -3-chloroaniline. 4-bromo-3- (trifluoromethyl) aniline was converted to 4-bromo-3- (trifluoromethyl) phenyl isocyanate according to method B1. 4-bromo-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (2- (N-ethylcarbamoyl) -4-pyridyloxy) -3-chloroaniline to form urea according to procedure C1 a.
Compound 89: synthesis of 4-chloro-N-methyl-2-pyridinecarboxamide according to method A2, step 3a, followed by reaction with 3-aminophenol according to method A2, step 4, to form 3- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline. 4-bromo-3- (trifluoromethyl) aniline was converted to 4-bromo-3- (trifluoromethyl) phenyl isocyanate according to method B1. 4-bromo-3- (trifluoromethyl) phenyl isocyanate was reacted with 3- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline according to procedure C1a to form a urea.
Compound 90: the 4, 5-amino-2-methylphenol, step A2, was then reacted with 4-chloro-N-methyl-2-pyridinecarboxamide, prepared according to step 3b, method A2, to form 3- (2- (N-methylcarbamoyl) -4-pyridyloxy) -4-methylaniline. 4-bromo-3- (trifluoromethyl) aniline was converted to 4-bromo-3- (trifluoromethyl) phenyl isocyanate according to method B1. 4-bromo-3- (trifluoromethyl) phenyl isocyanate was reacted with 3- (2- (N-methylcarbamoyl) -4-pyridyloxy) -4-methylaniline according to procedure C1a to form a urea.
Compound 91: 4-chloropyridine-2-carbonyl chloride was reacted with dimethylamine in procedure A2, step 3 b. The 4-chloro-N, N-dimethyl-2-pyridinecarboxamide formed was reacted with 4-aminophenol according to method A2 step 4 to form 4- (2- (N, N-dimethylcarbamoyl) -4-pyridyloxy) aniline. 4-bromo-3- (trifluoromethyl) aniline was converted to 4-bromo-3- (trifluoromethyl) phenyl isocyanate according to method B1. 4-bromo-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (2- (N, N-dimethylcarbamoyl) -4-pyridyloxy) aniline according to procedure C1a to form a urea.
Compound 92: synthesis of 4-chloro-N-methylpyridine carboxamide according to procedure A2, step 3 b. The chloropyridine is reacted with 4-aminothiophenol according to method A2 step 4 to form 4- (4- (2- (N-methylcarbamoyl) thiophenyl) aniline 4-bromo-3- (trifluoromethyl) phenyl isocyanate is converted according to method B1 and 4-bromo-3- (trifluoromethyl) phenyl isocyanate is reacted with 4- (4- (2- (N-methylcarbamoyl) thiophenyl) aniline according to method C1a to form urea.
Compound 93: synthesis of 4-chloro-N-methylpyridine carboxamide according to procedure A2, step 3 b. The chloropyridine is reacted with 3-aminothiophenol according to method A2 step 4 to form 3- (4- (2- (N-methylcarbamoyl) thiophenyl) aniline 4-bromo-3- (trifluoromethyl) phenyl isocyanate is converted according to method B1 and 4-bromo-3- (trifluoromethyl) phenyl isocyanate is reacted with 3- (4- (2- (N-methylcarbamoyl) thiophenyl) aniline according to method C1a to form urea.
Compound 94: synthesis of 4- (2- (N- (2-morpholin-4-ylethyl) carbamoyl) pyridyloxy) aniline according to method A10. 4-bromo-3- (trifluoromethyl) aniline was converted to 4-bromo-3- (trifluoromethyl) phenyl isocyanate according to method B1. According to method C1a, 4-bromo-3- (trifluoromethyl) phenyl isocyanate was reacted with 4- (2- (N- (2-morpholin-4-ylethyl) carbamoyl) pyridyloxy) aniline to form a urea.
Compound 95: synthesis of 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline according to method A2. Synthesis of 4-chloro-2-methoxy-5- (trifluoromethyl) aniline according to method A7. Following procedure B1, 4-chloro-2-methoxy-5- (trifluoromethyl) aniline was converted to 4-chloro-2-methoxy-5- (trifluoromethyl) phenyl isocyanate. According to method C1a, 4-chloro-2-methoxy 5- (trifluoromethyl) phenyl isocyanate is reacted with 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline to form urea.
Compound 96: synthesis of 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-chloroaniline according to method A6. Synthesis of 4-chloro-2-methoxy-5- (trifluoromethyl) aniline according to method A7. Following procedure B1, 4-chloro-2-methoxy-5- (trifluoromethyl) aniline was converted to 4-chloro-2-methoxy-5- (trifluoromethyl) phenyl isocyanate. According to method C1a, 4-chloro-2-methoxy 5- (trifluoromethyl) phenyl isocyanate is reacted with 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -2-chloroaniline to form urea.
Compound 97: step 4, 4-amino-2-chlorophenol according to procedure A2 was reacted with 4-chloro-2-pyridinecarboxamide prepared according to procedure A2, step 3b to form 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -3-chloroaniline. Synthesis of 4-chloro-2-methoxy-5- (trifluoromethyl) aniline according to method A7. Following procedure B1, 4-chloro-2-methoxy-5- (trifluoromethyl) aniline was converted to 4-chloro-2-methoxy-5- (trifluoromethyl) phenyl isocyanate. According to method C1a, 4-chloro-2-methoxy 5- (trifluoromethyl) phenyl isocyanate and 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) -3-chloroaniline were reacted to form urea.
Compound 98: the 4-chloro-N-methyl-2-pyridinecarboxamide prepared according to method A2, step 3a was reacted with 3-aminophenol according to method A2, step 4, to form 3- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline. Synthesis of 4-chloro-2-methoxy-5- (trifluoromethyl) aniline according to method A7. Following procedure B1, 4-chloro-2-methoxy-5- (trifluoromethyl) aniline was converted to 4-chloro-2-methoxy-5- (trifluoromethyl) phenyl isocyanate. According to method C1a, 4-chloro-2-methoxy 5- (trifluoromethyl) phenyl isocyanate and 3- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline are reacted to form urea.
Compound 99: 4-Chloropyridine-2-carbonyl chloride was reacted with ethylamine as in procedure A2 step 3 b. The 4-chloro-N-ethyl-2-pyridinecarboxamide formed was reacted with 4-aminophenol according to method A2 step 4 to form 4- (2- (N-ethylcarbamoyl) -4-pyridyloxy) aniline. Synthesis of 4-chloro-2-methoxy-5- (trifluoromethyl) aniline according to method A7. Following procedure B1, 4-chloro-2-methoxy-5- (trifluoromethyl) aniline was converted to 4-chloro-2-methoxy-5- (trifluoromethyl) phenyl isocyanate. According to method C1a, 4-chloro-2-methoxy 5- (trifluoromethyl) phenyl isocyanate and 4- (2- (N-ethylcarbamoyl) -4-pyridyloxy) aniline are reacted to form urea.
Compound 100: 4-chloropyridine-2-carbonyl chloride was reacted with dimethylamine in procedure A2, step 3 b. The 4-chloro-N, N-dimethyl-2-pyridinecarboxamide formed was reacted with 4-aminophenol according to method A2 step 4 to form 4- (2- (N, N-dimethylcarbamoyl) -4-pyridyloxy) aniline. Synthesis of 4-chloro-2-methoxy-5- (trifluoromethyl) aniline according to method A7. Following procedure B1, 4-chloro-2-methoxy-5- (trifluoromethyl) aniline was converted to 4-chloro-2-methoxy-5- (trifluoromethyl) phenyl isocyanate. According to method C1a, 4-chloro-2-methoxy 5- (trifluoromethyl) phenyl isocyanate was reacted with 4- (2- (N, N-dimethylcarbamoyl) -4-pyridyloxy) aniline to form urea.
Compound 101: 4-chloro-N-methyl-2-pyridinecarboxamide synthesized according to method A2, step 3a, was reacted with 3-aminophenol according to method A2, step 4, to form 3- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline. Synthesis of 2-amino-3-methoxynaphthalene according to method A1. According to method C3, 2-amino-3-methoxynaphthalene is reacted with bis (trichloromethyl) carbonate and then with 3- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline to form urea.
Compound 102: synthesis of 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline according to method A2. Synthesis of 5-tert-butyl-2- (2, 5-dimethylpyrrolyl) aniline according to method A4. Following procedure C2d, 5-tert-butyl-2- (2, 5-dimethylpyrrolyl) aniline was reacted first with CDI and then with 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline to form urea.
Compound 103: synthesis of 4-chloro-N-methyl-2-pyridinecarboxamide according to procedure A2, step 3 b. Following method A2, step 4, 4-chloro-N-methyl-2-pyridinecarboxamide with DMAC instead of DMF was reacted with 4-aminophenol to form 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline. Following procedure C2d, 3-amino-2-methoxyquinoline was reacted first with CDI and then with 4- (2- (N-methylcarbamoyl) -4-pyridyloxy) aniline to form bis (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea.
Listed in the following table are compounds synthesized according to the examples detailed above.
The compounds in tables 1-6 were prepared according to the general procedure above, with specific procedures as described above and characteristics as described in the tables.
TABLE 13 tert-butylphenyl ureas
Figure A0080268500762
Table 2: 5-tert-butyl-2-methoxyphenyl urea
Figure A0080268500763
Figure A0080268500764
Table 3: 5- (trifluoromethyl) -2-methoxyphenyl urea
Figure A0080268500773
Figure A0080268500781
Figure A0080268500791
Figure A0080268500801
Table 4: 3- (III)Fluoromethyl) -4-chlorophenyl urea
Figure A0080268500802
Figure A0080268500803
Figure A0080268500811
Figure A0080268500831
Table 5: 3- (trifluoromethyl) -4-bromophenylurea
Figure A0080268500851
Table 6: 5- (trifluoromethyl) -4-chloro-2-methoxyphenyl urea
Figure A0080268500853
Table 7: other ureas
Figure A0080268500854
Similar results were achieved with equal success if the reagents and/or reaction conditions outlined or specified were substituted for those used in the above examples.
In view of the foregoing, it will be seen that those skilled in the art are not aware of the fact that the invention is susceptible to particular embodiments and that various modifications may be made without departing from the spirit and scope of the invention to adapt it to various usages and conditions.

Claims (67)

1. A compound of the formula:
A-D-B (I) wherein D is-NH-C (O) -NH-,
a is a compound of the formula-L- (M-L)1)qHas less than 40 carbons, whereinL is a 5-6 membered ring directly linked to D, L1Is an at least 5-membered, substituted ring, M is a bridging group of at least one atom, q is an integer from 1 to 3; rings L and L1Each containing 0 to 4 nitrogen, oxygen or sulfur,
b is a substituted or unsubstituted, up to tricyclic, below 30-carbon aryl or heteroaryl radical in which at least one 6-membered ring is directly connected to D and contains 0 to 4 nitrogen, oxygen or sulfur,
wherein L is1Is at least one selected from-SO2Rx，-C(O)Rxand-C (NR)y)RzThe substituent (b) of (a) is substituted,
Ryis hydrogen, or a carbon skeleton group of 24 carbons or less, may contain heteroatoms selected from N, S and O, may be halogenated or up to perhalogenated,
Rzis hydrogen, or a carbon skeleton group of 30 or less carbons, which may contain heteroatoms selected from N, S and O, which may be substituted by halogen, hydroxy or another carbon skeleton group of 24 or less carbons, which may contain heteroatoms selected from N, S and O, and which may be halogenated;
Rxis RzOr NRaRbWherein R isaAnd RbIs that
a) Each of which is hydrogen, is a hydrogen atom,
carbon skeleton groups of 30 carbons or less, which may contain heteroatoms selected from N, S and O, which may be substituted by halogen, hydroxy and further carbon skeleton groups of 24 carbons or less, which may contain heteroatoms selected from N, S and O and which may be halogenated; or
-OSi(Rf)3，RfIs hydrogen or a carbon skeleton group of 24 carbons or less, may contain heteroatoms selected from N, S and O, may be substituted by halogen, hydroxy and a further carbon skeleton group of 24 carbons or less, may contain heteroatoms selected from N, S and O and may be halogenated; or
b)RaAnd RbTaken together to form a 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from N, S and O, or a 5-7 membered substituted heterocyclic ring containing 1-3 heteroatoms selected from N, S and O, and substituted with halogen, hydroxy or another 24 carbon or less carbon backbone group, which may contain heteroatoms selected from N, S and O and which may be halogenated; or
c)RaAnd RbOne of them being-C (O) -, C1-5Divalent alkylene radicals or C1-5Divalent substituted alkylene which is bonded to L to form a ring having at least 5 members, C1-5The substituent of the divalent substituted alkylene group is selected from halogen, hydroxyl and carbon skeleton group of 24 carbon or less, the substituent may contain hetero atom selected from N, S and O and may be halogenated;
wherein B is substituted, L is substituted, or L1Is further substituted with a substituent selected from the group consisting of halogen, perhalogenated, and Wn, n is 0 to 3;
w is each selected from-CN, -CO2R7，-C(O)NR7R7，-C(O)-R7，-NO2，-OR7-，-SR7，-NR7R7，-NR7C(O)OR7，-NR7C(O)R7Q-Ar and a carbon skeleton group of less than 24 carbons which may contain heteroatoms of N, S and O and which may be mono-or polysubstituted, the substituents being selected from the group consisting of-CN, -CO2R7，-C(O)-R7，-C(O)NR7R7，-OR7-，-SR7，-NR7R7，-NO2，-NR7C(O)R7，-NR7C(O)OR7And halo or to perhalo; each R7Carbon skeleton groups selected from H or less than 24 carbon, which may contain heteroatoms of N, S and O and which may be halogenated,
q is-O-, -S-, -N (R)7)-，-(CH2)m-，-C(O)-，-CH(OH)-，-(CH2)m-O-，-(CH2)m-S-，-(CH2)mN(R7)-，-O(CH2)m-，-CHXa-，-CXa 2-，-S-(CH2)m-, and-N (R)7)(CH2)m-, m ═ 1 to 3, XaIs halogen;
ar is a 5-or 6-membered aromatic structure containing 0 to 2 heteroatoms selected from nitrogen, oxygen and sulfur, which may be halogenated or up to perhalogenated, or by Zn1Substituted, n1 is 0 to 3, each Z is independently selected from-CN, -CO2R7，-C(O)R7，-C(O)NR7R7，-NO2，-OR7，-SR7，-NR7R7，-NR7C(O)OR7，-NR7C(O)R7And a carbon skeleton group of 24 carbons or less, which may contain hetero atoms of N, S and O and may be mono-or polysubstituted by halogen, the substituents being selected from the group consisting of-CN, -CO2R7，-COR7，-C(O)NR7R7，-OR7，-SR7，-NO2，-NR7R7，-NR7C(O)R7and-NR7C(O)OR7，R7As previously described.
2. A compound according to claim 1, wherein:
Ryis hydrogen, C1-10Alkyl radical, C1-10Alkoxy, C containing 0 to 3 hetero atoms3-10Cycloalkyl radical, C2-10Alkenyl radical, C1-10Alkenoyl radical, C6-12Aryl, C containing 1-3 hetero atoms of N, S or O3-12Heteroaryl group, C7-24Alkylaryl group, C7-24Aralkyl radical, C1-10Substituted alkyl radical, C1-10Substituted alkoxy, C containing 0-3 hetero atoms of N, S or O3-10Substituted cycloalkyl radical, C6-14Substituted aryl radicals, C containing 1-3 hetero N, S or O atoms3-12Substituted heteroaryl radical, C7-24Substituted alkylaryl or C7-24Substituted aralkyl, said RyMay be halogenated or up to perhalogenated,
Rzis hydrogen, C1-10Alkyl radical, C1-10Alkoxy, C containing 0 to 3 hetero atoms3-10Cycloalkyl radical, C2-10Alkenyl radical, C1-10Alkenoyl radical, C6-12Aryl, C containing 1-3 hetero atoms of N, S or O3-12Heteroaryl group, C7-24Alkylaryl group, C7-24Aralkyl radical, C1-10Substituted alkyl radical, C1-10Substituted alkoxy radical, C6-14Substituted aryl radicals, C containing 0-3 hetero N, S or O atoms3-10Substituted cycloalkyl, substituted C containing 1-3 hetero atoms of N, S or O3-12Heteroaryl group, C7-24Substituted alkylaryl or C7-24Substituted alkaryl radical, said RzMay be halogenated or up to perhalogenated, or substituted with: hydroxy radical, C1-10Alkyl, C containing 0-3 hetero atoms of N, S or O3-12Cycloalkyl, C containing 1-3 hetero atoms of N, S or O3-12Heteroaryl group, C1-10Alkoxy radical, C6-12Aryl, halo or to perhalo C1-6Alkyl, halo or to perhalo C6-12Aryl, halo or to perhalo C containing 0-3 hetero atoms of N, S or O3-12Cycloalkyl, halo or to perhalo C containing 1-3 hetero N, S or O atoms3-12Heteroaryl, halo or to perhalo C7-24Aralkyl or halo or to perhalo C7-24Alkylaryl, and-C (O) Rg，
RaAnd RbIs that
a) Each of which is hydrogen, is a hydrogen atom,
C1-10alkyl radical, C1-10Alkoxy radical, C3-10Cycloalkyl radical, C2-10Alkenyl radical, C1-10Alkenoyl radical, C6-12Aryl, C containing 1-3 hetero atoms of N, S or O3-12Heteroaryl, C containing 0-3 hetero atoms of N, S or O3-12Cycloalkyl radical, C7-24Alkylaryl group, C7-24Aralkyl radical, C1-10Substituted alkyl radical, C1-10Substituted alkoxy, C containing 0-3 hetero atoms of N, S or O3-10Alkyl radical, C6-12Substituted aryl radicals, C containing 1-3 hetero N, S or O atoms3-12Substituted heteroaryl radical, C7-24Substituted alkylaryl radical, C7-24Substituted aralkyl when RaAnd RbWhen substituted, the substituents are selected from: halo or to perhalo, hydroxy, C1-10Alkyl, C containing 0-3 hetero atoms of N, S or O3-12Cycloalkyl, C containing 1-3 hetero atoms of N, S or O3-12Heteroaryl group, C1-10Alkoxy radical, C6-12Aryl, halo or to perhalo C1-6Alkyl, halo or to perhalo C6-12Aryl, halo or to perhalo C containing 0-3 hetero atoms of N, S or O3-12Cycloalkyl, halo or to perhalo C containing 1-3 hetero N, S or O atoms3-12Heteroaryl, halo or to perhalo C7-24Aralkyl or halo or to perhalo C7-24Alkylaryl, and-C (O) Rg(ii) a Or
-OSi(Rf)3，RfIs hydrogen, C1-10Alkyl radical, C1-10Alkoxy, C containing 0-3 hetero atoms of N, S or O3-10Cycloalkyl radical, C6-12Aryl, C containing 1-3 hetero atoms of N, S or O3-12Heteroaryl group, C7-24Aralkyl radical, C1-10Substituted alkyl radical, C1-10Substituted alkoxy, C containing 0-3 hetero atoms of N, S or O3-12Substituted cycloalkyl, substituted C containing 1-3 hetero atoms of N, S or O3-12Heteroaryl group, C6-12Substituted aryl and C7-24Substituted alkylaryl, when RfWhen substituted, the substituents are selected from: halo or to perhalo, hydroxy, C1-10Alkyl, C containing 0-3 hetero atoms of N, S or O3-12Cycloalkyl, C containing 1-3 hetero atoms of N, S or O3-12Heteroaryl group, C1-10Alkoxy radical, C6-12Aryl radical, C7-24Alkylaryl group, C7-24Aralkyl, halo or to perhalo C1-6Alkyl, halo or to perhalo C6-12Aryl, halo or to perhalo C containing 0-3 hetero atoms of N, S or O3-12Cycloalkyl, halo or to perhalo C containing 1-3 hetero N, S or O atoms3-12Heteroaryl, halo or to perhalo C7-24Aralkyl or halo or to perhalo C7-24Alkylaryl, and-C (O) Rg(ii) a Or
b)RaAnd RbTogether form a 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from N, S and O, or a 5-7 membered substituted heterocyclic ring containing 1-3 heteroatoms selected from N, S and O, the substituents being selected from: halo or to perhalo, hydroxy, C1-10Alkyl, C containing 0-3 hetero atoms of N, S or O3-12Cycloalkyl, C containing 1-3 hetero atoms of N, S or O3-12Heteroaryl group, C1-10Alkoxy radical, C6-12Aryl radical, C7-24Alkylaryl group, C7-24Aralkyl, halo or to perhalo C1-6Alkyl, halo or to perhalo C6-12Aryl, halo or to perhalo C containing 0-3 hetero atoms of N, S or O3-12Cycloalkyl, halo or to perhalo C containing 1-3 hetero N, S or O atoms3-12Heteroaryl, halo or to perhalo C7-24Aralkyl, halo or to perhalo C7-24Alkylaryl, and-C (O) Rg(ii) a Or
c)RaAnd RbOne of them being-C (O) -, C1-5Divalent alkylene radicals or C1-5Divalent substituted alkylene which is bonded to L to form a ring having at least 5 members, C1-5The substituent of the divalent substituted alkylene is selected from halogen, hydroxyl, C1-10Alkyl, C containing 0-3 hetero atoms of N, S or O3-12Cycloalkyl, C containing 1-3 hetero atoms of N, S or O3-12Heteroaryl group, C1-10Alkoxy radical, C6-12Aryl radical, C7-24Alkylaryl group, C7-24Aralkyl, halo or to perhalo C1-6Alkyl, halo or to perhalo C6-12Aryl, halo or to perhalo C containing 0-3 hetero atoms of N, S or O3-12Cycloalkyl, halo or to perhalo C3-12Heteroaryl, halo or to perhalo C7-24Alkylaryl, halo or to perhalo C7-24Alkylaryl, and-C (O) Rg；
Wherein R isgIs C1-10Alkyl, -CN, -CO2Rd，-ORd-，-SRd，-NO2，-C(O)Rd，-NRdRe，-NRdC(O)ORe，-NRdC(O)Re，RdAnd ReEach is selected from H, C1-10Alkyl radical, C1-10Alkoxy, C containing 0-3 hetero atoms of N, S or O3-10Cycloalkyl radical, C6-12Aryl, C containing 1-3 hetero atoms of N, S or O3-12Heteroaryl group, C7-24Alkylaryl group, C7-24Aralkyl, halo or to perhalo C1-10Alkyl, halo or to perhalo C containing 0-3 hetero atoms of N, S or O3-10Cycloalkyl, halo or to perhalo C6-14Aryl, halo or to perhalo C containing 1-3 hetero atoms of N, S or O3-12Heteroaryl, halo or to perhalo C7-24Alkylaryl, halo or to perhalo C7-24An alkylaryl group,
w is each selected from-CN, -CO2R7，-C(O)NR7R7，-C(O)-R7，-NO2，-OR7-，-SR7，-NR7R7，-NR7C(O)OR7，-NR7C(O)R7，C1-10Alkyl radical, C1-10Alkoxy radical, C2-10Alkenyl radical, C1-10Alkenoyl, C containing 0-3 hetero atoms of N, S or O3-10Cycloalkyl radical, C6-14Aryl radical, C7-24Alkylaryl group, C7-24Aralkyl, C containing 1-3 hetero atoms of N, S or O3-12Heteroaryl, C containing 1-3 hetero atoms of N, S or O4-23Alkyl heteroaryl radical, C1-10Substituted alkyl radical, C1-10Substituted alkoxy radical, C2-10Substituted alkenyl, C1-10Substituted alkenoyl, C containing 0-3 hetero atoms of N, S or O3-10Substituted cycloalkyl radical, C6-12Substituted aryl radicals, C containing 1-3 hetero N, S or O atoms3-12Substituted heteroaryl radical, C7-24Substituted alkylaryl radical, C7-24Substituted alkaryl radicals, C containing 1-3 hetero atoms of N, S or O4-23Substituted alkylheteroaryl, and-Q-Ar;
R7selected from: h, C1-10Alkyl radical, C1-10Alkoxy radical, C1-10Alkoxy radical, C2-10Alkenyl radical, C1-10Alkenoyl, C containing 0-3 hetero atoms of N, S or O3-10Cycloalkyl radical, C6-14Aryl, C containing 1-3 hetero atoms of N, S or O3-13Heteroaryl group, C7-14Alkylaryl group, C7-24Aralkyl, C containing 1-3 hetero atoms of N, S or O4-23Alkylheteroaryl, halo or to perhalo C1-10Alkyl, halo or to perhalo C containing 0-3 hetero atoms of N, S or O3-10Cycloalkyl, halo or to perhalo C6-14Aryl, halo or to perhalo C containing 1-3 hetero atoms of N, S or O3-13Heteroaryl, halo or to perhalo C7-24Aralkyl, halo or to perhalo C7-24Alkylaryl, halo or to perhaloalkyl C4-23A heteroaryl group;
z is selected from-CN, -CO2R7，-C(O)-R7，-C(O)NR7R7，-NO2，-OR7-，-SR7，-NR7R7，-NR7C(O)OR7，-NR7C(O)R7，C1-10Alkyl radical, C1-10Alkoxy radical, C2-10Alkenyl radical, C1-10Alkenoyl, C containing 0-3 hetero atoms of N, S or O3-10Cycloalkyl radical, C6-14Aryl, C containing 1-3 hetero atoms of N, S or O3-13Heteroaryl group, C7-24Alkylaryl group, C7-24Aralkyl, C containing 1-3 hetero atoms of N, S or O4-23Alkyl heteroaryl radical, C1-10Substituted alkyl radical, C1-10Substituted alkoxy radical, C2-10Substituted alkenyl, C1-10Substituted alkenoylRadical, C containing 0-3 hetero atoms of N, S or O3-10Substituted cycloalkyl radical, C6-12Substituted aryl radicals, C7-24Substituted alkylaryl radical, C7-24Substituted aralkyl radicals, C containing 1-3 hetero atoms of N, S or O4-23Substituted alkylheteroaryl, when Z is mono-or polysubstituted, with substituents selected from: -CN, -CO2R7，-C(O)-R7，-C(O)NR7R7，-NO2，-OR7-，-SR7，-NR7R7，-NR7C(O)OR7，-NR7C(O)R7。
3. The compound of claim 1 wherein M is one or more bridging groups selected from the group consisting of: -O-, -S-, -N (R)7)-，-(CH2)m-，-C(O)-，-CH(OH)-，-(CH2)m-O-，-(CH2)m-S-，-(CH2)mN(R7)-，-O(CH2)m-，-CHXa-，-CXa 2-，-S-(CH2)m-, and-N (R)7)(CH2)m-, m ═ 1 to 3, XaIs halogen, R7As claimed in claim 1.
4. The compound of claim 1, wherein ring structures B and L directly connected to D are free of ortho-OH substitution.
5. The compound of claim 1, wherein the ring structures B and L directly attached to D are not capable of having a dissociable hydrogen with a pKa of 10 or less in the ortho position.
6. The compound of claim 1, wherein B in formula I is a substituted or unsubstituted 6-membered aromatic or 6-membered heteroaryl group, said heteroaryl group containing 1-4 heteroatoms selected from N, O and S, the remainder being carbon atoms.
7. A compound according to claim 1, wherein B in formula I is unsubstituted phenyl, unsubstituted pyridyl, unsubstituted pyrimidinyl, halo or Wn substituted phenyl, halo or Wn substituted pyridyl, halo or Wn substituted pyrimidinyl, wherein W and n are as defined in claim 1.
8. The compound of claim 6, wherein B in formula I is substituted phenyl, substituted pyrimidinyl, substituted pyridinyl, which are mono-to trisubstituted, and the substituents are selected from the group consisting of: -CN, halogen, C1-10Alkyl radical, C1-10Alkoxy, -OH, halo or to perhalo C1-10Alkyl, halo or to perhalo C1-10Alkoxy, halo or to perhalophenyl.
9. The compound of claim 1, wherein the 6-membered ring L to which D is attached is a substituted or unsubstituted 6-membered aromatic group, or a substituted or unsubstituted 6-membered heteroaryl group, said aryl group containing 1 to 4 heteroatoms selected from N, O and S, the remainder being carbon atoms, one or more of the substituents being halogen or Wn, wherein W and N are as defined in claim 1.
10. The compound of claim 8, wherein the 6-membered ring L to which D is attached is substituted or unsubstituted phenyl, substituted or unsubstituted pyrimidinyl, substituted or unsubstituted pyridyl.
11. The compound of claim 1, wherein the substituted ring L1Comprises aA 5-6 membered aryl or heteroaryl group containing 1-4 heteroatoms selected from N, O and S.
12. The compound of claim 1, wherein the substituted ring L1Is phenyl, pyridyl or pyrimidinyl.
13. The compound of claim 3, wherein the substituted ring L1Is phenyl, pyridyl or pyrimidinyl.
14. The compound of claim 6, wherein the substituted ring L1Is phenyl, pyridyl or pyrimidinyl.
15. The compound of claim 8, wherein the substituted ring L is1Is phenyl, pyridyl or pyrimidinyl.
16. The compound of claim 9, wherein the substituted ring L1Is phenyl, pyridyl or pyrimidinyl.
17. The compound of claim 10, wherein the substituted ring L1Is phenyl, pyridyl or pyrimidinyl.
18. The compound of claim 14 wherein M is one or more bridging groups selected from the group consisting of: -O-, -S-, -N (R)7)-，-(CH2)m-，-C(O)-，-CH(OH)-，-(CH2)m-O-，-(CH2)m-S-，-(CH2)mN(R7)-，-O(CH2)m-，-CHXa-，-CXa 2-，-S-(CH2)m-, and-N (R)7)(CH2)m-, m ═ 1 to 3, XaIs halogen, R7Is H or a carbon skeleton group of 24 carbons or less, which may contain heteroatoms selected from N, S and O, and may be halogenated or fully halogenated.
19. The compound of claim 15 wherein M is one or more bridging groups selected from the group consisting of: -O-, -S-, -N (R)7)-，-(CH2)m-，-C(O)-，-CH(OH)-，-(CH2)m-O-，-(CH2)m-S-，-(CH2)mN(R7)-，-O(CH2)m-，-CHXa-，-CXa 2-，-S-(CH2)m-, and-N (R)7)(CH2)m-, m ═ 1 to 3, XaIs halogen, R7Is H or a carbon skeleton group of 24 carbons or less, which may contain heteroatoms selected from N, S and O, and may be halogenated or fully halogenated.
20. The compound of claim 16 wherein M is one or more bridging groups selected from the group consisting of: -O-, -S-, -N (R)7)-，-(CH2)m-，-C(O)-，-CH(OH)-，-(CH2)m-O-，-(CH2)m-S-，-(CH2)mN(R7)-，-O(CH2)m-，-CHXa-，-CXa 2-，-S-(CH2)m-, and-N (R)7)(CH2)m-, m ═ 1 to 3, XaIs halogen, R7Is H or a carbon skeleton group of 24 carbons or less, which may contain heteroatoms selected from N, S and O, and may be halogenated or fully halogenated.
21. The compound of claim 17 wherein M is one or more bridging groups selected from the group consisting of: -O-, -S-, -N (R)7)-，-(CH2)m-，-C(O)-，-CH(OH)-，-(CH2)m-O-，-(CH2)m-S-，-(CH2)mN(R7)-，-O(CH2)m-，-CHXa-，-CXa 2-，-S-(CH2)m-, and-N (R)7)(CH2)m-, m ═ 1 to 3, XaIs halogen, R7Is H or a carbon skeleton group of 24 carbons or less, which may contain hetero atoms selected from N, S and OAnd may be halogenated or to perhalogenated.
22. The compound of claim 1, wherein L1May be mono-to trisubstituted, the substituents being selected from C1-10Alkyl, halo or to perhalo C1-10Alkyl, -CN, -OH, halogen, C1-10Alkoxy and haloOr to perhalogenated C1-10An alkoxy group.
23. The compound of claim 13, wherein L1May be mono-to trisubstituted, the substituents being selected from C1-10Alkyl, halo or to perhalo C1-10Alkyl, -CN, -OH, halogen, C1-10Alkoxy and halo or to perhalo C1-10An alkoxy group.
24. The compound of claim 18, wherein L1May be mono-to trisubstituted, the substituents being selected from C1-10Alkyl, halo or to perhalo C1-10Alkyl, -CN, -OH, halogen, C1-10Alkoxy and halo or to perhalo C1-10An alkoxy group.
25. The compound of claim 19, wherein L1May be mono-to trisubstituted, the substituents being selected from C1-10Alkyl, halo or to perhalo C1-10Alkyl, -CN, -OH, halogen, C1-10Alkoxy and halo or to perhalo C1-10An alkoxy group.
26. The compound of claim 20, wherein L1May be mono-to trisubstituted, the substituents being selected from C1-10Alkyl, halo or to perhalo C1-10Alkyl, -CN, -OH, halogen, C1-10Alkoxy and halo or to perhalo C1-10An alkoxy group.
27. The compound of claim 21, wherein L1May be mono-to trisubstituted, the substituents being selected from C1-10Alkyl radicalHalo or to perhalo C1-10Alkyl, -CN, -OH, halogen, C1-10Alkoxy and halo or to perhalo C1-10An alkoxy group.
28. The compound of claim 1, wherein L1Is represented by-C (O) RxAnd (4) substitution.
29. The compound of claim 1, wherein L1is-SO2RxAnd (4) substitution.
30. The compound of claim 1, wherein L1Only by-C (O) RxAnd (4) substitution.
31. The compound of claim 1, wherein L1Is only-SO2RxAnd (4) substitution.
32. The compound of claim 1, wherein L1Is represented by-C (O) Rxor-SO2RxSubstituted, wherein RxIs RaRb。
33. The compound of claim 13, wherein L1Is represented by-C (O) Rxor-SO2RxSubstituted, wherein RxIs RaRb，RaAnd RbIs that
a) Each of which is hydrogen, is a hydrogen atom,
carbon skeleton groups of 30 carbons or less, which may contain heteroatoms selected from N, S and O, which may be substituted by halogen, hydroxy and further carbon skeleton groups of 24 carbons or less, which may contain heteroatoms selected from N, S and O and which may be halogenated; or
-OSi(Rf)3，RfIs hydrogen or a carbon skeleton group of 24 carbons or less, may contain heteroatoms selected from N, S and O, may be substituted by halogen, hydroxy and a further carbon skeleton group of 24 carbons or less, may contain heteroatoms selected from N, S and O and may be halogenated; or
b)RaAnd RbTogether form a 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from N, S and O,or a 5-7 membered substituted heterocyclic ring containing 1-3 heteroatoms selected from N, S and O, and substituted with halogen, hydroxy or another carbon skeleton group of 24 carbons or less, which substituent may contain heteroatoms selected from N, S and O and may be halogenated; or
c)RaAnd RbOne of them being-C (O) -, C1-5Divalent alkylene radicals or C1-5Divalent substituted alkylene which is bonded to L to form a ring having at least 5 members, C1-5The divalent substituted alkylene substituents are selected from the group consisting of halogen, hydroxy and 24 carbon or less carbon backbone groups, which may contain heteroatoms selected from the group consisting of N, S and O and which may be halogenated.
34. The compound of claim 18, wherein L1Is represented by-C (O) Rxor-SO2RxSubstituted, wherein RxIs RaRb，RaAnd RbEach is: hydrogen or a carbon skeleton group of 30 or less carbons, which may contain heteroatoms selected from N, S and O, may be substituted by halogen, hydroxy and a further carbon skeleton group of 24 or less carbons, which may contain heteroatoms selected from N, S and O and may be halogenated.
35. The compound of claim 19, wherein L1Is represented by-C (O) RxSubstituted, wherein RxIs RaRb，RaAnd RbEach is: hydrogen or a carbon skeleton group of 30 or less carbons, which may contain heteroatoms selected from N, S and O, may be substituted by halogen, hydroxy and a further carbon skeleton group of 24 or less carbons, which may contain heteroatoms selected from N, S and O and may be halogenated.
36. The compound of claim 20, wherein L1Is represented by-C (O) Rxor-SO2RxSubstituted, wherein RxIs RaRb，RaAnd RbEach is:hydrogen or a carbon skeleton group of 30 or less carbons, which may contain heteroatoms selected from N, S and O, may be substituted by halogen, hydroxy and a further carbon skeleton group of 24 or less carbons, which may contain heteroatoms selected from N, S and O and may be halogenated.
37. The compound of claim 21, wherein L1Is represented by-C (O) Rxor-SO2RxSubstituted, wherein RxIs RaRb，RaAnd RbEach is: hydrogen or a carbon skeleton group of 30 or less carbons, which may contain heteroatoms selected from N, S and O, may be substituted by halogen, hydroxy and a further carbon skeleton group of 24 or less carbons, which may contain heteroatoms selected from N, S and O and may be halogenated.
38. A compound of the formula:
A-D-B (I) wherein D is-NH-C (O) -NH-,
a is a compound of the formula-L- (M-L)1)qWherein L is a 6-membered aryl or 6-membered heteroaryl, directly linked to D, L is a substituent group1Is an at least 5-membered, substituted ring, M is a bridging group of at least one atom, q is an integer from 1 to 3; rings L and L1Each containing 0 to 4 nitrogen, oxygen or sulfur,
b is a substituted or unsubstituted, up to tricyclic, below 30-carbon aryl or heteroaryl radical in which at least one 6-membered ring is directly connected to D and contains 0 to 4 nitrogen, oxygen or sulfur,
wherein L is1Is at least one selected from-SO2Rx，-C(O)Rxand-C (NR)y)RzThe substituent (b) of (a) is substituted,
Ryis hydrogen, or a carbon skeleton group of 24 carbons or less, may contain a hetero atom selected from N, S and O, may be halogenIs substituted or is fully halogenated,
Rzis hydrogen, or a carbon skeleton group of 30 or less carbons, may contain hetero atoms selected from N, S and O, may be substituted by halogen, hydroxy or a carbon skeleton of 24 or less carbonsSubstituted with a group which may contain a heteroatom selected from N, S and O, and which may be halogenated;
Rxis RzOr NRaRbWherein R isaAnd RbIs that
a) Each of which is hydrogen, is a hydrogen atom,
carbon skeleton groups of 30 carbons or less, which may contain heteroatoms selected from N, S and O, which may be substituted by halogen, hydroxy and further carbon skeleton groups of 24 carbons or less, which may contain heteroatoms selected from N, S and O and which may be halogenated; or
-OSi(Rf)3，RfIs hydrogen or a carbon skeleton group of 24 carbons or less, may contain heteroatoms selected from N, S and O, may be substituted by halogen, hydroxy and a further carbon skeleton group of 24 carbons or less, may contain heteroatoms selected from N, S and O and may be halogenated; or
b)RaAnd RbTaken together to form a 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from N, S and O, or a 5-7 membered substituted heterocyclic ring containing 1-3 heteroatoms selected from N, S and O, and substituted with halogen, hydroxy or another 24 carbon or less carbon backbone group, which may contain heteroatoms selected from N, S and O and which may be halogenated; or
c)RaAnd RbOne of them being-C (O) -, C1-5Divalent alkylene radicals or C1-5Divalent substituted alkylene which is bonded to L to form a ring having at least 5 members, C1-5The divalent substituted alkylene group is substituted with a substituent selected from the group consisting of halogen, hydroxyl, and a carbon skeleton group of 24 carbons or less, the substituent may contain a hetero atom selected from the group consisting of N, S and O and may be halogenated;
wherein B is substituted, L is substituted, or L1Is further substituted with a substituent selected from the group consisting of halogen, perhalogenated, and Wn, n is 0 to 3;
w is each selected from-CN, -CO2R7，-C(O)NR7R7，-C(O)-R7，-NO2，-OR7-，-SR7，-NR7R7，-NR7C(O)OR7，-NR7C(O)R7Q-Ar and a carbon skeleton group of less than 24 carbons which may contain N, S ando may be mono-or polysubstituted and the substituents are selected from the group consisting of-CN, -CO2R7，-C(O)-R7，-C(O)NR7R7，-OR7，-SR7，-NR7R7，-NO2，-NR7C(O)R7，-NR7C(O)OR7And halo or to perhalo; each R7Carbon skeleton groups selected from H or less than 24 carbon, which may contain heteroatoms of N, S and O and which may be halogenated,
q is-O-, -S-, -N (R)7)-，-(CH2)m-，-C(O)-，-CH(OH)-，-(CH2)m-O-，-(CH2)m-S-，-(CH2)mN(R7)-，-O(CH2)m-，-CHXa-，-CXa 2-，-S-(CH2)m-, and-N (R)7)(CH2)m-, m ═ 1 to 3, XaIs halogen;
ar is a 5-or 6-membered aromatic structure containing 0 to 2 heteroatoms selected from nitrogen, oxygen and sulfur, which may be halogenated or to perhalogenated, or which may be Zn1Substituted, n1 is 0 to 3, each Z is independently selected from-CN, -CO2R7，-C(O)R7，-C(O)NR7R7，-NO2，-OR7，-SR7，-NR7R7，-NR7C(O)OR7，-NR7C(O)R7And a carbon skeleton group of 24 carbons or less, which may contain a hetero atom selected from N, S and O and may be mono-or polysubstituted, the substituent being selected from-CN, -CO2R7，-COR7，-C(O)NR7R7，-OR7，-SR7，-NO2，-NR7R7，-NR7C(O)R7and-NR7C(O)OR7，R7As described above; and also
Wherein M is one or more bridging groups selected from: -O-, -S-, -N (R)7)-，-(CH2)m-，-C(O)-，-CH(OH)-，-(CH2)m-O-，-(CH2)m-S-，-(CH2)mN(R7)-，-O(CH2)m-，-CHXa-，-CXa 2-，-S-(CH2)m-, and-N (R)7)(CH2)m-, m ═ 1 to 3, XaIs a halogen.
39. A compound of the formula:
A-D-B (I) wherein D is-NH-C (O) -NH-,
a is a compound of the formula-L- (M-L)1)qWherein L is a substituted or unsubstituted phenyl or pyridyl (peritoneal) group directly attached to D, L is1Substituted phenyl, pyridyl or pyrimidinyl, M is a bridging group of at least one atom, q is an integer from 1 to 3;
b is a substituted or unsubstituted phenyl or pyridyl group, directly linked to D,
wherein L is1Is at least one selected from-SO2Rx，-C(O)Rxand-C (NR)y)RzThe substituent (b) of (a) is substituted,
Ryis hydrogen, or a carbon skeleton group of 24 carbons or less, may contain heteroatoms selected from N, S and O, may be halogenated or up to perhalogenated,
Rzis hydrogen, or a carbon skeleton group of 30 or less carbons, which may contain a heteroatom selected from N, S and O, which may be substituted by halogen, hydroxy or a carbon skeleton group of 24 or less carbons, which may contain a heteroatom selected from N, S and O, and which may be halogenated;
Rxis RzOr NRaRbWherein R isaAnd RbIs that
a) Each of which is hydrogen, is a hydrogen atom,
carbon skeleton groups of 30 carbons or less, which may contain heteroatoms selected from N, S and O, which may be substituted by halogen, hydroxy and further carbon skeleton groups of 24 carbons or less, which may contain heteroatoms selected from N, S and O and which may be halogenated; or
-OSi(Rf)3，RfIs hydrogen or substituted by a carbon skeleton group of 24 carbons or less, and may contain a substituent selected from the group consisting of N,heteroatoms of S and O, which may be substituted by halogen, hydroxyl and further carbon backbone groups of 24 carbons or less, which substituents may contain heteroatoms selected from N, S and O and which may be halogenated; or
b)RaAnd RbTaken together to form a 5-7 membered heterocyclic ring containing 1-3 heteroatoms selected from N, S and O, or a 5-7 membered substituted heterocyclic ring containing 1-3 heteroatoms selected from N, S and O, and substituted with halogen, hydroxy or another 24 carbon or less carbon backbone group, which may contain heteroatoms selected from N, S and O and which may be halogenated; or
c)RaAnd RbOne of them being-C (O) -, C1-5Divalent alkylene radicals or C1-5Divalent substituted alkylene which is bonded to L to form a ring having at least 5 members, C1-5The divalent substituted alkylene group is substituted with a substituent selected from the group consisting of halogen, hydroxyl, and a carbon skeleton group of 24 carbons or less, the substituent may contain a hetero atom selected from the group consisting of N, S and O and may be halogenated;
wherein B is substituted, L is substituted, or L1Is further substituted with a substituent selected from the group consisting of halogen, perhalogenated, and Wn, n is 0 to 3;
w is each selected from-CN, -CO2R7，-C(O)NR7R7，-C(O)-R7，-NO2，-OR7-，-SR7，-NR7R7，-NR7C(O)OR7，-NR7C(O)R7Q-Ar and a carbon skeleton group of less than 24 carbons which may contain heteroatoms of N, S and O and which may be mono-or polysubstituted, the substituents being selected from the group consisting of-CN, -CO2R7，-C(O)-R7，-C(O)NR7R7，-OR7-，-SR7，-NR7R7，-NO2，-NR7C(O)R7，-NR7C(O)OR7And halo or to perhalo; each R7Carbon skeleton groups selected from H or less than 24 carbon, which may contain heteroatoms of N, S and O and which may be halogenated,
q is-O-, -S-, -N (R)7)-，-(CH2)m-，-C(O)-，-CH(OH)-，-(CH2)m-O-，-(CH2)m-S-，-(CH2)mN(R7)-，-O(CH2)m-，-CHXa-，-CXa 2-，-S-(CH2)m-, and-N (R)7)(CH2)m-, m ═ 1 to 3, XaIs halogen;
ar is a 5-or 6-membered aromatic structure containing 0 to 2 heteroatoms selected from nitrogen, oxygen and sulfur, which may be halogenated or up to perhalogenated, or by Zn1Substituted, n1 is 0 to 3, each Z is independently selected from-CN, -CO2R7，-C(O)R7，-C(O)NR7R7，-NO2，-OR7，-SR7，-NR7R7，-NR7C(O)OR7，-NR7C(O)R7And a carbon skeleton group of 24 carbons or less, which may contain hetero atoms of N, S and O and may be mono-or polysubstituted by halogen, the substituents being selected from the group consisting of-CN, -CO2R7，-COR7，-C(O)NR7R7，-OR7，-SR7，-NO2，-NR7R7，-NR7C(O)R7and-NR7C(O)OR7(ii) a And wherein M is one or more bridging groups selected from: -O-, -S-, -N (R)7)-，-(CH2)m-，-C(O)-，-CH(OH)-，-(CH2)m-O-，-(CH2)m-S-，-(CH2)mN(R7)-，-O(CH2)m-，-CHXa，-CXa 2，-S-(CH2)m-, and-N (R)7)(CH2)m-, m ═ 1 to 3, XaIs a halogen.
40. The compound of claim 38, wherein rings B and L attached to D are not ortho-OH substituted.
41. The compound of claim 38, wherein the ring structures B and L directly attached to D are not capable of having a dissociable hydrogen with a pKa of 10 or less in the ortho position.
42. The compound of claim 39, wherein rings B and L attached to D are not ortho-OH substituted.
43. The compound of claim 39, wherein the ring structures B and L directly attached to D are not capable of having a dissociable hydrogen with a pKa of 10 or less in the ortho position.
44. The compound of claim 38, wherein substituents of B and L1The other substituents are selected from: c1-10Alkyl, halo or to perhalo C1-10Alkyl, -CN, -OH, halogen, C1-10Alkoxy radicalRadical, halo or to perhalo C1-10An alkoxy group.
45. The compound of claim 39, wherein substituents of B and L1The other substituents are selected from: c1-10Alkyl, halo or to perhalo C1-10Alkyl, -CN, -OH, halogen, C1-10Alkoxy, halo or to perhalo C1-10An alkoxy group.
46. The compound of claim 38, wherein L1is-SO2Rxor-C (O) RxAnd (4) substitution.
47. A compound according to claim 39, wherein L1is-SO2Rxor-C (O) RxAnd (4) substitution.
48. A compound according to claim 46, wherein RxIs NRaRbWherein R isaAnd RbEach hydrogen, a carbon skeleton group of 30 carbons or less, which may contain a heteroatom selected from N, S and O, may be substituted by halogen, hydroxyl and another carbon skeleton group of 24 carbons or less, which may contain a heteroatom selected from N, S and O and may be halogenated.
49. The compound of claim 47, whereinRxIs NRaRbWherein R isaAnd RbEach hydrogen, a carbon skeleton group of 30 carbons or less, which may contain a heteroatom selected from N, S and O, may be substituted by halogen, hydroxyl and another carbon skeleton group of 24 carbons or less, which may contain a heteroatom selected from N, S and O and may be halogenated.
50. The compound of claim 1 which is a pharmaceutically acceptable salt of formula I selected from:
a) basic salts of inorganic and organic acids, said acids being selected from: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, 1-naphthalenesulfonic acid, 2-naphthalenesulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid;
b) acid salts of organic and inorganic bases, the cation being selected from: alkali metal cations, alkaline earth metal cations, ammonium cations, aliphatically substituted ammonium cations, and aromatic-substituted ammonium cations.
51. The compound of claim 2 which is a pharmaceutically acceptable salt of formula I selected from:
a) basic salts of inorganic and organic acids, said acids being selected from: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, 1-naphthalenesulfonic acid, 2-naphthalenesulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid;
b) acid salts of organic and inorganic base cations selected from the group consisting of: alkali metal cations, alkaline earth metal cations, ammonium cations, aliphatically substituted ammonium cations, and aromatic-substituted ammonium cations.
52. The compound of claim 33 which is a pharmaceutically acceptable salt of formula I selected from:
a) basic salts of inorganic and organic acids, said acids being selected from: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, 1-naphthalenesulfonic acid, 2-naphthalenesulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid;
b) acid salts of organic and inorganic base cations selected from the group consisting of: alkali metal cations, alkaline earth metal cations, ammonium cations, aliphatically substituted ammonium cations, and aromatic-substituted ammonium cations.
53. The compound of claim 38 which is a pharmaceutically acceptable salt of formula I selected from:
a) basic salts of inorganic and organic acids, said acids being selected from: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, 1-naphthalenesulfonic acid, 2-naphthalenesulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid;
b) acid salts of organic and inorganic bases, the cation being selected from: alkali metal cations, alkaline earth metal cations, ammonium cations, aliphatically substituted ammonium cations, and aromatic-substituted ammonium cations.
54. The compound of claim 39 which is a pharmaceutically acceptable salt of formula I selected from:
a) basic salts of inorganic and organic acids, said acids being selected from: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, 1-naphthalenesulfonic acid, 2-naphthalenesulfonic acid, acetic acid, trifluoroacetic acid, malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid, benzoic acid, salicylic acid, phenylacetic acid, and mandelic acid;
b) acid salts of organic and inorganic base cations selected from the group consisting of: alkali metal cations, alkaline earth metal cations, ammonium cations, aliphatically substituted ammonium cations, and aromatic-substituted ammonium cations.
55. A pharmaceutical composition comprising a compound of claim 1 represented by formula I or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.
56. A pharmaceutical composition comprising a compound of claim 2 represented by formula I or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.
57. A pharmaceutical composition comprising a compound of claim 33 represented by formula I or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.
58. A pharmaceutical composition comprising a compound of claim 38 represented by formula I or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.
59. A pharmaceutical composition comprising the compound of claim 39 represented by formula I or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier.
60. A compound selected from:
3-tert-butylphenyl urea in table 1;
5-tert-butyl-2-methoxyphenyl urea in table 2;
5- (trifluoromethyl) -2-phenylurea in table 3;
3- (trifluoromethyl) -4-chlorophenyl ureas in table 4;
3- (trifluoromethyl) -4-bromophenyl urea in table 5;
5- (trifluoromethyl) -4-chloro-2-methoxyphenyl urea in table 6; and
urea 101-.
61. A compound selected from:
the following 3-tert-butylphenyl ureas: n- (3-tert-butylphenyl) -N '- (4- (3- (N-methylcarbamoyl) phenoxy) phenylurea, and N- (3-tert-butylphenyl) -N' - (4- (4-acetyl) phenoxy) phenylurea;
the following 5-tert-butyl-2-methoxyphenyl urea: n- (5-tert-butyl-2-methoxyphenyl) -N '- (4- (1, 3-dioxoisoindol-5-yloxy) phenyl) urea, N- (5-tert-butyl-2-methoxyphenyl) -N' - (4- (1-oxoisoindol-5-yloxy) phenyl) urea, N- (5-tert-butyl-2-methoxyphenyl) -N '- (4- (4-methoxy-3- (N-methylcarbamoyl) phenoxy) phenyl) urea, and N- (5-tert-butyl-2-methoxyphenyl) -N' - (4- (3- (N-methylcarbamoyl) phenoxy) phenyl) urea;
the following 2-methoxy- (5-trifluoromethyl) phenylurea: n- (2-methoxy- (5-trifluoromethyl) phenyl) -N '- (3- (2-carbamoyl-4-pyridyloxy) phenyl) urea, N- (2-methoxy- (5-trifluoromethyl) phenyl) -N' - (3- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (2-methoxy- (5-trifluoromethyl) phenyl) -N '- (4- (2-carbamoyl-4-pyridyloxy) phenyl) urea, N- (2-methoxy- (5-trifluoromethyl) phenyl) -N' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, n- (2-methoxy- (5-trifluoromethyl) phenyl) -N ' - (4- (2- (N-methylcarbamoyl) -4-pyridylthio) phenyl) urea, N- (2-methoxy- (5-trifluoromethyl) phenyl) -N ' - (2-chloro-4- (2- (N-methylcarbamoyl) (4-pyridyloxy)) phenyl) urea, N- (2-methoxy- (5-trifluoromethyl) phenyl) -N ' - (3-chloro-4- (2- (N-methylcarbamoyl) (4-pyridyloxy)) phenyl) urea;
the following 4-chloro-3- (trifluoromethyl) phenylurea: n- (4-chloro-3- (trifluoromethyl) phenyl) -N '- (3- (2-carbamoyl-4-pyridyloxy) phenyl) urea, N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (3- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (4-chloro-3- (trifluoromethyl) phenyl) -N '- (4- (2-carbamoyl-4-pyridyloxy) phenyl) urea, N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea;
the following 4-bromo-3- (trifluoromethyl) phenylurea: n- (4-bromo-3- (trifluoromethyl) phenyl) -N '- (3- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (4-bromo-3- (trifluoromethyl) phenyl) -N' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (4-bromo-3- (trifluoromethyl) phenyl) -N '- (3- (2- (N-methylcarbamoyl) -4-pyridylthio) phenyl) urea, N- (4-bromo-3- (trifluoromethyl) phenyl) -N' - (2-chloro-4- (2- (N-methylcarbamoyl) (4) -pyridyloxy)) phenyl) urea; n- (4-bromo-3- (trifluoromethyl) phenyl) -N' - (3-chloro-4- (2- (N-methylcarbamoyl) (4-pyridyloxy)) phenyl) urea;
the following 2-methoxy-4-chloro-5- (trifluoromethyl) phenylurea: n- (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) -N ' - (3- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) -N ' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) -N ' - (2-chloro-4- (2- (N-methylcarbamoyl) (4-pyridyloxy)) phenyl) urea, n- (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) -N' - (3-chloro-4- (2- (N-methylcarbamoyl) (4-pyridyloxy)) phenyl) urea.
62. A method of controlling the growth of cancer cells mediated by raf kinase comprising administering a compound of formula I as claimed in claim 1.
63. A method of controlling the growth of cancer cells mediated by raf kinase comprising administering a compound of formula I as claimed in claim 33.
64. A method of controlling the growth of cancer cells mediated by raf kinase comprising administering a compound of formula I as claimed in claim 38.
65. A method of controlling the growth of cancer cells mediated by raf kinase comprising administering a compound of formula I as claimed in claim 39.
66. A method of controlling raf kinase mediated cancer cell growth comprising administering the following compounds:
3-tert-butylphenyl urea in table 1;
5-tert-butyl-2-methoxyphenyl urea in table 2;
5- (trifluoromethyl) -2-phenylurea in table 3;
3- (trifluoromethyl) -4-chlorophenyl ureas in table 4;
3- (trifluoromethyl) -4-bromophenyl urea in table 5;
5- (trifluoromethyl) -4-chloro-2-methoxyphenyl urea in table 6; and
urea 101-.
67. A method of controlling raf kinase mediated cancer cell growth comprising administering the following compounds:
the following 3-tert-butylphenyl ureas: n- (3-tert-butylphenyl) -N '- (4- (3- (N-methylcarbamoyl) phenoxy) phenylurea, and N- (3-tert-butylphenyl) -N' - (4- (4-acetyl) phenoxy) phenylurea;
the following 5-tert-butyl-2-methoxyphenyl urea: n- (5-tert-butyl-2-methoxyphenyl) -N '- (4- (1, 3-dioxoisoindol-5-yloxy) phenyl) urea, N- (5-tert-butyl-2-methoxyphenyl) -N' - (4- (1-oxoisoindol-5-yloxy) phenyl) urea, N- (5-tert-butyl-2-methoxyphenyl) -N '- (4- (4-methoxy-3- (N-methylcarbamoyl) phenoxy) phenyl) urea, and N- (5-tert-butyl-2-methoxyphenyl) -N' - (4- (3- (N-methylcarbamoyl) phenoxy) phenyl) urea;
the following 2-methoxy- (5-trifluoromethyl) phenylurea: n- (2-methoxy- (5-trifluoromethyl) phenyl) -N '- (3- (2-carbamoyl-4-pyridyloxy) phenyl) urea, N- (2-methoxy- (5-trifluoromethyl) phenyl) -N' - (3- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (2-methoxy- (5-trifluoromethyl) phenyl) -N '- (4- (2-carbamoyl-4-pyridyloxy) phenyl) urea, N- (2-methoxy- (5-trifluoromethyl) phenyl) -N' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, n- (2-methoxy- (5-trifluoromethyl) phenyl) -N ' - (4- (2- (N-methylcarbamoyl) -4-pyridylthio) phenyl) urea, N- (2-methoxy- (5-trifluoromethyl) phenyl) -N ' - (2-chloro-4- (2- (N-methylcarbamoyl) (4-pyridyloxy)) phenyl) urea, N- (2-methoxy- (5-trifluoromethyl) phenyl) -N ' - (3-chloro-4- (2- (N-methylcarbamoyl) (4-pyridyloxy)) phenyl) urea;
the following 4-chloro-3- (trifluoromethyl) phenylurea: n- (4-chloro-3- (trifluoromethyl) phenyl) -N '- (3- (2-carbamoyl-4-pyridyloxy) phenyl) urea, N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (3- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (4-chloro-3- (trifluoromethyl) phenyl) -N '- (4- (2-carbamoyl-4-pyridyloxy) phenyl) urea, N- (4-chloro-3- (trifluoromethyl) phenyl) -N' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea;
the following 4-bromo-3- (trifluoromethyl) phenylurea: n- (4-bromo-3- (trifluoromethyl) phenyl) -N '- (3- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (4-bromo-3- (trifluoromethyl) phenyl) -N' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (4-bromo-3- (trifluoromethyl) phenyl) -N '- (3- (2- (N-methylcarbamoyl) -4-pyridylthio) phenyl) urea, N- (4-bromo-3- (trifluoromethyl) phenyl) -N' - (2-chloro-4- (2- (N-methylcarbamoyl) (4) -pyridyloxy)) phenyl) urea; n- (4-bromo-3- (trifluoromethyl) phenyl) -N' - (3-chloro-4- (2- (N-methylcarbamoyl) (4-pyridyloxy)) phenyl) urea;
the following 2-methoxy-4-chloro-5- (trifluoromethyl) phenylurea: n- (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) -N ' - (3- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) -N ' - (4- (2- (N-methylcarbamoyl) -4-pyridyloxy) phenyl) urea, N- (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) -N ' - (2-chloro-4- (2- (N-methylcarbamoyl) (4-pyridyloxy)) phenyl) urea, n- (2-methoxy-4-chloro-5- (trifluoromethyl) phenyl) -N' - (3-chloro-4- (2- (N-methylcarbamoyl) (4-pyridyloxy)) phenyl) urea.
CNB008026858A 1999-01-13 2000-01-12 W-carboxyaryl substituted diphenyl ureas as RAF kinase inhibitors Expired - Lifetime CN1219764C (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US11587799P 1999-01-13 1999-01-13
US60/115,877 1999-01-13
US25726699A 1999-02-25 1999-02-25
US09/257,266 1999-02-25
US42522899A 1999-10-22 1999-10-22
US09/425,228 1999-10-22

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100895046A Division CN100522934C (en) 1999-01-13 2000-01-12 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

Publications (2)

Publication Number Publication Date
CN1341098A true CN1341098A (en) 2002-03-20
CN1219764C CN1219764C (en) 2005-09-21

Family

ID=27381740

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB008026858A Expired - Lifetime CN1219764C (en) 1999-01-13 2000-01-12 W-carboxyaryl substituted diphenyl ureas as RAF kinase inhibitors
CNB2005100895046A Expired - Lifetime CN100522934C (en) 1999-01-13 2000-01-12 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2005100895046A Expired - Lifetime CN100522934C (en) 1999-01-13 2000-01-12 Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors

Country Status (40)

Country Link
JP (2) JP3845792B2 (en)
KR (3) KR101091101B1 (en)
CN (2) CN1219764C (en)
AR (1) AR035310A1 (en)
AT (2) ATE460398T1 (en)
AU (1) AU2501600A (en)
BG (1) BG65945B1 (en)
BR (2) BRPI0017535B8 (en)
CA (1) CA2359510C (en)
CU (1) CU23213A3 (en)
CY (2) CY2200149T2 (en)
CZ (2) CZ302846B6 (en)
DE (4) DE60026822T2 (en)
DK (1) DK1140840T3 (en)
DZ (1) DZ3004A1 (en)
EE (1) EE04913B1 (en)
EG (1) EG24407A (en)
ES (2) ES2255971T3 (en)
GT (2) GT200000002A (en)
HK (2) HK1045504B (en)
HR (1) HRP20010580B1 (en)
HU (2) HU230863B1 (en)
IL (2) IL144030A0 (en)
JO (1) JO2373B1 (en)
LU (1) LU91280I2 (en)
MA (1) MA26038A1 (en)
ME (1) MEP36908A (en)
MY (1) MY138897A (en)
NL (1) NL300242I2 (en)
NO (3) NO321059B1 (en)
NZ (1) NZ556598A (en)
PA (1) PA8489701A1 (en)
PL (1) PL215029B1 (en)
PT (2) PT1690853E (en)
RS (1) RS51497B (en)
SK (2) SK287419B6 (en)
SV (1) SV2001000004A (en)
TN (1) TNSN00010A1 (en)
TR (1) TR200102020T2 (en)
TW (1) TWI269791B (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1656073B (en) * 2002-05-29 2010-05-26 诺瓦提斯公司 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
WO2010083649A1 (en) * 2009-01-22 2010-07-29 沈阳药科大学 Bisarylurea derivatives and their use
CN101830847A (en) * 2010-05-18 2010-09-15 苏州麦迪仙医药科技有限公司 Anticancer compound and preparation method thereof
CN102219733A (en) * 2010-04-14 2011-10-19 上海医药工业研究院 Method for preparing sorafenib
CN101372475B (en) * 2008-03-19 2012-01-04 南京工业大学 Aromatic heterocyclic substituted acardite derivative and use thereof
CN101052619B (en) * 2004-09-29 2012-02-22 拜耳先灵制药股份公司 Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}n-methylpyridine-2-carboxamide
CN101298427B (en) * 2008-06-26 2012-03-21 中国科学院广州生物医药与健康研究院 Diaryl urea compound and use thereof
CN102770426A (en) * 2010-02-05 2012-11-07 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
CN102875460A (en) * 2012-05-17 2013-01-16 上海奥博生物医药技术有限公司 Method for preparing sorafenib
CN101362717B (en) * 2008-09-28 2013-02-06 四川大学 4-(4-amidoanilino)-2-(methylcarbamoyl) pyridine, derivates thereof and preparation, application thereof
CN103228274A (en) * 2010-10-01 2013-07-31 拜耳知识产权有限责任公司 Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
CN103254126A (en) * 2008-09-19 2013-08-21 苏州泽璟生物制药有限公司 Deuterated omega-diphenyl carbamide as well as derivative and pharmaceutical composition including compounds
CN103408488A (en) * 2013-08-13 2013-11-27 张家港威胜生物医药有限公司 Optimal synthetic method of sorafenib
WO2015154535A1 (en) * 2014-04-08 2015-10-15 北大方正集团有限公司 Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition
CN105348186A (en) * 2015-10-15 2016-02-24 青岛海洋生物医药研究院股份有限公司 Deuterated bisarylurea compound and preparation method thereof, and application of compound in preparation of antitumor drug
CN105753841A (en) * 2016-01-18 2016-07-13 西安交通大学 N-indazole substituted thiourea derivatives and preparation method and application thereof
CN105924390A (en) * 2016-05-19 2016-09-07 广州南新制药有限公司 Synthesis method of metafenib
CN107417604A (en) * 2017-07-25 2017-12-01 新发药业有限公司 Benzamide compound of 4 substituted pyridines 2 and preparation method and application
CN113831491A (en) * 2021-09-30 2021-12-24 南昌大学 Preparation method and adsorption application of pyrimidazole covalent organic framework

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003209118A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
EP1730111A2 (en) * 2004-01-30 2006-12-13 MERCK PATENT GmbH Substituted bisarylurea derivatives as kinase inhibitors
TW200530236A (en) * 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
DE102005015253A1 (en) * 2005-04-04 2006-10-05 Merck Patent Gmbh New pyrazole derivatives are tyrosine kinase inhibitors useful to treat e.g. solid tumors, diabetic retinopathy, age-related macular degeneration or inflammatory disease, osteoarthritis and rickets
WO2007075650A2 (en) 2005-12-21 2007-07-05 Bayer Healthcare Ag Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
WO2008044688A1 (en) * 2006-10-11 2008-04-17 Daiichi Sankyo Company, Limited Urea derivative
CN101674833A (en) * 2007-03-20 2010-03-17 柯瑞斯公司 Raf kinase inhibitors containing a zinc binding moiety
KR101553211B1 (en) * 2007-09-10 2015-09-15 씨아이피엘에이 엘티디. Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
TW201012467A (en) 2008-09-16 2010-04-01 Taiho Pharmaceutical Co Ltd Antitumor agent containing 4-[[3,5-bis(trimethylsilyl)benzoyl]amino]benzoic acid
JO3101B1 (en) * 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co Benzothiazole derivatives as anticancer agents
CN102617458A (en) * 2010-05-18 2012-08-01 张南 Preparation method for anticancer compound
CA2824028A1 (en) * 2011-01-06 2012-07-12 Beta Pharma Canada Inc. Novel ureas for the treatment and prevention of cancer
CN103508961B (en) * 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 Antitumor drug
CN103435553A (en) * 2013-09-16 2013-12-11 中国药科大学 Piperazine structure-based aryl formamide Raf kinase inhibitor and preparation method as well as application thereof
CN104672129B (en) * 2013-11-26 2019-06-25 广东东阳光药业有限公司 A kind of preparation method of carbamide compounds
CN104177292A (en) * 2014-08-08 2014-12-03 亿腾药业（泰州）有限公司 Method for industrial production of sorafenib tosylate polymorphic form I
WO2016049774A1 (en) * 2014-10-03 2016-04-07 The Royal Institution For The Advancement Of Learning/Mcgill University Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
CN106699652B (en) * 2016-11-07 2020-11-13 天津大学 Sorafenib alpha-aminobutyrate and preparation method thereof
CN108264510A (en) 2017-01-02 2018-07-10 上海喆邺生物科技有限公司 A kind of selective depression kinases compound and application thereof
JP2022528780A (en) * 2019-04-12 2022-06-15 ナショナル ヘルス リサーチ インスティトゥーツ Heterocyclic compounds as kinase inhibitors for therapeutic use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973675A (en) * 1989-04-13 1990-11-27 University Of Tennessee Research Center Hybrid nitrosoureidoanthracyclines having antitumor activity
US5447987A (en) * 1993-12-24 1995-09-05 Shin-Etsu Chemical Co., Ltd. Organopolysiloxane compositions
US5447957A (en) * 1994-06-02 1995-09-05 Smithkline Beecham Corp. Anti-inflammatory compounds
WO1995033458A1 (en) * 1994-06-02 1995-12-14 Smithkline Beecham Corporation Anti-inflammatory compounds
AU7585598A (en) * 1997-05-23 1998-12-11 Bayer Corporation Raf kinase inhibitors
EP1019040B1 (en) * 1997-05-23 2004-09-29 Bayer Corporation Aryl ureas for the treatment of inflammatory or immunomodulatory diseases
AU9802198A (en) * 1997-10-21 1999-05-10 Pharmacia & Upjohn Company Antiinflammatory thiadiazolyl ureas which act as lfa-1 and mac-1 inhibitors
WO1999032436A1 (en) * 1997-12-22 1999-07-01 Bayer Corporation Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1656073B (en) * 2002-05-29 2010-05-26 诺瓦提斯公司 Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
CN101052619B (en) * 2004-09-29 2012-02-22 拜耳先灵制药股份公司 Process for the preparation of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenyoxy}n-methylpyridine-2-carboxamide
CN101372475B (en) * 2008-03-19 2012-01-04 南京工业大学 Aromatic heterocyclic substituted acardite derivative and use thereof
CN101298427B (en) * 2008-06-26 2012-03-21 中国科学院广州生物医药与健康研究院 Diaryl urea compound and use thereof
CN103254126A (en) * 2008-09-19 2013-08-21 苏州泽璟生物制药有限公司 Deuterated omega-diphenyl carbamide as well as derivative and pharmaceutical composition including compounds
CN101362717B (en) * 2008-09-28 2013-02-06 四川大学 4-(4-amidoanilino)-2-(methylcarbamoyl) pyridine, derivates thereof and preparation, application thereof
WO2010083649A1 (en) * 2009-01-22 2010-07-29 沈阳药科大学 Bisarylurea derivatives and their use
CN102216280B (en) * 2009-01-22 2014-06-18 沈阳药科大学 Bisarylurea derivatives and their use
CN102770426B (en) * 2010-02-05 2016-03-23 诺瓦提斯公司 As compound and the composition of kinases inhibitor
CN102770426A (en) * 2010-02-05 2012-11-07 Irm责任有限公司 Compounds and compositions as protein kinase inhibitors
CN102219733A (en) * 2010-04-14 2011-10-19 上海医药工业研究院 Method for preparing sorafenib
CN101830847B (en) * 2010-05-18 2012-10-10 张南 Anticancer compound and preparation method thereof
WO2011143864A1 (en) * 2010-05-18 2011-11-24 苏州麦迪仙医药科技有限公司 Anticancer compounds and preparation methods thereof
CN101830847A (en) * 2010-05-18 2010-09-15 苏州麦迪仙医药科技有限公司 Anticancer compound and preparation method thereof
CN103228274A (en) * 2010-10-01 2013-07-31 拜耳知识产权有限责任公司 Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
US9381177B2 (en) 2010-10-01 2016-07-05 Bayer Intellectual Property Gmbh Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
CN102875460A (en) * 2012-05-17 2013-01-16 上海奥博生物医药技术有限公司 Method for preparing sorafenib
CN103408488A (en) * 2013-08-13 2013-11-27 张家港威胜生物医药有限公司 Optimal synthetic method of sorafenib
WO2015154535A1 (en) * 2014-04-08 2015-10-15 北大方正集团有限公司 Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition
KR101821516B1 (en) 2014-04-08 2018-01-23 피킹 유니버시티 파운더 그룹 컴퍼니, 리미티드 Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition
US9902709B2 (en) 2014-04-08 2018-02-27 Peking University Founder Group Co., Ltd. Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition
CN105348186A (en) * 2015-10-15 2016-02-24 青岛海洋生物医药研究院股份有限公司 Deuterated bisarylurea compound and preparation method thereof, and application of compound in preparation of antitumor drug
CN105348186B (en) * 2015-10-15 2018-05-22 青岛海洋生物医药研究院股份有限公司 Deuterated substituted bisarylurea compound and preparation method thereof and the application in anti-tumor drug is prepared
CN105753841A (en) * 2016-01-18 2016-07-13 西安交通大学 N-indazole substituted thiourea derivatives and preparation method and application thereof
CN105753841B (en) * 2016-01-18 2018-01-05 西安交通大学 A kind of N indazoles substituting thioureido analog derivative and its preparation method and application
CN105924390A (en) * 2016-05-19 2016-09-07 广州南新制药有限公司 Synthesis method of metafenib
CN107417604A (en) * 2017-07-25 2017-12-01 新发药业有限公司 Benzamide compound of 4 substituted pyridines 2 and preparation method and application
CN113831491A (en) * 2021-09-30 2021-12-24 南昌大学 Preparation method and adsorption application of pyrimidazole covalent organic framework

Also Published As

Publication number Publication date
BRPI0017535B8 (en) 2021-09-14
JP3845792B2 (en) 2006-11-15
YU49101A (en) 2004-05-12
BRPI0007487B1 (en) 2015-07-07
JP2003526613A (en) 2003-09-09
HK1087689A1 (en) 2006-10-20
HU230863B1 (en) 2018-10-29
AR035310A1 (en) 2004-05-12
DK1140840T3 (en) 2006-07-31
CY1110177T1 (en) 2015-01-14
CY2200149T2 (en) 2010-07-28
IL144030A0 (en) 2002-04-21
LU91280I9 (en) 2019-01-02
NL300242I1 (en) 2006-12-01
CA2359510A1 (en) 2000-07-20
DE05028442T1 (en) 2007-02-22
BRPI0017535B1 (en) 2018-02-14
RS51497B (en) 2011-04-30
BR0007487A (en) 2003-09-23
PL360085A1 (en) 2004-09-06
DE60044004D1 (en) 2010-04-22
EE200100368A (en) 2003-04-15
CN1219764C (en) 2005-09-21
NO337326B1 (en) 2016-03-07
DE122006000059I1 (en) 2007-02-15
TNSN00010A1 (en) 2002-05-30
KR20010103738A (en) 2001-11-23
ATE460398T1 (en) 2010-03-15
KR101091101B1 (en) 2011-12-09
ES2272203T1 (en) 2007-05-01
EE04913B1 (en) 2007-10-15
KR20070020158A (en) 2007-02-16
CZ302846B6 (en) 2011-12-14
ES2272203T3 (en) 2010-07-13
LU91280I2 (en) 2006-12-13
DZ3004A1 (en) 2004-03-27
ATE321027T1 (en) 2006-04-15
CU23213A3 (en) 2007-06-20
IL144030A (en) 2010-06-30
CZ299125B6 (en) 2008-04-30
SV2001000004A (en) 2001-01-10
SK287419B6 (en) 2010-09-07
NO20013463L (en) 2001-09-12
HU0600871D0 (en) 2007-01-29
SK9882001A3 (en) 2002-04-04
HUP0300866A3 (en) 2006-04-28
JP4472669B2 (en) 2010-06-02
NO2007002I1 (en) 2007-01-05
DE60026822D1 (en) 2006-05-11
BG65945B1 (en) 2010-06-30
NO20013463D0 (en) 2001-07-12
MA26038A1 (en) 2004-04-01
SK285532B6 (en) 2007-03-01
JP2006328075A (en) 2006-12-07
EG24407A (en) 2009-05-20
HRP20010580A2 (en) 2002-08-31
HUP0300866A2 (en) 2003-07-28
MY138897A (en) 2009-08-28
PL215029B1 (en) 2013-10-31
CZ20012489A3 (en) 2002-01-16
TR200102020T2 (en) 2003-01-21
BG109688A (en) 2007-05-31
PA8489701A1 (en) 2002-11-18
HK1045504A1 (en) 2002-11-29
NO321059B1 (en) 2006-03-06
MEP36908A (en) 2011-02-10
ES2255971T3 (en) 2006-07-16
PT1140840E (en) 2006-05-31
KR100719166B1 (en) 2007-05-17
KR20110063595A (en) 2011-06-10
HK1045504B (en) 2006-04-07
CA2359510C (en) 2007-02-13
GT200000002A (en) 2002-01-09
TWI269791B (en) 2007-01-01
PT1690853E (en) 2010-04-23
CN1721397A (en) 2006-01-18
DE60026822T2 (en) 2006-08-24
AU2501600A (en) 2000-08-01
HRP20010580B1 (en) 2010-07-31
HU225780B1 (en) 2007-08-28
NL300242I2 (en) 2007-04-02
NO2007002I2 (en) 2009-10-05
CN100522934C (en) 2009-08-05
GT200000002AA (en) 2007-06-15
JO2373B1 (en) 2006-12-12
BRPI0007487B8 (en) 2021-05-25
NZ556598A (en) 2008-11-28
NO20055863L (en) 2001-09-12

Similar Documents

Publication Publication Date Title
CN1341098A (en) W-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CN1213022C (en) Inhibition of raf kinase using symmerical and unsymmerical substituted diphenyl ureas
CN1171872C (en) Compounds for modulation of PPAP gamma activity
CN1066436C (en) Compounds
CN1114402C (en) Isothiazolones
CN1263755C (en) Pyrazolopyridine derivatives as selective COX-2 inhibitors
US7351834B1 (en) ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CN1544420A (en) Inhibition of raf kinase using substituted heterocyclic ureas
US8124630B2 (en) ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7235576B1 (en) Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20010027202A1 (en) Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors
CN1050018A (en) Benzoylguanidines, they the preparation method, they are as the application of medicament and the medicament that contains them
CN1370152A (en) 5-cyano-2-aminopyrimidine derivatives
CN1159292C (en) Aryl substituted cyclic amines as selective dopamine D3 ligands
CN1254337A (en) N-hydroxy 4-sulfonyl butyramide compounds
CN1602191A (en) Compounds and uses thereof for decreasing activity of hormone-sensitive lipase
CN1213306A (en) Novel substituted imidazolium compounds
US20120040986A1 (en) Omega carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CN1138851A (en) Metalloproteinase inhibitors
CN1168720C (en) Aryl alkanoylpyridazines
CN1175253A (en) Piperazine 2, 5 dione derivatives as modulators of multi-drug resistance
CN1048030A (en) Promote the phenol derivatives of growth factor of human nerve
CN1058015A (en) Benzoic acid derivative
CN1404471A (en) Substituted piperazine compounds
CN1134413C (en) Sulfonyl pyrrolidone containing compound and its preparation and pharmaceutical application

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: BAYER PHARMACEUTICALS CORP.

Free format text: FORMER OWNER: BAYER CORP.

Effective date: 20071019

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20071019

Address after: American Connecticut

Patentee after: Bayer Pharmaceuticals Corp.

Address before: American Pennsylvania

Patentee before: Bayer Corp.

C57 Notification of unclear or unknown address
DD01 Delivery of document by public notice

Addressee: Wang Xiurong

Document name: Notification of Acceptance of Request for Invalidation

ASS Succession or assignment of patent right

Owner name: BAYER AG HEALTH CARE CO.,LTD.

Free format text: FORMER OWNER: BAYER MEDICINE CO., LTD.

Effective date: 20090417

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20090417

Address after: American New York

Patentee after: BAYER ESSURE INC.

Address before: American Connecticut

Patentee before: Bayer Pharmaceuticals Corp.

C56 Change in the name or address of the patentee

Owner name: BAYER SCHERING PHARMACEUTICAL AG

Free format text: FORMER NAME: BAYER AG HEALTH CARE CO.,LTD.

CP01 Change in the name or title of a patent holder

Address after: American New York

Patentee after: Bayer Pharmaceuticals Corp.

Address before: American New York

Patentee before: BAYER ESSURE INC.

CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: new jersey

Patentee after: Bayer Pharmaceuticals Corp.

Address before: American New York

Patentee before: Bayer Pharmaceuticals Corp.

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20050921